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Hepatitis G virus (HGV) or GB virus C (GBV-C) is a novel member of the
Flaviviridae family, discovered by two independent research groups. HGV/GBV-
C has a single-stranded, positive-sense RNA genome of approximately 9.4 kb in
length which contains a single open reading frame (ORF). The genome
organization is similar to that of hepatitis C virus (HCV) with 25% amino acid
identity. Extensive studies have been carried out to assess the clinical importance
and epidemiology of this new agent.
This thesis describes the genetic analysis of the heterogeneity of
HGV/GBV-C and the characterization of the terminal regions of the viral
genome. The sequence diversity across the HGV/GBV-C genome was
significantly lower than that observed with HCV isolates. Comparative analysis
of twenty-seven complete genome HGV/GBV-C sequences indicated the
presence of four phylogenetic groups and this study demonstrated that these
groupings could be reproduced by analysis of the 5'-untranslated region (5'-
UTR) and of various sub-fragments. At the same time, the analysis of the 5'-
UTR variability indicated the existence of group-specific polymorphisms, many
of which are covariant and consistent with the proposed secondary structure of
this region.
An important difference between the polyproteins of HGV/GBV-C and
HCV is the absence of a putative HGV/GBV-C core protein which is usually
encoded at the 5'-end of the genome of flaviviruses. The buoyant density of
vi
HGV/GBV-C particles in human plasma was estimated to be between 1.07-1.12
g/ml, much lower than that of the other members of Flaviviridae family, except
HCV. No HGV/GBV-C RNA was detected in fractions with densities higher
than 1.17 g/ml, which is expected for virus particles in immune complexes, or in
fractions with densities higher than 1.21 g/ml, density range of HCV
nucleocapsids. These biophysical properties correlate with the absence of a core¬
like protein in the genome of HGV/GBV-C isolates from different phylogenetic
groups. The absence of the HGV/GBV-C nucleocapsid was also revealed by the
sequence analysis data since no conserved open reading frame capable of
encoding a core-like protein was identified.
Generally, the untranslated regions at the 5' and 3' termini of a RNA
virus genome contain regulatory elements important for viral RNA replication,
transcription, translation and viral packaging. A comprehensive comparison and
analysis of the primary sequence and secondary structure of the 3'-UTR of
different HGV/GBV-C isolates allowed the construction of a common secondary
structure model for this region and the identification of structural elements that
may be involved in viral replication.
Finally, the susceptibility of various types of cultured cells (peripheral
blood mononuclear cells, U937 and HepG2 cells) to HGV/GBV-C infection was
examined in an attempt to develop a reliable cell culture system that will allow
detailed investigation of the in vitro replication of HGV/GBV-C.
Together these investigations clarify basic features of the structure,
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CHAPTER 1
1. GENERAL INTRODUCTION: HEPATITIS G VIRUS/GB VIRUS-C
1.1 VIRAL HEPATITIS AND THE SEARCH FOR NANB AGENTS
Viral hepatitis represents an important public health problem throughout
the world. Initially, the disease was known to be caused by two viruses - hepatitis
A virus (HAV) and hepatitis B virus (HBV) - each with its own specific mode
of transmission and replication. HAV, originally classified as an Enterovirus
(type 72), is a small unenveloped RNA virus which has been classified as
member of the Picornaviridae family and causes infectious and epidemic hepatitis
transmissible by faecal-oral route (Melnick, 1982). HBV, a double-stranded
DNA virus which replicates by reverse transcription (RT), belongs to the
hepadnavirus group. It is endemic in the human population and closely related
viruses infect woodchucks, squirrels and ducks (Zuckerman, 1990).
Infections due to these two viruses can be identified by tests for specific
serological and enzymatic markers such as: hepatitis B surface antigen (HBsAg),
anti-hepatitis B core antibody (anti-HBc), immunoglobulin M antibody to HAV.
However, it was reported in the 1970s that a number of cases of transfusion-
associated hepatitis were serologically unrelated to either HAV or HBV, and so
were described as non-A, non-B hepatitis (NANBH). NANBH appears to be a
mild, frequently asymptomatic, disease only causing jaundice in some cases.
Acute infection can progress to chronicity in a higher proportion (50%)
compared to approximately 5% for HBV infection. At the same time, the
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incubation period from exposure to liver function abnormalities is shorter (8
weeks) than usually observed for HBV infection (longer than 12 weeks) but
longer than that for HAV infection (between 3 and 5 weeks) (Conn and
Atterbury, 1993).
Since cytomegalovirus (CMV) and Epstein-Barr virus (EBV) are known
to cause liver damage and these viruses can be transmitted by blood transfusion,
it was suggested that these viruses may be responsible for some of NANBH
cases (Luby et al. 1974). However, serological investigations showed that CMV
or EBV are rarely involved, so they cannot be considered as causative agents of
NANBH (Feinstone et al. 1975; Alter et al. 1978). As a result, diagnosis of
NANBH was made by exclusion of HAV, HBV and herpesviruses such as CMV
and EBV.
The first direct evidence for a third human hepatitis virus was provided
by immunofluorescence microscopy in the midl970s (Rizzetto et al. 1977). A
new viral antigen, identified in the nuclei of hepatocytes from Italian patients
with chronic hepatitis B, proved to be a small single-stranded circular RNA virus
with a number of similarities to certain plant viral satellites and viroids. It was
named hepatitis D virus (HDV) and it was shown that it requires HBV to
establish infection, and that it causes both fulminant hepatitis and accelerated
progression of pre-existing hepatitis B virus infection (Polish et al. 1993). These
particular features indicated that HDV cannot be considered as a potential
NANBH agent. At the same time, epidemiological studies revealed that
NANBH represents more than 90% of transfusion-associated hepatitis cases in
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The United States (Aach et al. 1981). Screening of blood donors for serum
alanine aminotransferase levels (ALT) (Aach et al. 1981) and for antibodies to
hepatitis B core antigen (anti-HBc) (Koziol et al. 1986) was proposed in order
to reduce the high risk of transmitting NANB agent by blood transfusions.
Different investigations using these "surrogate markers" for the detection of
NANBH virus carriers indicated that exclusion of anti-HBc positive donors
would prevent 42-43% of the NANBH cases (Koziol et al. 1986; Sugg et al.
1988).
The hypothesis that a novel viral hepatitis agent was responsible for
NANBH was further supported by epidemiological studies in humans which
showed that hepatitis was transmitted by serum derived from patients with
chronic and acute hepatitis when there was no serological evidence of type A or
B hepatitis (Prince et al. 1974; Alter et al. 1978). In addition, studies in primates
(Feinstone et al. 1975; Hoofnagle et al. 1977) indicated that the NANBH agent
may be a small, enveloped virus, between 30 and 60 nm in diameter, that is
transmissible to chimpanzees (He et al. 1987) and can be inactivated by
chloroform treatment (Feinstone et al. 1983). Major progress was subsequently
achieved using a recombinant complementary DNA (cDNA) approach in 1989
(Choo et al. 1989). A cDNA library derived from infectious plasma containing
the NANBH agent was produced using Escherichia coli bacteriophage Agtll and
then screened for clones expressing viral antigen using serum from a chronic
NANBH patient. This immunoscreening procedure led to the identification and
isolation of a positive cDNA clone designated 5-1-1. Hybridization analysis
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indicated that this clone was not derived from host DNA but from an exogenous
RNA molecule associated with NANBH infection. This single-stranded RNA
molecule with an approximate size of 9,400 nucleotides was designated hepatitis
C virus (HCV) (Choo et al. 1989; Choo et al. 1991). The HCV viral genome of
positive polarity consists of a single continuous open reading frame (ORF),
encoding a single polyprotein and flanked by untranslated regions at both its 5'
and 3'ends (Figure 1.1). The polyprotein of approximately 3,010 amino acids is
cleaved post-translationally into individual viral proteins: core (C), El, E2
(envelope), p7, NS2, NS3, NS4A, NS4B, NS5A and NS5B (non-structural)
proteins (Choo et al. 1991; Takamizawa et al. 1991).
Comparison with other positive-strand RNA virus groups revealed that
HCV is distantly related to the pestiviruses and flaviviruses, both of which are
members of the Flaviviridae family (Kato et al. 1990; Miller and Purcell, 1990;
Koonin, 1991). For example, sequence alignment of amino acid sequences of the
RNA-dependent RNA polymerases (NS5B region) of all positive-strand RNA
virus groups identified three large phylogenetic supergroups of RNA
polymerases (RdRp); supergroup II included pestiviruses, HCV, and flaviviruses
together with carmoviruses, tombusviruses and single-stranded RNA
bacteriophages (Koonin, 1991).
Following the discovery and characterization of HCV, specific
radioimmuno- and enzyme-linked assays for the detection of circulating HCV
antibodies were developed by expression of a viral polypeptide in recombinant
































NS2=protease NS3=protease/RNAhelicase NS4=cofactor NS5B=RNApolymerase
NS4 protein of the HCV prototype isolate (Choo et al. 1989; Kuo et al. 1989;
Choo et al. 1991) was used to coat the wells of microtitre plates, that were then
incubated with human sera previously shown to transmit NANBH to
chimpanzees (Kuo et al. 1989). Using this assay, antibodies to the cl00-3 protein
were detected in about 80% of sera from chronic, post-transfusion NANBH (PT-
NANBH) patients from Italy and Japan. Antibodies were also present frequently
in sporadic, community-acquired NANBH cases, such as patients from the USA
with no identifiable source of parental exposure to the virus (Kuo et al. 1989).
In addition, the immunoassay revealed a similar frequency of positive samples
for linked donors and recipients, indicating that these antibodies were present
in nearly all cases of PT-NANBH, and were particularly associated with chronic
infections (Alter et al. 1989). As a result, it became apparent that HCV was the
major cause of parenterally transmitted NANBH (Alter et al. 1989; Kuo et al.
1989).
1.2 NON-A,B,C,D HEPATITIS AGENTS
After the characterisation of HCV and the development of a specific
screening assay for HCV antibodies, the use of molecular cloning techniques led
to the successful isolation and identification of a cDNA clone of another human
hepatitis virus designated hepatitis E virus (HEV) (Reyes et al. 1990). HEV is
a non-enveloped single-stranded RNAvirus which shares many biophysical (size,
sedimentation, lack of a viral envelope) and biochemical features with
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caliciviruses (Reyes et al. 1990). It was identified as a main cause of enterically-
transmitted non-A, non-B hepatitis (Bradley, 1990; Reyes et al. 1990). Large
"water-borne" epidemics of acute hepatitis in the Indian subcontinent, Central
and South East Asia, parts of Africa, Central America were then found to be
caused by HEV (Zuckerman, 1990; Velazquez et al. 1990).
More recently, virus particles of 27 to 37 nm diameter were detected by
electron microscopy in liver samples from rhesus monkeys which had been
inoculated with stool samples collected from patients with sporadic non-A, non-
B hepatitis (Deka et al. 1994). The new virus, which was provisionally named
hepatitis F virus (HFV), is a DNA virus with a genome of 20 kb (Deka et al.
1994). Research related to HFV is still at early stage and further investigations
are necessary in order to examine its clinical importance in infectious hepatitis.
Despite these advances, the aetiology of about 20% cases of acute and
community-acquired non-A, non-E hepatitis remained unknown, suggesting the
existence of other causative agents (Alter et al. 1989; Aach et al. 1991). Further
evidence for the existence of another potential infectious agent was provided by
reports that 3 to 10% of patients with chronic hepatitis and cirrhosis were
"ciyptogenic" (Conn and Atterbury, 1993; Hammel et al. 1994; Kodali et al.
1994). The aetiology of these cases was unknown despite research into patient
histories, histology, or the presence of serum markers of HBV or HCV infection,
or evidence of autoimmune diseases. Results from extensive epidemiological
studies provided additional evidence for this possibility. For example, in a five-
year prospective study of acute NANB hepatitis in Greece in which 182 patients
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were investigated, 47% of cases were established to be non-A,B,C,D related
(Tassopoulos et al. 1992) with a small number of community-acquired NANBH
cases associated with HEV infection (Tassopoulos et al. 1994). Earlier,
biophysical and challenge studies in chimpanzees experimentally infected with
factor VIII concentrate, suggested that there were two NANBH agents which
induced separate and distinct episodes of NANBH (Bradley et al. 1983). Both
agents could be recovered from liver tissue and plasma collected from a
chimpanzee, one during the acute phase, and the other during the chronic phase
of infection. One of the infectious agents proved to be chloroform sensitive and
induced formation of cytoplasmic tubules, convoluted endoplasmic reticulum and
dense reticular inclusion bodies in infected hepatocytes. In contrast, the second
NANB agent was chloroform resistant and did not induce structural changes in
hepatocytes.
1.3 DISCOVERY OF GB AGENTS
Early in 1967, the existence of a so-called "GB agent" was reported
following experimental infection of laboratory animals (Deinhardt et al. 1967).
Different serum samples from patients with unknown hepatitis were used to
inoculate marmoset monkeys (Saguinus sp.). One of the inocula was obtained on
the third day of jaundice from a 34-year old surgeon with acute hepatitis whose
initials were GB. Five serial marmoset-to-marmoset passages were then carried
out with this isolate. Elevation of liver enzyme levels and histological changes
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in liver biopsies were observed in animals inoculated directly with GB serum and
also in those inoculated during the serial passages. After the identification of
HAV (Feinstone et al. 1973), further work was carried out to document the
morphological characteristics of the GB agent (Almeida et al. 1976). Electron
microscopy of the highly infectious serum collected from a marmoset infected
with the GB agent identified aggregates of 20 to 22 nm particles, smaller than
HAV particles which were about 27 nm in diameter (Almeida et al. 1976).
Passage and cross-challenge experiments of the GB agent in tamarins
(Saguinus labiatus) were also carried out (Karayiannis et al. 1989). In these
studies, intravenous inoculation of three tamarins (two of which were immune
to HAV) with plasma containing the GB agent induced biochemical and
histological changes consistent with acute hepatitis, indicating that GB and HAV
are antigenically distinct. At the same time, the possibility that GB was an
enterovirus shed in faeces was tested using extracts from faeces collected during
the acute phase of the disease to inoculate two other tamarins. Neither of them
developed hepatitis. This result indicated that GB is unlikely to be an
enterovirus or related to enterally transmitted NANB hepatitis virus
(Karayiannis et al. 1989). However, the detailed molecular characterization of
the GB agent genome was only accomplished recently using a technique called
representative differential analysis (RDA) (Lisitsyn and Wigler, 1993).
Nucleic acids were extracted from infected tamarin plasma (tester) and
uninfected pre-inoculation plasma (driver). After cDNA synthesis by randomly-
primed reverse transcription, second-strand synthesis was carried out using
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random hexamers as primers. The double-stranded DNA products were digested
with the restriction enzyme (Sau3A I). The digested tester DNA fragments were
then ligated to the R Bgl primer set as initially described (Lisitsyn and Wigler,
1993) followed by hybridization of tester and driver DNAs. The selective
amplification of tester-tester hybrids which were flanked by the R Bgl adaptor
was performed by PCR using adaptor-specific primers. As a result, no tester-
driver or driver-driver hybrids would be amplified and repeated rounds of
hybridization and selective amplification are expected to lead to the selection of
presumed exogenous nucleic acids.
Following the isolation of 76 clones, cross-hybridization experiments
identified eleven unique clones, seven of which were examined extensively.
Southern blot analysis failed to detect sequences from these clones in the
genomes of human, uninfected tamarin, Saccharomyces cerevisiae or Escherichia
coli. These sequences could only be detected after RT-PCR of samples from
infectious tamarin plasma, suggesting that the corresponding clones were
originally derived from an RNA molecule. Sequence analysis followed by
searches of the GenBank and Swiss-Prot databases indicated that five of the
seven clones had limited sequence similarity to the non-structural proteins of
HCV. Further cloning revealed the existence in infected plasma of two unique
plus-strand RNA genomes with similarity to flaviviruses, designated GBV-A and
GBV-B, respectively (Simons et al. 1995b). More than 30 overlapping cDNA
clones for each genome were isolated from serum and liver samples from a GB-
infected tamarin using PCR-based techniques in order to generate the entire
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nucleotide sequences of GBV-A and GBV-B (Muerhoffet al. 1995). GBV-A was
found to contain 9,493 nucleotides while GBV-B comprises 9,143 nucleotides,
each virus having a single ORF encoding potential polyproteins of 2,972 and
2,864 amino acids, respectively.
Comparison of the hydropathy profiles ofGBV-A, GBV-B, HCV, bovine
viral diahrroea virus (BVDV) and yellow fever virus (YFV) demonstrated that
the polyproteins of these viruses had similar structures and organization
although the overall amino acid sequence identity is low (Muerhoff et al. 1995).
The polyproteins of GBV-A and GBV-B show limited identity to the helicase
and RNA polymerase regions of HCV and other viruses encoding supergroup
II helicases and polymerases (Koonin, 1991). Phylogenetic analysis of amino acid
sequences within the helicase and RdRp domains revealed that GBV-A and
GBV-B are neither genotypes of HCV nor genotypes of the same virus
(Muerhoff et al. 1995) since the maximum distance between any two HCV
genotypes for the RdRp region is 0.37 while the minimum distance calculated
between GBV-A or GBV-B and any HCV genotype is 0.96. These results were
supported by phylogenetic trees produced for either the helicase or RdRp
sequence alignments of GBVs, HCV and other viruses in the Flaviviridae family;
the GBVs were not present on the same major branch as the HCVs, indicating
that GB agents could be classified into a new genera within the Flaviviridae
(Muerhoff et al. 1995).
More transmission studies of the GB agents, together or separately, in
tamarins were carried out in order to study the nature of GB virus infections
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(Schlauder et al. 1995). Viraemia was monitored using the RT-PCR assay
developed for detection of GBV-A and GBV-B RNAs, while antibody responses
to GBV-A and GBV-B recombinant proteins were evaluated by enzyme-linked
immunoassay (ELISA). The antigens were fragments of the putative NS3/NS4
and NS5 regions of GBV-A and fragments of the core, NS3/NS4 and NS5
regions of GBV-B. Antibodies to GBV-B epitopes were detected in serum
samples collected from tamarins inoculated with both GB viruses or GBV-B
alone but there were no detectable antibody responses to the GBV-A epitopes
in any of the animals. GBV-B viraemia, detected by RT-PCR, caused an
elevation of ALT after inoculation of GBV-B, either alone or together with
GBV-A. On the contrary, no enzyme elevation was observed in tamarins with
only GBV-A viraemia. These results indicated that GBV-B causes hepatitis in
inoculated tamarins (Schlauder et al. 1995). However, the peak levels ofALT in
GBV-B infected animals was lower than in GBV-A/GBV-B coinfected tamarins
suggesting that the severity of hepatitis is related to the presence of both GB
agents.
In order to examine the seroprevalence of antibodies to GBV-A and
GBV-B in humans, serum samples collected from different individuals were
screened for GB viruses (Simons et al. 1995a) using ELISA assays for
recombinant proteins of GBV-A and GBV-B (Schlauder et al. 1995). Three
distinct groups were examined: volunteer blood donors previously tested negative
for HBsAg, anti-HCV and anti-HBc; intravenous drug users (IVDUs) with a
high prevalence of antibody to HCV (99%) and HBV (76%); and a group from
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Western Africa where infection with agents of viral hepatitis is relatively
common. Amongst volunteer blood donors, a seroprevalence of 0.3% (3/860)
was observed for antibodies to GBV-A recombinant proteins and 1.2% (12/960)
for GBV-B recombinant proteins. In contrast, screening of the IVDU group
showed the presence of antibodies to GBV-A and GBV-B in 14%. A similar
seroprevalence was obtained in the samples from West Africa where antibodies
to GBV-A were detected in 8.4% and to GBV-B in 14.6% with 3.07% of
samples positive for both viruses (Simons et al. 1995a).
These immunoreactive sera were then tested for the presence of viral
sequences by RT-PCR using degenerate primers based on GBV-A, GBV-B and
HCV sequences from the NS3 (helicase) region. An amplification product was
obtained from a West African sample, and this had limited nucleotide sequence
identity to GBV-A (59%), GBV-B (47.9%) and HCV-type la (57.3%). Further
sequence analysis and alignment of the predicted translation product with
sequences of other members of the Flaviviridae family suggested that this
sequence belonged to a new virus. Because of the relatively high degree of
identity with GBV-A at both nucleotide and amino acid levels (59% and 64%,
respectively), this virus was named GB virus C (GBV-C) (Simons et al. 1995a).
No PCR product was obtained when the RT step was omitted, and GBV-
C sequences could not be detected in DNA samples from human, Rhesus
monkey, Saccharomyces cerevisiae or Escherichia coli. These results confirmed
that the GBV-C sequences were derived from an RNA virus. Finally, sequence
analysis of regions up- and downstream of the helicase region obtained from
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overlapping genomic clones revealed that the GBV-C genome is 9,125
nucleotides in length with an ORF of 2,906 amino acids (Leaiy et al. 1996b).
Serological studies of the prevalence of GBV-C were initiated by
screening serum samples obtained from individuals diagnosed with non-A-E
hepatitis (Simons et al. 1995a). For this purpose, fragments of the virus genome
were expressed as recombinant proteins in E. coli and then used to detect
immunoreactive GBV-C sera by ELISA. From a total of 161 samples, 5 (3.1%)
were immunoreactive to GBV-C proteins while 26 (16.1%) were positive for
recombinant proteins of GBV-A, GBV-B or GBV-C. Eight out of these 26 sera
were positive by RT-PCR using GBV-C specific primers. The samples originated
from individuals with distinct clinical background: one patient was co-infected
with HCV, another patient had hepatitis-associated aplastic anaemia, two
patients had acute hepatitis without markers for infection with hepatitis A-E
viruses, and the four remaining patients were Africans for whom no clinical
information was available. The presence of GBV-C RNA in individuals with
unknown hepatitis suggested, for the first time, that the GBV-C might be one
of the causative agents of nonA-E hepatitis. However, since GBV-C and HCV
co-infected one patient, there may have been common risk factors for acquiring
these infections, and it was not clear whether the hepatitis symptoms were due
to HCV, GBV-C or both (Simons et al. 1995a).
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1.4 HEPATITIS G VIRUS
In parallel, a search for potential new infectious agents associated with
nonA-E hepatitis cases by another group of scientists led to the identification
and characterisation of a novel RNA virus designated hepatitis G virus (HGV)
(Linnen et al. 1996). The source of this virus was plasma from an American
patient (PNF2161) with chronic NANB hepatitis. The patient was initially found
to be negative for HCV using a first-generation immunoassay, but was positive
by second-generation HCV immunoassay and also for HCV RNA by RT-PCR
using HCV 5'UTR-specific primers (Linnen et al. 1996).
RNA extracted from the plasma sample and reverse-transcribed with
random primers was amplified by sequence-independent single primer
amplification (SISPA) followed by cloning of the amplified products into the E.
coli expression vector A gtll. The same plasma was then used to screen colonies
from the cDNA library, and a single immuno-reactive clone was identified and
sequenced. Using primers derived from the clone sequence, PCR amplification
was performed on various templates such as human genomic DNA, E. coli DNA
and S. cerevisiae DNA. The absence of any PCR products in these reactions
indicated that the immuno-reactive clone contained exogenous sequences. No
PCR product was obtained from the plasma sample when reactions were carried
out without a RT step, demonstrating that the sequence derived from RNA.
Anchored PCR was used to generate multiple overlapping clones whose
combined sequence 9,392 nucleotides encoding a putative viral polyprotein of
14
2,873 amino acids. This new RNA virus was designated hepatitis G virus (HGV)
(Linnen et al. 1996).
The genome organization of HGV resembles that of HCV (e.g. structural
genes located towards the 5'end and non-structural genes towards the 3'end of
the genome), indicating the existence of a flavivirus-like RNA genome.
Comparison of the predicted amino acid sequence of the HGV polyprotein to
other flaviviruses showed limited identity to HCV type 1 (26.8%), GBV-B
(28.4%) or GBV-A (43.8%), indicating that HGV is not a new HCV genotype
(Linnen et al. 1996). A second HGV sequence of 9,103 nucleotides was isolated
from the plasma of an asymptomatic individual (R10291) with a history of
intermittent elevations in liver enzyme concentrations (Linnen et al. 1996). The
sample was serologically negative for both HBV and HCV and was also HCV
negative by RT-PCR. The sequence identity between PNF2161 and R10291
isolates was 90.5% at nucleotide level and 97.5% at amino acid level. However,
comparison of HGV and GBV-C indicated that the two isolates were 85.5%
nucleotide identical and 100% amino acid identical in the NS3 helicase region
(Linnen et al. 1996). The suggestion that HGV and GBV-C are independent
isolates of the same virus was subsequently confirmed by comparison of their
entire genomes which revealed amino acid and nucleotide sequence identities
of 95% and 85%, respectively (Zuckerman, 1996). The terminology HGV/GBV-
C will be used throughout this study.
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1.5 GENOME ORGANIZATION OF HGV/GBV-C
5'-UNTRANSLATED REGION
HGV/GBV-C genome is a single-stranded positive sense RNA molecule
of approximately 9,400 nucleotides with a single long open reading frame (ORF)
flanked by untranslated regions at both its 5' and 3'ends (Figure 1.1) (Simons
etal. 1995a; Leary etal. 1996a). The 5'-untranslated region (5'-UTR) is relatively
long (553 nucleotides) and has limited sequence identity to the 5'-UTR of GBV-
A but not with the 5'-UTRs of HCV, GBV-B or pestiviruses (Simons et al.
1996). Because this region contains many nucleotide deletions/insertions and
substitutions, no consistent ORF exists upstream of the El gene that would be
capable of encoding a core-like protein (Erker et al. 1996; Muerhoff et al. 1996;
Okamoto et al. 1997; Takahashi et al. 1997; Wang et al. 1997).
Although up to five potential in-frame AUG codons are present within
the 5'-UTR, the AUG codon located immediately upstream of the putative
signal sequence for El protein is considered to be the site of translation
initiation (Simons et al. 1996). This conclusion was reached following in vitro
transcription translation (IVTT) reactions ofmono-cistronic plasmids containing
5'-terminal fragments of the HGV/GBV-C with artificially introduced mutations
and sequencing of the protein products by Edman degradation. In addition, this
AUG codon which is situated downstream of an oligopyrimidine tract is
conserved amongst all HGV/GBV-C isolates and is in - frame with the putative
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HGV/GBV-C polyprotein (Muerhoff et al. 1996b; Simons et al. 1996b; Pickering
et al. 1997b; Takahashi et al. 1997b), suggesting that the translation initiation in
HGV/GBV-C RNA is achieved through an internal ribosome entry mechanism.
Internal entry of ribosomes is observed for HCV (Tsukiyama Kohara et al.
1992), pestiviruses (Poole et al. 1995) and picornaviruses (Jackson et al. 1994),
and is dependent on the existence of an internal ribosome entry site (IRES) or
ribosome landing pad (RLP) represented by a defined fragment of the 5'-UTR
sequence to which the 40S ribosome unit can bind in order to initiate 5'cap-
independent protein synthesis. The presence of IRES elements within
HGV/GBV-C 5'-UTR was demonstrated using bicistronic vectors containing the
5'-UTR fragment cloned between bacterial chloramphenicol acetyltransferase
(CAT) gene and luciferase (Luc) gene in IVTT reactions followed by analysis
of the protein products (Simons et al. 1996). However, under the experimental
conditions tested, the HGV/GBV-C IRES seems to have a very low activity (2-
5%) compared with the HCV IRES.
Thermodynamic and phylogenetic analysis of HGV/GBV-C 5'-UTR
sequences from different isolates predict that this region folds into an RNA
secondary structure (Simons et al. 1996b; Pickering et al. 1997b), with structural
elements that are similar to the 5'-UTR of GBV-A but distinct from those
predicted for HCV (Simons et al. 1996).
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3'-UNTRANSLATED REGION
The 3'-untranslated region (3'-UTR) of the HGV/GBV-C genome is
characterised by a high degree of sequence conservation with a similarity
between isolates of 94.6% to 98.4% (Erker et al. 1996; Okamoto et al. 1997), and
there is evidence for a conserved RNA secondary structure (Erker et al. 1996;
Okamoto et al. 1997; Katayama et al. 1998) . Unlike HCV, no poly(U) or
poly(A) tail has been identified at the 3'terminus of the HGV/GBV-C genome
(Erker et al. 1996; Leary et al. 1996; Linnen et al. 1996; Nakao et al. 1997;
Okamoto et al. 1997; Katayama et al. 1998).
CODING REGIONS
Like HCV and other members of the Flaviviridae, the ORF of
HGV/GBV-C encodes a single polyprotein with the structural genes located
towards the amino-terminus and non-structural genes containing helicase,
protease and RNA-dependent RNA polymerase (RdRp) motifs towards the
carboxyl-terminus. Phylogenetic analysis of NS3 helicase region from various
members of Flaviviridae family demonstrated that HGV/GBV-C is more closely
related to GBV-A than GBV-B or any of HCV genotypes (Figure 1.2) (Simons
et al. 1995a).
The precursor polyprotein of HGV/GBV-C is post-translationally cleaved
by a combination of host and viral proteases into structural and non-structural
proteins (Leary et al. 1996c). Comparisons with HCV have identified
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homologues of the putative El and E2 envelope proteins as well as conserved
eukaryotic signal sequence-like motifs at cleavage sites between the E1/E2 and
E2/NS2 genes (Erker et al. 1996; Leary et al. 1996; Takahashi et al. 1997). An
Asn-Cys-Cys motif is located near the amino-terminus of the putative El protein
in GBV-A, GBV-B, HGV/GBV-C and HCV-1 (Erker et al. 1996; Leary et al.
1996; Takahashi et al. 1997). Other conserved sites are a potential N-linked
glycosylation site in the El region and three in the E2 region, suggesting that
HGV/GBV-C envelope proteins are glycosylated during cellular processing
(Leary et al. 1996; Okamotoeia/. 1997; Takahashi et al. 1997; Wang et al. 1997).
However, there are fewer glycosylation sites than for HCV in which El and E2
have five-six or eight-eleven N-linked glycosylation sites, respectively (Miyamura
and Matsuura, 1993). Another difference between HCV and HGV/GBV-C
concerns the E2 gene which for HCV represents the most variable region of the
genome. Domains of extreme hypervariability (HVR) have been identified
(Hijikata et al. 1991a; Weiner et al. 1991a) with HVR-1, representing the amino-
terminal 25-30 amino acids of the E2 protein, being the most variable and
intensively studied region. The HVR of HCV-1 is thought to play a role in HCV
neutralisation (Taniguchi et al. 1993; Kojima et al. 1994). In contrast, sequence
analysis of HGV/GBV-C structural proteins reveals lower degree of variability
within the envelope proteins (at most 10%), with no evidence of "hypervariable"
regions, although amino acid substitutions are often present at the amino-
terminus of E2 (Erker et al. 1996; Takahashi et al. 1997; Wang et al. 1997). It
was even suggested that the amino-terminus of HGV/GBV-C E2 which contains
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two consecutive amino acid positions that are highly variable, could be exposed
on the virion surface and be recognised by antibodies (Takahashi et al. 1997).
However, other studies have failed to identify hypervariable regions in the E2
gene of HGV/GBV-C (Lim et al. 1997; Kato et al. 1998).
Another difference between the genome organization of HGV/GBV-C
and HCV is that the HGV/GBV-C genome does not appear to encode a
nucleocapsid or core protein. In the case of HCV, the viral core protein is
located at the amino-terminus of the polyprotein (Choo et al. 1991), being
released from it by proteolytic cleavage mediated by host signal peptidase
(Hijikata et al. 1991b). However, analysis of sequences upstream of the putative
El gene obtained from various HGV/GBV-C isolates revealed amino acid
fragments of variable length and composition, and sometimes absent (Erker et
al. 1996; Linnen et al. 1996; Muerhoff et al. 1996; Okamoto et al. 1997;
Takahashi et al. 1997; Wang et al. 1997; Katayama et al. 1998). This observation
suggests that HGV/GBV-C may assemble in a capsid-free particle or by using
a host-encoded protein or a protein encoded by a different virus (Takahashi et
al. 1997; Theodore and Lemon, 1997).
The degree of similarity between the non-structural domains of
HGV/GBV-C and HCV is much higher. For example, the Zinc-protease motif,
identified originally in the NS2 gene of HCV (Grakoui et al. 1993), was also
found in HGV/GBV-C (Linnen et al. 1996). The HCV NS2 protein was shown
to play a role in NS2/NS3 cleavage with its catalytic activity being affected by
mutations of certain amino acids (His952 and Cys993) (Grakoui et al. 1993). The
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amino acids essential for the protease activity of HGV/GBV-C NS2 have been
identified by mutation analysis using a baculovirus expression system (Belyaev
et al. 1998). Following infection of Sf21 insect (Spodoptera frugiperda) cells with
constructs either containing wild type (wt) NS2 protease or carrying mutations
His^g^Tyr or Cys890-^Leu in the NS2 active site. Cell proteins were separated
by SDS-PAGE and analysed by Western blotting with rabbit antisera raised
against the HGV/GBV-C NS2 peptide. In the wt construct, NS2 was efficiently
cleaved from NS3 since NS2 was the only product reacting with anti-NS2
antibodies, and there was no protein-associated reactivity at higher molecular
mass (Belyaev et al. 1998). In contrast, no free NS2 and NS3 products were
obtained on immunoblots of protein expressed from mutated constructs,
indicating that NS2 protein activity was required for the NS2/NS3 cleavage.
As in HCV, the carboxy-terminus of the HGV/GBV-C NS3 region
encodes a polypolypeptide containing amino acid residues that are conserved in
the helicases of supergroup II positive-strand RNA viruses (Leary et al. 1996b).
In particular, the amino-terminus contains a catalytic triad composed of
Histidine, Aspartic acid and Serine which are specific to chymotrypsin-like serine
proteases (Leary et al. 1996c; Linnen et al. 1996c). The proteolytic activity of
HCV NS3 protein was shown to be required for cleavages between NS3/NS4A,
NS4A/NS4B, NS4B/NS5A and NS5A/NS5B in order to release the
corresponding mature proteins (Bartenschlager et al. 1993; Grakoui et al. 1993;
Lin et al. 1994; Manabe et al. 1994). Similarly, site-directed mutagenesis of the
catalytic site serine of HGV/GBV-C NS3 has demonstrated that this serine
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protease is essential for cleavage of NS3/NS4, NS4/NS5A and NS5A/NS5B
(Belyaev et al. 1998). Efficient cleavage at NS4B/NS5A was dependent on the
presence of the NS4A protein as a cofactor for NS3 activity, as previously
described for HCV (Belyaev et al. 1998). Identification of the NS4A active
domain was achieved by making various truncations at both ends of the NS4A
region in recombinant baculovirus constructs and analysing the ability of these
constructs to complement the NS3-mediated cleavage of NS4B/NS5A. Western
blot analysis of NS4B/NS5A cleavage products using antibodies to the NS4B
peptide showed that the domain critical for NS4A activity is located between
Leu1561 and Ala1598 (numbered as in PNF2161 sequence) (Belyaev et al. 1998).
The similarity between HCV and HGV/GBV-C polyproteins also extends
throughout the NS5B region where a number of amino acids, which are
conserved in otherFlaviviridae members, have been identified in the HGV/GBV-
C NS5B domain (Leaiy et al. 1996c; Linnen et al. 1996c). In particular, the
amino acid motif Gly-Asp-Asp located within the NS5B region is characteristic
of all known RNA-dependent RNA polymerases (Kamer and Argos, 1984) and
so, HGV/GBV-C NS5B is presumed to be the viral polymerase (Leary et al.
1996c; Linnen et al. 1996c).
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1.6 DETECTION OF HGV/GBV-C
At present, detection of HGV/GBV-C is based on nucleic acid
amplification by RT-PCR. Degenerate oligonucleotide PCR primers designed
from a consensus sequence of NS3 helicase genes of HCV, GBV-A and GBV-B
were initially used to isolate GBV-C RNA from serum samples of eight patients,
of whom four had cryptogenic hepatitis (Simons et al. 1995a). Comparison of the
nucleotide sequences from these isolates indicated that they were 83-86%
identical. In order to improve the detection of HGV/GBV-C, degenerate PCR
primers for the NS3 region were designed based on a consensus sequence of
these eight isolates (Leaiy et al. 1996a). The primers were more efficient than
the original set when used in a "touchdown" PCR assay to detect HGV/GBV-C
sequences in human clinical samples from three different groups: non-A, non-E
hepatitis cases, individuals with indeterminant anti-HCV and IVDUs. For
example, in case of 62 HCV indeterminants (samples seropositive for a single
HCV marker (NS5) but negative for other antigens), the RT-PCR for
HGV/GBV-C RNA indicated that 6.5% of samples were positive with the
original set (Simons et al. 1995a), while 16.1% were positive with the consensus
primer pair (Leaiy et al. 1996a). However, nucleotide variation in coding regions
means that the use of primers derived either from NS3 (Simons et al. 1995a;
Leary et al. 1996a) or NS5A regions (Linnen et al. 1996) of HGV/GBV-C
genome could reduce the sensitivity of PCR assay since there might be
mismatches between primers and the cDNA template (Simons et al. 1995a).
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The RT-PCR-based detection of HGV/GBV-C has therefore been
optimised by identifying domains with a high degree of sequence conservation.
Nucleotide sequence alignments of 5'-UTR fragments obtained from different
individuals revealed the presence of such localized conserved domains (Jarvis et
al. 1996; Muerhoff et al. 1996; Schlueter et al. 1996; Chayama et al. 1997) and
comparison of 5'-UTR primer sets with NS3 (Jarvis et al. 1996; Muerhoff et al.
1996; Chayama et al. 1997) or NS5A primer sets (Schlueter et al. 1996) suggested
that they increase the sensitivity of HGV/GBV-C RNA detection in nested PCR
assays. For example, of 12 samples found to be HGV/GBV-C positive using
several different 5'-UTR primer sets, only 11 were positive using NS3 primers
(Muerhoff et al. 1996a). Similarly, HGV/GBV-C RNA was detected in 8 out of
50 Japanese patients with hepatocellular carcinoma (16%) using 5'-UTR primers
but only in 5 out of 50 (10%) when samples were tested with NS3-derived
primers (Chayama et al. 1997).
Efforts have also been made to develop specific immunoassays for the
identification of individuals showing an immune response to HGV/GBV-C
infection (PilotMatias et al. 1996; Dille et al. 1997; Tacke et al. 1997). In contrast
to PCR-based assays, the antibody prevalence to HGV/GBV-C has proved
difficult to assess. Initially, attempts were made to identify immuno-reactive
epitopeswithin HGV/GBV-Cviral polyprotein (PilotMatias et al. 1996). Regions
covering the large ORF of HGV/GBV-C genome were cloned and then
expressed in E.coli as fusion proteins. These proteins were examined for
immuno-reactivity by Western blot analysis using sera from GB agent-infected
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tamarins, original GB serum and sera from different individuals considered at
risk for parenteral exposure. Although none of the HGV/GBV-C fragmentswere
reactive with either GB-infected tamarin serum or GB serum, fragments
spanning NS3-NS5B region were reactive with one or the other of two sera from
individuals with or at risk for nonA-E hepatitis (PilotMatias et al. 1996).
Epitopes within these potential immuno-reactive fragments were mapped by
generating small overlapping clones by PCR and expressing them as fusion
proteins to be tested by Western blot. As a result, four specific regions within
the NS3, NS4A/B and NS5A/B proteins of HGV/GBV-C were found to be
immuno-reactive although reactivity with some of the sera tested was weak and
inconsistent (PilotMatias et al. 1996).
Similar results were obtained in another study (Dawson et al. 1996) in
which three HGV/GBV-C recombinant proteins spanning NS3 through a portion
of NS5B region (PilotMatias et al. 1996) and two additional ones encoding E2
and NS5A gene fragments respectively, were used as antigens in ELISA assays
to detect the presence of antibodies in samples which were PCR-positive for
HGV/GBV-C RNA. Of 43 samples, 11 (25.6%) were antibody-positive for
HGV/GBV-C proteins, but no antigen was consistently recognised and, in almost
all cases, each serum was reactive with only one of the recombinant proteins
(Dawson et al. 1996). However, the prokaryotically expressed HGV/GBV-C
recombinant proteins used as antigens in these ELISAs did not represent their
native conformation since they were not glycosylated (in case of E2 fragment)
or they had abnormal amino or carboxyl termini. These modifications could
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significantly affect the secondary structure of the proteins and, so, alter
conformational epitopes, possibly explaining the lack of correlation between
HGV/GBV-C RNA detection and an antibody response to HGV/GBV-C
proteins.
Two research groups investigated the possibility of developing an ELISA
assay specific for antibodies to HGV/GBV-C E2 protein (Dille et al. 1997; Tacke
et al. 1997) following a similar approach used to validate the presence of
antibody to the HCV E2 protein as a useful marker of HCV infection
(Lesniewski et al. 1995). Recombinant plasmids containing a DNA fragment
encoding the HGV/GBV-C E2 protein were transfected into dihydrofolate
reductase deficient Chinese hamster ovary (CHO) cells (Dille et al. 1997a;
Surowy et al. 1997a; Tacke et al. 1997a). Two approaches have been carried out
in designing the expression construct. In the first report, the E2 fragment was
cloned downstream from a sequence encoding an eight-amino acid peptide
(FLAG) (Tacke et al. 1997a). After expression, solubilised protein was bound to
a streptavidin-coated ELISA plates using the biotin-conjugated FLAG-specific
antibody Ml. The plates were then incubated with samples of human sera and
antibodies to the HGV/GBV-C E2 protein detected using anti-human IgG-
peroxidase conjugate (Tacke et al. 1997a). In the second approach, the
HGV/GBV-C E2 sequence was cloned into a plasmid so as to encode a carboxy-
terminal truncated form of the protein in which a hydrophobic tail that might
prevent secretion was replaced with the FLAG sequence (Dille et al. 1997;
Surowy et al. 1997). After expression, the E2 protein was purified on an
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immuno-affinity column containing anti-FLAG monoclonal antibody. Purified
E2 protein was then coated onto polystyrene beads and dilutions of human sera
were tested for the presence of specific antibodies (Dille et al. 1997; Surowy et
al. 1997). Treatment of purified protein with N-Glycanase under both denaturing
and native conditions indicated that the secreted protein was N-glycosylated
while amino-terminal amino acid sequencing confirmed that the proper protein
was expressed (Surowy et al. 1997).
These assays were used to screen serum samples from population groups
such as volunteer blood donors, IVDUs and nonA-E hepatitis patients (Dille et
al. 1997; Surowy et al. 1997; Tacke et al. 1997). Surprisingly, antibodies to
HGV/GBV-C E2 protein were detected in individuals with a high risk for
parenterally-transmitted viruses but who were not viraemic (PCR-negative for
HGV/GBV-C RNA). For example, the prevalence of antibodies to E2 was
relatively low (3.0%-8.1%) in volunteer blood donors but was higher in IDVUs
(85.2%), and West African residents (13.3%), but all were PCR-negative for
HGV/GBV-C RNA (Dille et al. 1997). Similar findings were reported in other
studies and suggest that a humoral immune response to the HGV/GBV-C E2
protein is associated with viral clearance (Surowy et al. 1997; Tacke et al. 1997).
As a consequence and unlike HCV infection where anti-E2 antibodies and RNA
occur together (Lesniewski et al. 1995), antibodies to HGV/GBV-C E2 can be
considered as a marker for recovery from HGV/GBV-C infection.
The specificity of these E2 immuno-assays was assessed by testing
sequential samples obtained from eleven patients with post-transfusion hepatitis,
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seven of which were PCR-positive for both HCV RNA and HGV/GBV-C RNA
(Tacke et al. 1997a). All the patients were initially anti-E2 negative, while four
individuals developed antibodies to HGV/GBV-C E2 during the following year,
two of whom became HGV/GBV-C RNA negative while no cross-reacting
antibodies to HCV E2 could be detected.
An improved ELISA for the detection of antibodies to HGV/GBV-C E2
is based on the use of monoclonal antibodies to HGV/GBV-C E2 as capture
antibodies (Tacke et al. 1997b) instead of anti-FLAG monoclonal antibodies
(Tacke et al. 1997a). With this assay, several sera in a panel of 16 post¬
transfusion patients followed up for 16 years were found to be HGV/GBV-C E2
positive that had been found to be anti-E2 negative with previous assay.
However, an inverse correlation was still observed between the presence of viral
RNA and antibodies to E2. In addition, this study suggests that immunity to
HGV/GBV-C may be long-lasting since circulating antibodies to E2 could still
be detected 14 years after seroconversion (Tacke et al. 1997b).
1.7 EPIDEMIOLOGY
1.7.1 PREVALENCE OF HGV/GBV-C INFECTION
Since the discovery and characterisation ofHGV/GBV-C virus, there have
been numerous studies of the prevalence of HGV/GBV-C in different
population groups based on RT-PCR assays using primers derived from different
regions of the viral genome.
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The prevalence of viraemia amongst healthy blood donors from various
countries of the world ranges from 0.5% to 1.7% (Dawson et al. 1996; Linnen
et al. 1996; Orito et al. 1996; Feucht et al. 1997; Wang et al. 1997). Higher rates
have been found in British (3.2%) (Jarvis et al. 1996), Australian (4%) (Moaven
et al. 1996a) and Vietnamese blood donors (7.4%) (Brown et al. 1997a). In
contrast, the rate of active infection with HCV in similar populations was much
lower, at between 0.01-1% (Jarvis et al. 1996; Linnen et al. 1996; Wang et al.
1997). These data imply that HGV/GBV-C would be present in blood products
prepared from large plasma pools such as clotting factor concentrates and
immunoglobulin batches (Jarvis et al. 1996; Linnen et al. 1996; Nubling and
Lower, 1996; Feucht et al. 1997; Sheng et al. 1997). Investigations revealed that
HGV/GBV-C RNA was present in 94% of non-virus-inactivated factor VIII
concentrates compared to 6% of heat- or solvent-detergent-treated concentrates
(Jarvis et al. 1996) and in 7-40% of commercial plasma pools used for
production of blood products (Nubling and Lower, 1996). Similarly, 33-44% of
immunoglobulin preparations were found to be contaminated with HGV/GBV-C
(Jarvis et al. 1996; Nubling and Lower, 1996), although only 4 of 57 (7%)
immunoglobulin recipients were found to be positive for viral RNA (Jarvis et al.
1996). The presence of HGV/GBV-C RNA has also been investigated in serum
samples from haemophiliacs since these patients have been exposed to unheated
and/or dry heated pooled clotting factor concentrates, and have been found to
have high frequencies of HCV infection, and to be at risk of developing chronic
hepatitis (Watson et al. 1992). Studies have revealed that 14-35% of
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haemophiliacs treated with non-virus-inactivated concentrates were positive for
HGV/GBV-C RNA (Jarvis et al. 1996; Linnen et al. 1996; Feucht et al. 1997;
Sheng et al. 1997) while 83% were found to be infected with HCV (Jarvis et al.
1996). The difference in the prevalence of HCV and HGV/GBV-C in
haemophiliacs suggests that recovery from HGV/GBV-C infection could be a
more frequent event than recovery from HCV infection (Jarvis et al. 1996). This
hypothesis is supported by later studies reporting that the presence of antibodies
to the HGV/GBV-C E2 protein, considered as a marker of recovery from
viraemia (Tacke et al. 1997a), are detected in 58% of haemophiliacs
(Karayiannis et al. 1997b).
A high rate of HGV/GBV-C viraemia was also observed amongst other
groups of individuals with risk factors for viral transmission by blood such as
IVDUs (16-49%, with 54-100% coinfected with HCV) (Dawson et al. 1996;
Linnen et al. 1996; Schreier et al. 1996; Diamantis et al. 1997; Feucht et al. 1997),
haemodialysis patients (3.1-55%, with 44-81% coinfected with HCV) (Masuko
et al. 1996; Tsuda et al. 1996; Feucht et al. 1997; Wang et al. 1997) and multiply
transfused patients with aplastic anaemia (Simons et al. 1995b; Brown et al.
1997b). The virus can produce persistent infections since HGV/GBV-C RNA
remained detectable in haemodialysis patients for up to 16 years (Masuko et al.
1996).
However, these epidemiological studies based on RT-PCR assays are
limited because they only give information about individuals or groups with
HGV/GBV-C viraemia. Serological tests indicate that the appearance of an
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antibody response to the envelope protein E2 of HGV/GBV-C generally
coincide with the decline and loss of viraemia (Dille et al. 1997a; Tacke et al.
1997a). In addition, population surveys revealed that the prevalence of anti-E2
was higher than that of HGV/GBV-C RNA in various groups (Dille et al. 1997;
Gutierrez et al. 1997; Lou et al. 1997; Ross et al. 1998). As a result, in order to
evaluate the total exposure to HGV/GBV-C infection in a population, assays for
both HGV/GBV-C RNA and HGV/GBV-C E2 antibody must be carried out.
In European countries, anti-E2 seropositivity ranges from 10.9% (Germany) to
15.3% (Austria) while higher rates have been recorded in South Africa (20.3%)
and Brazil (19.5%) (Ross et al. 1998). Total exposure, considered as a sum of
HGV/GBV-C RNA positive and anti-E2 positive samples, has been estimated
at between 5.5% (Gutierrez et al. 1997) and 8-13% (Lou et al. 1997) in
American volunteer blood donors and even higher in commercial blood donors
(40.5-50%) (Gutierrez et al. 1997; Lou et al. 1997), IVDUs (89.2%) and acute
HCV patients (70.7%) (Gutierrez et al. 1997). At the same time, the fact that
the exposure rate is higher than the active infection rate (e.g. 3 to 6 times higher
in volunteer donors) suggests that more than half of those infected with
HGV/GBV-C eventually clear the virus (Dille et al. 1997; Gutierrez et al. 1997;
Tacke et al. 1997). However, more studies are necessary to assess whether
antibodies to HGV/GBV-C E2 are protective against HGV/GBV-C reinfection.
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1.7.2 TRANSMISSION OF HGV/GBV-C
A conclusion common to these different epidemiological studies is that
there is an association between the presence of HGV/GBV-C RNA and
exposure to blood or blood products. A parenteral route of transmission was
first suggested by the observation that transfusion recipients negative for
HGV/GBV-C RNA prior to transfusion became HGV/GBV-C RNA positive
afterwards (Linnen et al. 1996). In a larger study of 400 adults who underwent
cardiac surgery, transfusion-related HGV/GBV-C infection was identified in 9%
of patients (Wang et al. 1996). In addition, a high rate of HCV and/or HBV
coinfection has been identified in HGV/GBV-C positive individuals emphasizing
the common parenteral mode of transmission for these viruses. For example, the
presence of HGV/GBV-C RNA was reported in 5.6-24.4% of chronic HCV
patients (Dawson et al. 1996; Linnen et al. 1996; Tanaka et al. 1996; Feucht et
al. 1997; Kao et al. 1997; Saiz et al. 1997; Pawlotsky et al. 1998), in 3.2-9% of
chronic HBV carriers (Linnen et al. 1996; Kao et al. 1997) and in 18.2-32% of
individuals with HIV infection (Feucht et al. 1997; Fiordalisi et al. 1997).
However, the higher prevalence ofHGV/GBV-C RNA in volunteer blood
donors than that of HCV suggested that alternative routes of viral transmission
may be responsible for the maintenance of virus at this rate in the general
population (Moaven et al. 1996; Chen et al. 1997; Fischler et al. 1997; Rubio et
al. 1997; Scallan et al. 1998). Mother-to-baby transmission was examined as a
potential mechanism of HGV/GBV-C infection. Preliminary evidence for this
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hypothesis was provided by a case of a mother who was HGV/GBV-C RNA
positive before and at delivery and whose baby tested HGV/GBV-C RNA
negative at birth but was positive at four and six weeks of age (Moaven et al.
1996b). Other studies involving follow-up of children of pregnant women,
considered as being at risk for parenterally-transmitted viruses, showed that
HGV/GBV-C infection was transmitted efficiently from mother to baby and that
the rate of transmission was much higher than that of HCV or HIV-1 (Feucht
et al. 1996; Zanetti et al. 1998). A similar study of women coinfected with HCV
and HGV/GBV-C suggested that HGV/GBV-C transmission from mother to
baby can occur independently of HCV transmission (Fischler et al. 1997). None
of these studies described any clinical or biochemical signs of liver disease in
HGV/GBV-C infected babies (Feucht et al. 1996; Fischler et al. 1997; Zanetti et
al. 1998).
The possibility of sexual transmission of HGV/GBV-C has also been
investigated. HGV/GBV-C RNAwas detected in 13.9-21% of prostitutes (Rubio
et al. 1997; Wu et al. 1997) and in 13.4% of homosexual men (Rubio et al. 1997).
The prevalence of HGV/GBV-C infection was significantly higher in
heterosexual partners of HGV/GBV-C infected index cases (individuals with
elevated ALT levels and/or at risk for parenterally/sexually transmitted viral
disease) than in HGV/GBV-C negative index patients (21.7% versus 6.2%)
(Rubio et al. 1997). More evidence for the spread of virus by the sexual route
was revealed in a recent study in which the combined frequencies of HGV/GBV-
C viraemia and anti-E2 antibody were measured and used to estimate total
33
exposure to the virus of individuals at risk for sexually transmitted diseases
(Scallan et al. 1998). The frequency of total exposure was higher in prostitutes
(40%) compared to the control group (5%) while amongst homosexual men, the
total exposure to the HGV/GBV-C in HIV-positive individuals was 63%
compared with 37% in HIV-negative individuals. A higher frequency of
persistent infection was also observed among HIV-positive male homosexuals
from whom retrospective samples were available since 7 of 11 retrospective
samples were PCR positive for HGV/GBV-C.
HGV/GBV-C RNA has been detected in saliva samples of some infected
individuals (Chen et al. 1997; Blair et al. 1998). Two saliva samples and six serum
samples collected from 34 patients with chronic HCV infection were found to
be positive for HGV/GBV-C RNA by RT-PCR, suggesting that saliva from
HGV/GBV-C infected individuals may be infectious (Chen et al. 1997). In the
other study, HGV/GBV-C was detected at relatively high levels (mean level,
8 x 103 RNA copies/ml) in 13 of 17 saliva samples collected from HGV/GBV-C
viraemic volunteer blood donors who were seronegative for HIV, HBV and
HCV (Blair et al. 1998). However, further studies are required to investigate
whether secretion of HGV/GBV-C in saliva may be considered a route of
transmission.
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1.7.3 HGV/GBV-C AND LIVER TRANSPLANTATION
HGV/GBV-C RNA has been detected in HCV infected and HCV/HBV
coinfected liver transplant recipients both before and after operation at
frequencies of 15% and 44-53%, respectively (Dickson et al. 1997; Fried et al.
1997; Haagsma et al. 1997; Vargas et al. 1997). The increase in the frequency of
infection after transplantation has been attributed to blood transfusions received
by patients during operation. However, HGV/GBV-C infection did not seem to
influence the outcome of liver transplantation in these patients (Dickson et al.
1997; Fried et al. 1997; Haagsma et al. 1997; Vargas et al. 1997).
1.7.4 DISEASE ASSOCIATION
The detection of HGV/GBV-C in sera from patients with hepatitis of
unknown aetiology suggested that HGV/GBV-C might be responsible for some
cases of nonA-E hepatitis (Simons et al. 1995a; Linnen et al. 1996a). HGV/GBV-
C RNA was found in 23% of patients with post-transfusion non-A, non-E
hepatitis from the USA and Australia, in 9.5% of patients with chronic non-A,
non-C hepatitis (Linnen et al. 1996), and in 35% of Italian patients with acute
non-A, non-E hepatitis (Fiordalisi et al. 1996). In addition, HGV/GBV-C
infection was associated with cases of fulminant hepatitis of unknown aetiology
in a study where three of six patients with fulminant hepatitis and without
evidence of infection with known hepatitis viruses were found to be positive for
HGV/GBV-C RNA (Healey et al. 1995). It has also been suggested that a
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specific strain of HGV/GBV-C might be associated with fulminant hepatic
failure since a specific sequence motif within the HGV/GBV-C NS3 region
containing six nucleotide mutations was identified in all of eleven German
patients with fulminant hepatic failure (Heringlake et al. 1996). However, it is
difficult to assess the role of HGV/GBV-C in the development of these cases
since such patientswould have received multiple transfusions before testing (Kao
et al. 1996a). Another study in Japan showed that HGV/GBV-C RNA was not
detected in any of the pre-transfusion sera collected from ten non-A, non-E
fulminant hepatitis patients (Kanda et al. 1997); after fresh frozen plasma was
transfused to these patients, four of them were found to be HGV/GBV-C RNA
positive, suggesting that HGV/GBV-C was transmitted by transfusion, and so
was not the causative agent.
Other clinical studies have also indicated a lack of causative association
between HGV/GBV-C infection and liver disease. The rate of HGV/GBV-C
viraemia in blood donors with raised serum ALT levels was reported to be the
same as in those with normal ALT levels (Linnen et al. 1996; Leucht et al. 1997),
although another report showed a significant difference (0.8% positive for
HGV/GBV-C RNAwith normal ALT versus 3.9% with elevated ALT) (Dawson
et al. 1996). An extensive retrospective study in which the prevalence, clinical
features, incidence and natural history of HGV/GBV-C were investigated in a
large sample of the Scottish donor population indicated that although there was
a relatively high incidence ofHGV/GBV-C infection (170-200 new infections per
100,000 donor-years), no evidence for hepatitis or for shared nonhepatic disease
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could be identified by clinical examination of the infected donors (Blair et al.
1998).
Of 16 HGV/GBV-C positive patients on dialysis with persistent
HGV/GBV-C viraemia, none had elevated ALT levels or clinical evidence of
liver disease (Masuko et al. 1996) and similar observations were made in
prospective studies of HGV/GBV-C infected transfusion recipients (Alter et al.
1997).
No significant differences have been observed between HGV/GBV-C
infected and non-infected patients with chronic hepatitis C virus infection with
regard to liver function tests, level of viraemia or biochemical response to
interferon (Berg et al. 1996; Tanaka et al. 1996; Saiz et al. 1997; Enomoto et al.
1998; Pawlotsky et al. 1998). HGV/GBV-C seems to be sensitive to interferon
alpha treatment but the response is usually transient, with a relapse after therapy
ceases (Karayiannis et al. 1997a; Saiz et al. 1997a; Pawlotsky et al. 1998a).
Because the level of serum ALT does not necessarily correlate with the
severity of liver disease, the role of HGV/GBV-C in the pathogenesis of chronic
liver disease has also been investigated in various population groups by
histological examination (liver biopsy and laparoscopic liver inspection) (Bralet
et al. 1997; Fried et al. 1997; Haagsma et al. 1997; Sarrazin et al. 1997; Hanley
et al. 1998). No association between the severity of liver disease and HGV/GBV-
C viraemia was identified in a cohort of haemophiliacs previously exposed to
non-virus-inactivated coagulation factor concentrates (Hanley et al. 1998). A
similar conclusion was reached in a study of patients with elevated
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aminotransferase levels of unknown aetiologywhere the histological examination
indicated minimal inflammatory activity in both HGV/GBV-C-positive and
-negative individuals (Sarrazin et al. 1997). In the case of liver transplantation
patients, the presence of HGV/GBV-C infection seemed to have a minimal
influence on the clinical outcome. Comparison of hepatic histology showed
similar degrees of inflammation and fibrosis between HGV/GBV-C-positive and
-negative patients whether or not they were coinfected with HCV (Fried et al.
1997; Haagsma et al. 1997; Pessoa et al. 1997).
1.8 QUESTIONS TO BE ANSWERED
Despite extensive epidemiological studies, research into the molecular
characterisation of HGV/GBV-C and the clinical significance of HGV/GBV-C
infection are at an early stage. At the same time, no definitive conclusions can
be made regarding the virus heterogeneity, although some investigations into the
sequence diversity of the HGV/GBV-C have been carried out (Muerhoff et al.
1996; Muerhoff et al. 1997; Wang et al. 1997). To address this issue, a detailed
analysis was carried out of the phylogenetic HGV/GBV-C groupings obtained
by comparison of all currently available complete genome sequences together
with examination into the phylogenetic relationships between 5'-UTR sequences
from different HGV/GBV-C isolates. Additionally, variation in the HGV/GBV-C
5'-UTR was examined in detail in order to establish its implications for
secondary structure and virus classification (Chapter 3. "Identification of
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HGV/GBV-C variants by phylogenetic analysis of the 5'-UTR").
Although the genome organization of HGV/GBV-C resembles that of
HCV, several interesting questions about the virus structure are still to be
answered. The potential lack of a core protein encoded usually at the amino
terminus of the polyprotein in flaviviruses together with the limited degree of
variation amongstHGV/GBV-C variants suggested by preliminary studies (Erker
et al. 1996; Linnen et al. 1996; Okamoto et al. 1997) could have a major effect
upon virus pathogenicity and its interaction with the host immune system.
Chapter 4 "Buoyant density and sedimentation behaviour of HGV/GBV-C"
examines the physicochemical properties of HGV/GBV-C particles by
comparison to those of HCV. The presence of the core protein is also
investigated by analysing the amino acid sequences of the putative core region
of HGV/GBV-C complete genome sequences from different phylogenetic
groupings.
At the same time, very little is known concerning the specific features of
the terminal regions of HGV/GBV-C genome, which can contain structural
elements critical for viral RNA replication, transcription, translation and viral
packaging. One way to determine the characteristic structural elements of the
HGV/GBV-C 3'-UTR was to perform a comprehensive comparative analysis of
the primary sequence and secondary structure ofvarious 3'-UTR sequences. This
has also led to the construction of a consensus secondary structure model for the
whole 3'-UTR of the HGV/GBV-C genome (Chapter 5. "Analysis of the primary
and secondary structure of the HGV/GBV-C").
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Nothing is really known about the cellular tropism of HGV/GBV-C.
Initially, the virus was considered "hepatotropic" and thought to be associated
with human liver disease although the site of HGV/GBV-C replication had not
been identified. The absence of a cell system for virus culture in vitro represents
a major impediment to the investigation of the mechanisms of replication and
pathogenicity of the HGV/GBV-C virus. To address this problem, the
susceptibility of different cultured cells to HGV/GBV-C infection was tested and
analysed (Chapter 6).
Finally, the results of the study described in this thesis may be considered
as answers to these crucial questions regarding HGV/GBV-C.
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CHAPTER 2
2. MATERIALS AND METHODS
2.1 DENSITY GRADIENT ULTRACENTRIFUGATION
Density gradient ultracentrifugation allows not only the complete
separation of several or all the components in a mixture, it also permits
analytical measurements to be made.
This method involves a supporting column of fluid whose density
increases towards the bottom of the centrifuge tube. The density gradient fluid
consists of a suitable low molecular weight solute in a solvent in which the
sample can be suspended. Each component will sediment only to the position
in the centrifuge tube at which the gradient density is equal to its own density,
and there it will remain. In this experiment, sucrose (AnalaR-BDH) was chosen
as a density material for preparing the density gradient because of its lack of
influence upon the stability of viral particles (Miyamoto et al. 1992). A stepwise
density gradient was produced ranging from 10% to 60% (w/w) sucrose in TEN
buffer (50 mM Tris-HCl pH 8.0, 1 mM EDTA, 150 mM NaCl) as follows: 1 ml
of 60% and 0.7 ml each of 50, 40, 30, 20 and 10% sucrose. Each serum sample
(0.5 ml) was layered on top of 5 ml of sucrose gradient and centrifuged at 27,800
rpm for 44 h at 10°C in a Beckman SW50.1 ultracentrifuge rotor. 10 fractions
(0.5 ml each) were collected from the bottom of each centrifugation tube and
the density of each fraction was determined from its refractive index using an
Abbe refractometer. Viral RNA was extracted from 100 /xl of each fraction by
41
Proteinase K method (section 2.2.1). Reverse Transcription (RT) and nested
Polymerase Chain Reaction (PCR) were carried out using primers specific for
5'-UTR of HCV and 5'-UTR of HGV/GBV-C, respectively as described in
sections 2.2.3 and 2.2.4.
2.2 POLYMERASE CHAIN REACTION
2.2.1 EXTRACTION OF VIRAL RNA FROM SERUM SAMPLES
Viral RNA was extracted by incubating 100 /xl of serum sample with 400
li1 of lysis buffer (50 mM Tris-HCl pH 8.0, 0.1 M NaCl, 0.5% SDS, 1 mM
EDTA, 40 /xg/ml polyadenylic acid, 1 mg/ml proteinase K) at 37°C for 90 min.
450 /xl of phenol (Rathburn Chemicals Ltd.) was then added to each extraction
tube and mixed thoroughly. After centrifugation at 15,000rpm for 10 min, the
aqueous layer was transferred to a new eppendorf tube containing 450 /xl of
chloroform :isoamylalcohol (50:1). This mixture was again vortexed thoroughly
and centrifuged at 15,000rpm for 10 min. The aqueous layer was transferred to
a new eppendorf tube. The nucleic acid was precipitated overnight at -20°C by
the addition of one tenth volume of sodium acetate (pH 5.2) and 2 volumes of
ice-cold 100% ethanol (AnalaR) to the extraction tube. The nucleic acid extract
was collected by centrifugation at 15,000rpm at 0°C for 15 min. The pellet was
then washed with ice-cold 80% ethanol and air-dried at 42°C for 15 min. The
dried pellet was resuspended in 25 /xl of diethylpyrocarbonate-treated water
(DEPC-water). During each extraction process, aliquots of known positive and
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negative serum samples (controls) were included in order to ensure that no
contamination was present.
The same RNA extraction method was performed to isolate RNA from
each supernatant sample obtained from cultured cells at different times of
collection and sampling ( section 2.5.2).
2.2.2 EXTRACTION OF RNA FROM CULTURED CELLS
The purity and integrity of RNA isolated from tissue or cultured cells are
critical for its effective use in application as RT-PCR (sections 2.2.3 and 2.2.4).
The RNA was extracted from cell pellets obtained at each time of collection and
sampling (section 2.5.2) using RNAgents Total RNA Isolation System (Promega)
according to the manufacturer's instructions. This system uses two potent
inhibitors of RNase, guanidine thiocyanate and /3-mercaptoethanol. In addition,
all procedures were performed on ice to significantly slow the rate of RNA
degradation. 30 /xl of 2 M sodium acetate (pH 4.0) was added to each cell pellet
previously homogenized in 300 jj\ of denaturing solution (26 mM sodium citrate
pH 4.0, 0 .5% N-laurylsarcosine, 0.125 M /3-mercaptoethanol, 4 M guanidine
thiocyanate) at different times of collection and sampling (section 2.5.2). The
mixture was mixed thoroughly by inverting the tube 4-5 times. 300/xl of
phenol:chloroform:isoamylalcohol (125:24:1), pH 4.7 was then added to the
extraction tubes. After mixing carefully and shaking vigorously for 10 s, the tubes
were kept on ice for 15 min. Following this, the tubes were centrifuged at
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15,000rpm at 4°C for 20 min and the top aqueous phase was carefully removed
to a new tube. The RNA was extracted from the aqueous layer by precipitation
with an equal volume of isopropanol overnight at -20°C. The nucleic acid was
then collected by centrifugation at 15,000rpm at 4°C for 20 min and washed with
ice-cold 80% ethanol. The pellet obtained after a second centrifugation was air-
dried and resuspended in 30 /xl of nuclease-free water.
2.2.3 REVERSE TRANSCRIPTION OF VIRAL RNA
DNA can be amplified from a single-stranded RNA template by
combining a standard PCR protocol with an initial reverse transcriptase reaction.
Synthesis of complimentary DNA (cDNA) was carried out at 42°C for 30 min
using 5 fi\ of extracted RNA, 10 units of avian myeloblastosis virus reverse
transcriptase AMV (Promega) and 1.5 /jlM of the outer, antisense primer (used
in the corresponding PCR as well) in 20 /xl buffer containing 50 mM Tris-HCl
pH 8.0, 5 mM MgCl2, 5 mM DTT, 50 mM KC1, 0.05 /xg//xl BSA, 15% DMSO,
600 /xM each of dGTP, dATP, dTTP, dCTP and 10 units RNAsin (Rnase
inhibitor, Promega). The samples were then heated to 98°C for 2 min to heat-
inactivate the reverse transcriptase. Prior to transfer to the thermal cycler
Techne GeneE for this reaction, each sample was covered with a drop of liquid
paraffin to prevent loss of sample mixture because of evaporation.
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2.2.4 HOT START PCR AMPLIFICATION
The Polymerase Chain Reaction (PCR) is a technique for the in vitro
amplification of specific DNA sequences by the simultaneous primer extension
of complementary strands of DNA. Problems with PCR sensitivity can arise
especially when dealing with low-copy number nucleic acid template. Using
nested PCR, the sensitivity and specificity of viral RNA amplification is
considerably improved. In this method, the PCR is repeated using a pair of
specific primers lying within the sequence within the sequence originally
amplified by an external pair of primers. The first PCR was carried out with 5
l±\ of cDNA (section 2.2.3) and 0.4 units of DNA Taq polymerase (Promega) in
50 jj\ PCR reaction buffer containing 50 mM KC1, 10 mM Tris-HCl pH 9.0,
Triton X-100, 1.5 mM MgCl2, 30 pM each of dGTP, dATP, dTTP, dCTP and
0.25 /xM of each of the outer primers (sense and antisense primers, respectively).
The second PCR was carried out in a 20 /xl volume for each sample,
containing 1 jA of primary PCR product, 8 /xM of each of the inner sense and
antisense primers, and 0.4 units of DNA Taq polymerase (Promega) in PCR
reaction buffer. Each sample was covered with a drop of liquid paraffin before
being transferred to Techne GeneE thermal cycler .
The conditions for the first round of PCR were hot start at 80°C for 2
min to enhance the specificity of the process followed by 30 cycles of 94°C for
18 s to allow denaturation of cDNA template, 55°C (for amplification of 5'UTR
of HCV and HGV/GBV-C, core region of HCV and NS-3 region of HGV/GBV-
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C) or 58°C (for amplification of 3'UTR of HGV/GBV-C) for 21 s to allow
primer annealing to single-stranded DNA and 72°C for 90 s to allow strand
extension. At the end of the last cycle, samples were heated to 72°C for 5 min
to allow termination of incomplete strands.
The second round of PCR was carried out for the same number of cycles
on the same thermal cycler at 94°C for 18 s, 55°C for 21 s and 72°C for 90 s. In
order to amplify 3'UTR of HGV/GBV-C-for further cloning and sequencing-
heminested PCR amplification was performed; the antisense primer was used as
outer as well as inner primer. The nucleotide sequences of the primers used for
cDNA synthesis and PCR amplification are described in Table 2.1. They were
synthesized by Oswell DNA Service, Department of Chemistry, University of
Edinburgh.
During each RT-PCR amplification, known positive and negative controls
were included in order to ensure that no contamination was present.
2.2.5 STRAND-SPECIFIC PCR AMPLIFICATION
In order to detect whether the replicative intermediates of HCV and
HGV/GBV-C were present in the infected cells (section 2.5.2), a sensitive
strand-specific nested PCR developed and validated by Mellor et al. (Mellor et
al. 1998) was performed. The primers for the putative core region of HCV and
for the NS3 region of HGV/GBV-C used in this modified nested PCR
amplification are listed in Table 2.1. A 'tag' sequence of 20 nucleotides
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Table 2.1
Primers used for PCR amplification of HCV and HGV/GBV-C
Primers Orientation Primer sequence Reference
5' 3'
HCV 5'-UTR
209 O/AS ATACTCGAGGTGCACGGTCTACGAGACCT *
939 O/S CTGTGAGGAACTACTGTCTT
211 I/AS CACTCTCGAGCACCCTATCAGGCAGT *
940 I/S TTCACGCAGAAAGCGTCTAG *
CORE
410 O/AS ATGTACCCCATGAGGTCGGC #
954 O/S ACTGCCTGATAGGGTGCTTGCGAG #
951 I/AS CAYGTRAGGGTATCGATGAC #
381 I/S CAGATCGTTGGYGGAGT +
380 O/AS-T TCATGGTGGCGAATAAATGTACCCCATGAGGTCGGC +,§





























3053 O/AS YTCRTTGATGATGGAACTGTC ll
3052 O/S ATCCCCTTTTATGGGCATGG t)
291 I/AS TCYTTWCCCCTRTAATAGGC +
290 I/S CCCTCGAGCGKATGMGRAC +
289 O/S-T TCATGGTGGCGAATAAATCCCCTTTTATGGGCAT + ,§
288 O/AS-T TCATGGTGGCGAATAAYTCRTTGATGATGGAAC + >§
3'-UTR
Z3580 O/S GGTGGTNCATCAATTGGATT this work
Z3281 I/S GGTTCTTAGCCCTGCTGATC this work
Z3282 O&I/AS AGTAGAACCCGGCCTTTGGG this work
* Chan et ah, 1992. \\ Mellor et al., 1998.
# Mellor et al., 1992. § 'Tagged'-primers used in strand-specific PCR (section 2.2.5)
IjJarvis et al., 1996. Y = C,T
R = A,G
unrelated to any part of HCV or HGV/GBV-C genomes was present at the
5'end of each outer primer in order to avoid the amplification of falsely primed
cDNA products. For this purpose, PCR amplification of a tagged cDNA was
performed using only the tag portion of the cDNA primer as one of the primers
and an HCV- or HGV/GBV-C-specific oligonucleotide for the opposing primer.
For example, to amplify negative strand HCV cDNA, primer 379 (Table 2.1) was
used while antisense primer 380 (Table 2.1) was used for positive strand
synthesis. In case of HGV/GBV-C, primers 288 and 289 (Table 2.1) were used
for positive and negative strand, respectively. In the first round of PCR, the tag
sequence alone together with the untagged opposing primer were used (e.g., for
HCV negative strand, the tag sequence was the sense primer and 410 was the
antisense primer; for HGV/GBV-C negative strand, the tag sequence was the
sense primer and 3053 was the antisense one).
The PCR conditions were highly stringent, including pre-denaturation of
the template RNA at 70°C for 10 min prior to addition of AMV reverse
transcriptase at 42°C, heat-inactivation of the enzyme at 98°C for 10 min after
RT reaction followed by HS-PCR (section 2.2.4) to reduce further non-specific
priming.
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2.2.6 ANALYSIS OF PCR PRODUCTS
The amplified PCR products were visualized under UV light after
electrophoresis (at 150 V for 10 min) through a 2% agarose gel in TBE IX
buffer stained with ethidium bromide. Any positive PCR products were detected
as fluorescent bands due to the presence of ethidium bromide, an intercalating
agent which exhibits a fluorescence under UV light.
2.2.7 LIMITING DILUTION METHOD
Quantification of HCV and HGV/GBV-C RNA was performed using a
previously described limiting dilution method in which cDNAwas titrated before
PCR amplification (Simmonds et al. 1990b; Simmonds et al. 1990b).
Initial limit dilution was carried out in a series of 10-fold steps which
allowed the cDNA to be quantified to within 1 log of its actual concentration.
The quantitation was further performed by the addition of a specific cDNA to
a number of replicate PCR reactions (5) which would give a Poisson distribution
of positive and negative samples and therefore allow the concentration of viral
cDNA to be determined. Positive and negative controls were included in each
assay and all necessary precautions were taken to avoid contamination. For the
RT step, an efficiency of 5% previously established (Zhang et al. 1991) was
assumed in this assay and the quantification results were expressed as the
number of copies of HCV or HGV/GBV-C RNA per ml of serum sample.
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2.3 DNA SEQUENCING
Determination of the nucleotide sequence gives a complete description
of the amplified DNA, and for many purposes, such as evolutionary and
epidemiological studies, it can provide more information than any other analysis
method. DNA sequencing is most commonly carried out by strand extension in
the presence of dideoxynucleoside triphosphates (ddNTPs) that will terminate
synthesis at specific bases (Sanger method). The reactions can be performed
directly using amplified DNA as template or cloned PCR products.
2.3.1 PREPARATION OF DNA FOR SEQUENCING
2.3.1.1 SOLID PHASE PURIFICATION OF PCR PRODUCTS
The sequencing reactions are highly sensitive to different components
present in the PCR product such as dNTPs, primers and buffer reagents.
Therefore, a solid phase purification method (Dynal) was carried out; it allows
efficient and simple isolation and purification of target PCR products.
The method is based on the highly specific interaction between
streptavidin (protein covalently attached to the surface of supermagnetic,
polystyrene beads) and biotin (incorporated into the PCR product). Therefore,
a second round of PCR amplification was performed as described in section
2.2.4 using one unlabelled primer and one biotinylated primer (the biotin is
attached at its 5'-end in order to maintain 3'-end free for elongation); 100 /i\
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volume for each sample was prepared containing 1 jA of primary PCR product,
10 /A of PCR reaction buffer, 1 /jl\ of dNTPs (approximately 33 mM), 0.25 /A of
biotinylated primer (approx.20 mM), 0.25 jA of unlabelled primer (20 mM), 87.1
/A of pyrogen-free water and 0.4 /A of DNA Taq enzyme (2 units per reaction).
The PCR biotinylated products were then purified by using Dynabeads M-280
Streptavidin (Dynal).
For each sample to be sequenced, 20 fA of re-suspended Dynabeads were
transferred to a 1.5 ml eppendorf tube and washed twice with BW (Binding and
Washing) buffer. The tube was placed in a magnet (Dynal MPC-6) and the
supernatant removed. The beads were then resuspended in 40 fA BW, mixed
with 40 yxl of the amplified biotinylated PCR product and incubated at room
temperature for 20 min. During this stage, the beads were resuspended
occasionally to allow the immobilization of PCR product to the Dynabeads
through the biotin/streptavidin linking system. The beads were then washed in
40 /A of BW and resuspended in 8 /A of 0.15 M NaOH and incubated at room
temperature for 10 min; the dsDNA bound to the beads was denatured to
ssDNA template. The supernatant containing unbound complementary sense
DNA, was then eluted.
The beads were washed once with 50 fA of BW and once with 50 /A of
TE to complete the separation of DNA strands. The beads were finally
resuspended in 20 /A of TE and stored at 4°C until sequencing experiment. The
presence of Dynabeads in sequencing reactions does not inhibit the enzymatic
activity of the sequencing enzyme. During handling, the beads suspension was
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mixed by gently pipetting up and down to preserve the integrity of the
polystyrene beads.
2.3.1.2 ALKALINE DENATURATION OF PLASMID DNA
The alkaline denaturation method of double-stranded plasmid DNA was
carried out in order to perform the sequencing reactions (section 2.3.3).
10 pd of ds plasmid DNA was denatured by adding 1 pd of 2M NaOH/2mM
EDTA and incubating at 37°C for 30 min. The mixture was neutralized by
adding 1.1 pd of 3 M sodium acetate (pH 4.5-5.5) and the DNA precipitated with
40 pd 100% ethanol at - 20°C overnight.
The denatured DNA was pelleted by centrifugation at 13,000rpm, at 4°C
for lOmin and then washed with 50 pd of ice-cold 70% ethanol. The washed
pellet was redissolved in 6 pd of DEPC-water and used as template for
sequencing reactions as described in section 2.3.3.
2.3.2 DIRECT SEQUENCING OF AMPLIFIED PCR PRODUCTS
Direct sequencing of amplified DNA was performed by using Sequenase
Version 2.0 DNA sequencing kit (United States Biochemical) with SequenaseIM
Version 2.0 T7 DNA polymerase. This enzyme created by in vitro genetic
manipulation is a genetic variant of bacteriophage T7 DNA polymerase, without
a 3' to 5' exonuclease activity. Due to its properties such as high purity, high
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processivity, high specific activity and efficient use of nucleotide analogues
important for sequencing , Sequenase™ Version 2.0 is a very suitable enzyme to
use for chain-termination sequencing.
The chain-termination method involves the synthesis of a DNA strand by
Sequenase DNA polymerase in vitro using a ssDNA template. This process is
carried out in two steps. In the first stage, the purified DNA template is
annealed to a oligonucleotide primer and the primer is extended using limiting
concentrations of the deoxynucleoside triphosphates (dNTPs), including
radioactively labelled dATP. In the second stage, proper mixtures of dNTPs and
one of the four 2',3'-dideoxynucleoside 5'-triphosphates (ddNTPs) are used.
Since these nucleotide analogues lack the 3'-OH group necessary for DNA chain
elongation, enzyme-catalyzed polymerization will end in a fraction of the
population of chains at each site where the ddNTP can be incorporated. Due to
the radioactively labelled nucleotide included in the synthesis, the labelled chains
of different lengths can be visualized by autoradiography after their separation
by high-resolution denaturing electrophoresis.
For each template, 2 /xl of the appropriate primer, 2 /xl of 5X Sequenase
reaction buffer, 1 /xl dimethylsulphoxide (DMSO) and 6 /A of DNA (bound to
magnetic beads) were mixed together in an eppendorf tube. The tube was then
heated at 65°C for approximately 5min and allowed to cool slowly to room
temperature over a period of 30min. To each annealed template-primer, the
following labelling (extension) mixture was added: 1 /A 0.1 M dithiothreitol
(DTT), 1 fA of diluted labelling nucleotide mix (1:20), 0.5 /xl of [a:35-S]dATP
52
(5 /xCi) and 1 /xl diluted Sequenase polymerase (1:6 in TE, 2 units) .The
annealing reaction and labelling mix were mixed throughouly and incubated at
room temperature for approximately 5min, during which time the termination
reaction was prepared. Four termination mixtures - ddGTP, ddATP, ddTTP,
ddCTP -were prepared (80 /xM of each dNTP, 8 /xM corresponding ddNTP, 50
mM NaCl, 10% DMSO) and 2/xl aliqouts of each mix were incubated at 37°C
in a waterbath in a microtitre-well plate. When the labelling reaction was
complete, 3 /xl were transferred to each of the four termination mixes and
incubated at 37°C for approximately 5 min and then 4 /xl of stop solution were
added to each termination reaction.
Following the sequencing reaction, the product was heated to 95°C for
approximately 5min and then loaded and electrophoresed on a 5% denaturing
polyaciylamide gel (PAGE).
2.3.3 SEQUENCING FROM CLONED DNA
Following the alkaline denaturation step (section 2.3.1.2), the DNA pellet
resuspended in 6 /xl of DEPC-water was used as a template for sequencing
reactions as described above. The primers used in the annealing step were the
plasmid primers: 8819 (sense) and 9130 (antisense) for sequencing DNA cloned
in pTAg vector (R&D Systems) or pUCfor (sense) and pUCrev (antisense) for
sequencing DNA cloned in pGemT vector (Promega). The PCR products of
HGV/GBV-C 3'-UTR cloned into pGemT vector were sequenced with internal
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primer Z4526. The nucleotide sequences of these primers are listed in Table 2.2.
2.3.4 DENATURING PAGE
The quality of gel electrophoresis is an important factor which limits the
extent of sequence information that can be determined in a sequencing
experiment. Therefore, electrophoresis grade reagents were used and the glass
plates were carefully cleaned before pouring the gel by swabbing them with
methanol and acetone. The gel solution was prepared by mixing the following
reagents : 21 g urea (AnalaR-BDH), 6 ml Ultrapure Sequagel concentrate (50%
stock, National Diagnostics), 5 ml 10X Sanger TBE (appendix x), 0.05 g
ammonium persulphate and distilled water up to 50 ml. When all the urea was
dissolved, 20 pi of TEMED (N,N,N',N'-tetramethylethlediamine, Sigma) was
added and the gel solution was poured into the assembly.
Each time, the gels were prepared at least 2 hours prior to use (to allow
complete polymerization to occur) and were pre-run for 15-30 min in IX TBE
electrophoresis buffer before loading the samples. The samples were then loaded
into the wells of the gel after being heated at 95°C for approximately 5 min.
Gels were run for 2 hours allowing approximately 250 to 300 bases to be read.




Primers used for DNA sequencing
Primer Orientation Primer sequence Comments
5' -» 3'
B-S4573 I/AS same as S4573 with Biotin at 5' used in direct sequencing
(section 2.3.2)
Z-4526 I/S GGAGGCATGGTGGTTACTAACC used as internal primer in
sequencing DNA clones of
3'-UTR
pTAg primers
8819 S GCTATGACCATGATTACGCCAA used in sequencing from cloned
DNA (section 2.3.3)
9130 AS ACACGTGTGGTCTAGAGC as above
pGemT primers*
pUC for S GTAAAACGACGGCCAGT as above
pUC rev AS CAGGAAACAGCTATGAC as above
# designed by C. Blake, University of Edinburgh.
2.4 CLONING OF PCR PRODUCTS
2.4.1 USING pTAg VECTOR
Certain thermostable polymerases such as Taq DNA polymerase
(Promega) often add single deoxyadenosine (A) overhangs, in a template-
independent fashion, to the 3'-ends of the amplified products. These fragments
can be easily cloned into the pTAg vector since it is pre-cut and has
complementary T overhangs, ready for direct ligation.
pTAg plasmid contains a LacZa peptide sequence, which when
functionally produced, complements the N-terminal truncated LacZ peptide
synthesized in the competent cells provided. The resulting enzyme, (3 -
galactosidase, cleaves X-Gal (5 Bromo-4 chloro-3 indolyl-/3-D galactopyranoside)
to give blue colonies. IPTG (isopropyl-thiogalactoside) derepresses the
expression of the LacZa gene in cells containing pTAg. When an insert is cloned
into the cut pTAg vector the LacZa peptide sequence is interrupted. This
interferes with the function of the peptide and usually white colonies are
produced on the plates.
2.4.1.1 PREPARATION OF PCR PRODUCT FOR CLONING
The amplified DNA to be cloned was analyzed on 3% agarose gel in IX
TAE buffer. Using long-wave UV light to minimize damage to DNA sample, the
band of expected size was excised with a scalpel blade. The DNA was extracted
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and purified using Geneclean kit (BIO 101 Inc). The Geneclean kit contains a
specially formulated silica matrix called glassmilk that binds single and double
stranded DNA without binding DNA contaminants.
The gel slice was transferred in a clean eppendorf tube and 450 /rl of Nal
stock solution was added. The tube was then placed in a waterbath at 45-55°C
for approximately 5 min. When the agarose was completely dissolved, 5 /xl of
glassmilk suspension was added to the tube. Before using it, the glassmilk tube
was vortexed throughouly in order to resuspend the insoluble silica particles.
The tube was incubated for approximately 5 min at room temperature to allow
binding of the DNA to the silica matrix. The bound DNA was then pelleted in
a microcentrifuge for approximately 5s. After removing the supernatant, the
DNA pellet was resuspended in 500 /A of ice-cold New wash solution
(NaCl/ethanol/water). After that, the pellet was collected in the bottom of the
tube by centrifugation and the supernatant was removed. This wash procedure
was repeated two more times. Finally, the DNA pellet was resuspended in 50 /A
of TE buffer and the tube incubated at 45°C for 3 min. After a brief
centrifugation, the supernatant containing the eluted DNA was carefully
transferred in a new tube. Eluted DNA was kept at -20°C to be used as insert
for cloning.
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2.4.1.2 LIGATION OF INSERT USING pTAg VECTOR
Each ligation reaction was set up in 1.5 ml eppendorf tube using 50 ng
(1 p,l) of pTAg vector, 2 pi of purified PCR product, 1 pi 10X ligase buffer (200
mM Tris-HCl pH 7.6, 50 mM MgCl2), 0.5 pi 10 mM ATP, 0.5 pi (2-3 Weiss
units) T4 DNA ligase and the volume made up to 10 pi with nuclease-free
water. The solution was mixed gently by pipetting and then incubated overnight
at 16°C. Two control ligations reactions were performed each time to enable
accurate interpretation of results: control insert reaction to test the efficiency of
the ligation reaction in which 2 pi (5 ng) of control insert provided with the kit
was used in place of the amplified fragment; self ligation reaction to test the
integrity of the T overhangs of the pTAg vector in which the control insert
ligation reaction was carried out without adding the insert (the total volume was
made up with nuclease-free water).
2.4.1.3 TRANSFORMATION REACTION
The genotype of the competent cells provided with the cloning kit is the
foilowing icn^AlA^fifRl 7 (rk12-mkl2 + )supF.4Athi-lrecAlgyrA96relAl
/ac[F'praA+B+/flclqZAM15::TnlO(TcR)].
The ligation mixture was collected at the bottom of the tube by pulsing
in a microfuge and 1 pi of each ligation reaction was transferred into sterile 1.5
ml eppendorf tube on ice. The competent cells were thawed on ice for 5min and
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an aliquot of 20 /_xl was carefully transferred into each tube containing the
ligation reaction. After taping gently the tubes to mix the contents, they were
incubated on ice for 30min. The tubes were then heat-shocked on waterbath at
42°C for 40 s and returned to ice for 2 min. 80 /xl of SOC medium was added
to each tube with transformed cells to allow them to grow at 37°C for 1 h in a
rotary shaking incubator at approximately 200 rpm.
Luria Broth (LB) agar plates, containing 50 /xg/ml Ampicillin, 15 /xg/ml
tetracycline, 80 /xg/ml X-Gal, and IPTG to 0.5 /xM, were prepared. Ampicillin
is used for selection to ensure the presence of only the transformants with the
plasmid that carries the gene for Ampicillin resistance (^-lactamase) while
tetracycline is necessary to maintain the F'plasmid containing LacZ gene in the
competent cells.
Following the incubation at 37°C , 50 /xl of the transformation reaction
was spread on each LB selective agar plate. The plates were incubated at 37°C
overnight. During transformation and plating, sterile technique was used to avoid
contamination.
2.4.1.4 SCREENING OF TRANSFORMANTS FOR DNA INSERTS
Successful cloning of an insert in pTAg vector interrupts the coding
sequence of /3-galactosidase and white colonies are produced on the plates.
White colonies were screened for the presence of DNA insert by colony PCR
(Gussow and Clackson, 1990).
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Using a sterile toothpick, the edge of a white colony was transferred into
0.5 ml PCR tube containing 20 /xl PCR reaction mixture (section 2.2.4) in which
plasmid primers 8819 (sense) and 9130 (antisense) were used (Table 2.2). Each
solution was covered with a drop of paraffin oil and the PCR tubes placed on
Techne Gene E thermal cycler for one cycle of 94°C for 1.5 min, 50°C for 30 s,
72°C for 3 min, and 29 cycles of 94°C for 30 s., 50°C for 30 s, 72°C for 3 min,
followed by an incubation at 20°C for 7 min. The samples were then
electrophoresed through a 2% agarose/TAE gel containing 0.05 /rg/ml EtBr for
20min next to molecular weight markers for reference. Recombinant
transformants of correct size were identified and the corresponding colonies
from the agar plates were selected.
2.4.1.5 PREPARATION OF PLASMID DNA
The positive colonies identified by PCR as described above were
transferred with a sterile toothpick in 3 ml of LB supplemented with 50-100
/xg/ml of ampicillin. The cultures were incubated overnight at 37°C in a rotary
shaking incubator at approximately 200 rpm.
Next day, 1.5 ml of culture was transferred into an eppendorf tube and
spun down in a microcentrifuge for 30 s. The supernatant was discarded and the
cell pellet was resuspended in 100 /xl GTE (50 mM glucose, 25 mM Tris-HCl pH
8.0, 10 mM EDTA) with lysosyme to degrade the bacterial cell wall. 200 /xl of
NaOH/SDS solution were added and the tubes were kept on ice for 5 min to
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allow the denaturation of DNA. By the addition of 150 pi of solution III
(Appendix), the denatured DNA was aggregated and became insoluble. After
5 min, the tubes were spun in a microcentrifuge for 8 min to separate the cell
debris and the supernatant containing plasmid DNA was transferred to a new
eppendorf tube.
In order to precipitate the DNA, 290 pi of isopropanol were added and
the tubes were incubated at room temperature for at least 15 min. The DNA
pellet was obtained by centrifuging the tubes at 13,000 rpm for lOmin, washed
with 500 pi 70% ethanol and the air-dried. The dry DNA pellet was resuspended
in 40pl of TE containing RNase to a final concentration of 20 pg/ml and stored
at -20°C. Before DNA sequencing, an aliquot of 10 pi was denatured by alkali
as described in section 2.3.1.2.
2.4.2 USING pGemT VECTOR
Similar to pTAg vector, pGemT vector (Promega) contains single 3'-T
overhangs at the insertion site to prevent recircularization of the plasmid and to
provide compatible overhang for the 3'-ends of PCR products generated by
certain thermostable polymerases, such as Taq DNA polymerase (Promega).
Since it contains a a-peptide coding sequence of the enzyme jS-galactosidase,
insertional inactivation of the ^-peptide allows recombinant clones to be directly
identified by colour screening on indicator plates.
The cloning conditions and procedures were similar to those described
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for pTAg vector (sections 2.4.1.2 to 2.4.1.5).
JM109 High Efficiency competent cells provided with the pGemT kit
were used for transformation reactions. The genotype of JM109 cells is the
following : recAl, endAl, gyrA96, thi, hsdR.ll (rK", mK+ ), relAl, supE44,A(lac-
proAB), [F', traD36, proAB, laclq ZAM15]. Selection for transformants was
similar to pTAg vector, on LB/Ampicillin/IPTG/X-Gal.
2.5 CELL CULTURE
2.5.1 CELL PREPARATION
The following cultured cells were used for in vitro infection experiments:
peripheral blood mononuclear cells (PBMCs), U937 cells, and HepG2 cells. For
each culture, cell counts and viability were assessed routinely by trypan blue
exclusion test (section 2.5.3). Sterile techniques were carried out at all stages
during the experiments to avoid contamination.
PBMCs were isolated from fresh heparinized blood of healthy donors by
centrifugation on Ficoll-Hypaque gradients (Lymophoprep, Nycomed) by C.
Forbes (University of Edinburgh). The cell suspension was then washed in PBS
and resuspended in RPMI 1640 growth medium (Gibco) supplemented with
10% heat-inactivated fetal calf serum (FCS, Gibco), lOOmM L-Glutamine
(L-Glu, Gibco), antibiotics (penicillin/streptomycin) at concentration of 104IU/ml
(Gibco), and interleukin-2 (IL-2, NIBSC) at concentration of 104IU/ml. The cell
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suspensions were maintained at 37°C in a 5% C02 atmosphere (ICN flow
incubator). Prior to virus inoculation, the PBMCs were incubated with
phytohaemagglutinin (PHA, Murex) at concentration of 5/xg/ml for 48h to
stimulate cell division.
The U937 continuous macrophage-like cell line derives from a human
histiocytic lymphoma and exhibits morphologic and functional characteristics of
normal human macrophages (Sundstrom and Nilsson, 1976). Unlike peripheral
macrophages, U937 cells are nonadherent. The cells were maintained in
suspension in RPMI 1640 medium containing 10% FCS, L-Glu and antibiotics.
U937 cells were kept at 37°C in a 5% C02 atmosphere and passaged weekly at
a ratio of 1:4.
Differentiation of U937 cells to macrophages was achieved by addition
of phorbol 12-myristate, 13-acetate (PMA) to cultured cells. Cell suspension was
washed once with PBS by centrifugation at lOOOrpm for 5min and resuspended
in fresh culture medium (supplemented RPMI 1640) with PMA (Sigma) at a
final concentration of 160 nM. The cells were then aliquoted into 6-well plates
(Nunc) at a concentration of 6 x 105 cells/ml and incubated for 24h at 37°C in
a 5% COz atmosphere. Prior to virus addition, the U937 cell monolayers were
washed gently to remove unattached cells and fresh culture medium without
PMA was added to the wells.
HepG2 cells are well differentiated hepatoblastoma cells derived from
human liver tumour, with biosynthetic characteristics similar to human
hepatocytes. Initially, the cells were cultured in RPMI 1640 medium
62
supplemented with 10% FCS and antibiotics (104IU/ml) as monolayers in culture
flasks (Nunc) at 37°C in a 5% C02 atmosphere. The culture medium was
renewed twice a week. Before the in vitro infection experiments, confluent
HepG2 cell monolayers were harvested by trypsinization (section 2.5.3) and the
cells were washed twice and resuspended at 1 x 106 cells/ml in FCS-free Ham's
F12 medium supplemented with growth factors, antibiotics and other
supplements (Appendix). At the same time, in order to upregulate the low-
density lipoprotein (LDL) receptors on the cell surface, lovastatin (Merck, Sharp
& Dohme) was added to Ham's F12 medium to a final concentration of 10 /z,M.
The cells were allowed to settle in 6-well plates at 37°C in a 5% C02
atmosphere. After 72h-exposure to lovastatin, the medium was removed, and the
cell monolayer washed three times with PBS. Fresh serum-free Ham's F12
supplemented medium (2 mL) was then added to each well.
2.5.2 INOCULATION PROCEDURES
HCV and HGV/GBV-C positive serum samples together with a negative
control of a HCV and HGV/GBV-C negative serum were used as inocula for in
vitro infection of the cells (Table 6.1). The viral titres of positive samples
(number of RNA copies/ml serum) were determined using the limiting dilution
method (section 2.2.7).
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IN VITRO INFECTION OF PBMCs
After PBMCs stimulation by PHA (section 2.5.1), the cells were washed
three times with PBS and resuspended in fresh RPMI 1640 medium with
supplements. Cells were then aliquoted into 6-well plates at a concentration of
1 x 106 cells/ml and inoculated with three separate serum samples (10 /i\
inoculum) for 4h (4h-incubation experiment) or 24h (24h-incubation experiment)
at 37°C in a 5% C02 atmosphere. After incubation, the cells were washed three
times with PBS to remove inoculum and then maintained in culture flasks with
RPMI 1640 medium containing 10% FCS, antibiotics, L-Glu and IL-2. Cultures
were harvested on days 1, 3, 8 post-inoculation (p.i.) for the 4h-incubation
experiment, and on days 1, 2, 7, 10 p.i. for the 24h-incubation experiment. At
each collection point, 1 ml aliquots of cell suspensions were removed and fresh
medium was added. Following the centrifugation of cell aliquots at 1000 rpm for
5 min, the supernatants were kept at -40°C for RNA extraction (section 2.2.1).
The corresponding cell pellets were washed three times with PBS, resuspended
in 300 /A of denaturing solution (Promega) and also stored at -40°C for RNA
extraction (section 2.2.2).
IN VITRO INFECTION OF U937 CELLS
Separate experiments using undifferentiated U937 cells (cell suspension)
and differentiated (PMA-treated) U937 cells (monolayers) were carried out in
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order to investigate the susceptibility of these cells to infection by HCV and
HGV/GBV-C.
Using U937 cell suspension (section 2.5.1), cells were washed once with
PBS, adjusted to a density of 2 x 105 cells/ml in fresh RPMI 1640 medium with
10% FCS, L-Glu and antibiotics in Bijou bottles (Sterilin) and incubated with
25 pi inoculum for 4h at 37°C in a 5% C02 atmosphere. After incubation, the
cells were pelleted by centrifugation at 1000 rpm for 5 min, washed three times
with PBS, and the cultures were maintained in flasks at a density of 2 x 105
cells/ml in fresh medium. They were harvested at days 1, 2, 3 and 4 p.i. and the
samples (supernatants and cells) stored at -40°C for RNA extraction in the same
way as described for PBMCs cultures.
A second experiment using U937 cell suspensions inoculated with the
same inocula (25 pi or 100 pi per each culture) for 24h was performed and
maintained as described above. In this case, the inoculated cultures were kept
for a longer period (18 days) and they were harvested at days 3, 9, 15 and 18 p.i.
In vitro infection of differentiated U937 cells were carried out in 6-well
plates by incubation of cell monolayers with 100 pi inoculum in 1.5 ml medium
for 4h. Following exposure, cells were washed gently three times with PBS to
remove inoculum and fresh medium (RPMI 1640 + 10%FCS + L-Glu +
antibiotics) was added to each well. At days 1, 2, 3 and 4 p.i., cell monolayers
and medium were removed from the corresponding wells mechanically using
disposable cell scrapers (Nunc) and pelleted by centrifugation at 100 rpm for 5
min. Supernatants were kept at -40°C for RNA extraction together with the cell
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pellets resuspended in 300 /xl denaturing solution after being washed three times
with PBS.
IN VITRO INFECTION OF HepG2 CELLS
The HepG2 cell monolayers prepared as described above (section 2.5.1)
were incubated with 100 /A inoculum for 90 min at 37°C in a 5% C02
atmosphere. After incubation, the monolayerswere washed three times with PBS
and grown in serum-free highly supplemented Ham's F12 medium. For RNA
extraction, at days 3, 7, 14 and 21 p.i., the culture media were centrifuged at
lOOOrpm for 5 min and supernatants stored at -40°C; the pelleted cells were
washed three times with PBS and then resuspended in 300 pd denaturing
solution to be kept at -40°C.
2.5.3 TRYPAN BLUE EXCLUSION TEST
During cell culture experiments, the stage of growth for each cell culture
was routinely estimated from its appearance under the microscope and counting
the cells and assessing their viability.
Cell counting was performed by trypan blue exclusion test in which the
cells mixed with viability dye are placed in an optically flat chamber (improved
Neubauer haemocytometer) under the microscope. For this purpose, 0.1 ml cell
suspension was mixed with 0.9 ml trypan blue. A small drop from this mixture
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was carefully transferred with a micropipette under the coverslip of improved
Neubauer haemocytometer. After placing the slide under the microscope, the
unstained (living) cells lying in 4 large corner squares of the grid were counted.
To calculate the number of cells/ml of initial suspension, the mean value/corner
square was multiplied by 104 and then by dilution (1:10). For example:
(35 + 40 + 42 + 36)/4 x 104 x 10 = 38 x 105 = 3.8 x 106 cells/ml culture.
To obtain a count statistically representative of the cell population, two
counts/cell culture have been carried out each time.
In case of HepG2 cell monolayers maintained initially in RPMI 1640
medium with 10% FCS and antibiotics (section 2.5.1), the cells were trypsinized
in order to be counted and seeded in FCS-free highly supplemented Ham's F12
medium. For this purpose, the culture medium was discarded and monolayer
washed twice with 5 ml PBS. 1 ml 0.25% trypsin (Gibco BRL) in PBS was added
and run few times over monolayer. When the cell layer became opaque, the
trypsin was discarded and the culture flask incubated at 37°C for 3-5 min.
2.6 PHYLOGENY ANALYSIS
Data generated as a result of sequencing nucleic acids and proteins can
be used to study molecular phylogeny, the reconstruction of the evolutionary
history of genes or organisms. The evolutionary relationships amongst genes or
groups or organisms can be represented graphically as phylogenetic trees. These
trees or dendodragms consist of nodes and branches that connect them. The
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branching pattern of a tree is called topology and the nodes are either external,
at the end of a branch, or internal, where two branches form a fork. Generally,
the characters at the external nodes are the data points that are used to
construct the tree (group of organisms, a gene, a region of a gene, etc.) and are
called operational taxonomic units (OTUs). Phylogenetic trees can be either
rooted or unrooted. A rooted tree indicates the direction of evolution, the root
representing the common ancestor of all the OTUs studied. An unrooted tree
indicates the relationship amongst the OTUs but does not define the
evolutionary path. An unrooted tree can become rooted by adding an OTU
which is evolutionarily related to the OTUs studied and had diverged from the
other OTUs prior to their divergence from one another.
There are different methods available for constructing phylogenetic trees
from molecular data (Nei, 1987): distance methods and discrete-character
methods. In distance methods, evolutionary distances are calculated for all
OTUs which are studied and the phylogenetic tree is constructed by certain
principles and algorithms. Discrete-character methods involve the use of discrete
character states (nucleotides or amino acids at a site), and a tree is constructed
by considering the evolutionary relationships of OTUs at each character state.
In general, in the construction of phylogenetic trees, the principle of
minimum evolution is often used. The standard algorithm of the tree-making
methods based on this principle is to examine all possible topologies or a certain
number of topologies that are likely to be close to the true tree and to select
one which shows the smallest amount of total evolutionary change as the final
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tree. Computer simulations have shown that the neighbor-joining (NJ) method
(Saitou and Nei, 1987), which has been used in this study as part of Molecular
Evolutionary Genetics Analysis (MEGA) package (Kumar et al. 1993), is one of
the most efficient methods in obtaining the correct tree topology under the
principle of minimum evolution. According to NJ method, a pair of neighbors
is a pair of OTUs connected through a single interior node in an unrooted,
bifurcating tree, it is possible to define the topology of a tree by successively
joining pairs of neighbors and producing new pairs of neighbors. Since this
method produces an unrooted tree, it usually requires an outgroup OTU to find
a root. In MEGA, unless outgroup OTUs are specific, the root is sometimes
given at the midpoint of the longest route connecting two OTU's in the tree
under the assumption of a constant rate of evolution.
Testing the reliability of a tree obtained can be done using two different
methods: the maximum likelihood method (Felsenstein, 1993) and the bootstrap
test. The maximum likelihood method examines the reliability of eveiy interior
branch of the tree. The bootstrap test involves randomly resampling the data
from which the tree was constructed, producing a new tree with the resampled
data. This process is repeated several times, and the frequency at which
particular branches are observed in the newly constructed tree is calculated
giving a probability to each branch in the original tree. MEGA package provides
bootstrap test for NJ trees.
Another software package used in sequence analysis was Simmonic 2000
sequence editor program created by Dr. P.Simmonds (University of Edinburgh).
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This program proved to be very useful because it provides a convenient format
to store aligned sets of sequences generated by DNA sequencing and from
import of published sequences from other databases such as GenBank. The
format was specially designed to hold sequence data and to provide a particular
sequence environment for sequence editing including information on how the
sequences are numbered, whether they are translated (and reading frame) or
whether they should be viewed in reverse complement. Simmonic 2000 sequence
editor program provides, through its commands, the interface to a number of
sequence analysis packages such as PHYLIP and MEGA. For example, its file
operations allow loading, saving and exporting sequences to and from Simmonic
file format to external files either for storage or for further analysis.
2.7 PREDICTION OF RNA SECONDARY STRUCTURE
The secondary structure of RNA is important for many functions,
including regulation of transcription, translation and replication. There are two
methods of predicting secondary structure: phylogeny and energy minimization.
Phylogeny relies on alignment and subsequent folding of several sequences into
similar structures for functionally analogous RNA. Energy minimization relies
on thermodynamic parameters and computer algorithms to determine the
minimum and near minimum free energy foldings of an RNA molecule.
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A very useful program in predicting RNA secondaiy structure in this
study was RNAdraw program (Matzura and Wennborg, 1996). The optimal
structure/basepair-probability matrix/heat curve calculation algorithms in this
program were imported from the Vienna RNA package (Hofacker et al. 1994).




3. IDENTIFICATION OF HGV/GBV-C VARIANTS BY PHYLOGENETIC
ANALYSIS OF THE 5'-UNTRANSLATED REGION
3.1 INTRODUCTION
Sequence diversity across the HGV/GBV-C genome is significantly lower
than that observed with HCV isolates. While major HCV genotypes vary by 31-
35% across the complete genome (Simmonds, 1995), the diversity between
HGV/GBV-C isolates was reported to be only 14-16% (Erker et al. 1996;
Mukaide et al. 1997; Okamoto et al. 1997; Wang et al. 1997).
Three genotypes of HGV/GBV-C have been defined by phylogenetic
analysis of full-genomic sequences of different HGV/GBV-C isolates (Erker et
al. 1996; Nakao et al. 1997; Okamoto et al. 1997; Katayama et al. 1998) while
similar analysis of nine complete genome sequences suggested that there is one
single genotype of HGV/GBV-C (Wang et al. 1997). At the same time, in
assessing HGV/GBV-C variability, sequence analysis of different subgenomic
regions had indicated conflicting results. For example, phylogenetic analysis of
5'-terminal 600 nucleotide-sequences amplified from the sera of HGV/GBV-C
infected individuals from around the world indicated the existence of the same
three major groups or types (1, 2, 3) as well as several subgroups or subtypes
(la, lb, 2a, 2b) (Muerhoff et al. 1996b). The distribution of the HGV/GBV-C
groups is well correlated with the geographic origin of the variants. Group 1
includes the GBV-C prototype and African isolates, group 2 consists of isolates
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mainly from Europe and North America while group 3 is related to isolates from
Asian countries. Similar groupingswere observed from comparisons of fragments
of the 5'-UTR (Fukushi et al. 1996; Orito et al. 1996; An et al. 1997; Katayama
et al. 1997; Mukaide et al. 1997).
In contrast, sequence analysis of different subgenomic coding regions did
not reveal the same HGV/GBV-C phylogenetic groups. For example,
comparison of sequences of 100 or 199 nucleotides in the NS3 region could not
differentiate between Indonesian, American and Asian HGV/GBV-C isolates
(Tsudaet al. 1996) or between European, American, Asian and African variants,
respectively (Pickering et al. 1997a). Another study based on phylogenetic
analysis of 446 nucleotide-fragments of NS3 region from Chinese isolates
suggested that there is only one predominant or major HGV/GBV-C genotype
in the world (Wang and Jin, 1997). On the other hand, when HGV/GBV-C
isolates from Taiwan were compared with isolates from Africa and North
America using a fragment of 118 nucleotides of NS3 domain, it was suggested
that a genetic heterogeneity exists amongst isolates from different geographic
areas (Kao et al. 1996b).
When the primary sequence of HGV/GBV-C isolates from Japan
corresponding to a longer fragment of 594 nucleotides of NS3 region was
determined and compared with that of a 385 nucleotide-fragment of the 5'-UTR
of the same isolates, the existence of three major clusters associated with the
geographic origin of the variants was confirmed (Katayama et al. 1997).
However, the groupings were more clearly distinguished by comparison of the
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5'-UTR sequences than by comparison of NS3 sequences.
No groupings were observed after analysis of NS5B sequences as
comparative analysis of a 354 nucleotide-fragment indicated that the HGV/GBV-
C isolates collected from different countries (USA, Germany, Russia, Brazil,
Spain, Indonesia, Zaire, Vietnam) belong to the same type (Viazov et al. 1997).
These observations are very different from similar studies of HCV
variability. Comparison of nucleotide sequences of complete genomes or
subgenomic regions resulted in the classification of at least six major HCV
genotypes, some of which being further divided in subtypes (Simmonds et al.
1993; Simmonds et al. 1994). Relatively short sequences (e.g. 222 nucleotide-
fragment of NS5) provided effective discrimination of types, subtypes and
isolates (Simmonds et al. 1993a) while sequence comparisons of the core, NS3,
NS5 and El regions indicated equivalent relationships between HCV variants
(Chan et al. 1992; Simmonds et al. 1994).
All of the six major HCV genotypes can be now identified from analysis
of any coding region of HCV genome (Simmonds et al. 1994) and may also be
imperfectly deduced from the presence of particular sequences in the 5'-UTR
(Simmonds et al. 1993b). Although highly conserved, this region contains several
type-specific nucleotide polymorphisms that would allow the identification of
genotypes 1 to 6 (Simmonds et al. 1993b). However, identifying novel HCV
genotypes by sequence comparison only in this region proved unreliable. For
example, new HCV variants from Vietnam and Thailand had sequences in the
5'-UTR similar or identical to those of type 1, while the phylogenetic analysis
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in the NS5 and El regions revealed that they were distantly related to type 6a
genotype (type 6 group) (Mellor et al. 1995). As a result, a genotyping assay in
which sequences in the core region of HCV were amplified and cleaved by
restriction enzymes was developed to differentiate type 1 variants from type 6
variants (Mellor et al. 1996).
In the face of the contradictory findings regarding HGV/GBV-C
heterogeneity, a detailed examination was undertaken of the phylogenetic
groupings obtained by comparison of all currently available complete genome
sequences and to determine if a specific region within 5'-UTR can be identified
as optimal for distinguishing between these HGV/GBV-C groupings.
3.2 HGV/GBV-C ISOLATES USED IN THIS ANALYSIS
Thirty-one complete genome sequences of HGV/GBV-C isolates were
available in the GenBank database as of May 1998. However, five of these
represented pairs or triplets of epidemiologically linked isolates that had over
99% nucleotide identity with each other: GSI85 (D87262) and GSI93 isolates
(D87263); T55875 (AF031827), HGV-1217 (AF031828) and HGV-1539
(AF031829); and K3732 (AB008335) and K1737 (D87709). Only one of each of
these groups of sequences were included leaving a total of twenty-six sequences.
K10-HGV isolate, which sequence is incomplete (6546 nucleotides), was also
included in the analysis (Table 3.1).
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Table 3.1 HGV/GBV-C complete genome sequences used in this analysis
Isolate GenBank accession Geographical Length
number origin (nucleotides)
1. GT110 D90600 Japan 9395
2. PNF2161 U44402 USA 9392
3. HGV-Iw D87255 Japan 9375
4. T55875 AF031827 Japan 9351
5. CG01BD AB003289 Japan 8953
6. R10291 U45966 USA 9103
7. GBVC-EA U63715 East Africa 9367
8. K2141 D87713 Japan 9391
9. K1741 D87710 Japan 9391
10. K606 D87708 Japan 9256
11. K1789 D87711 Japan 9391
12. GSI85 D87262 Japan 9391
13. GT230 D90601 Japan 9390
14. HGV-IFM1 AB008342 Japan 9387
15. K1775 D87715 Japan 9132
16. K1916 D87712 Japan 9391
17. K1668 D87714 Japan 9391
18. HGVCN U94695 China 9213
19. CG07BD AB003290 Japan 8952
Table 3.1 continued
20. G13HC AB003293 Japan 8930
21. BG1HC AB003288 Japan 8930
22. AF006500 AF006500 China 8982
23. GBV-C U36380 West Africa 9377
24. CG12LC AB003291 Japan 8965
25. G05BD AB003292 Japan 8930
26. HGVC 964 U94695 China 9128
27. K10-HGV * Thailand 6546
* Dr. S. Songsivlai (personal communication)
Additional 5'-UTR sequences were obtained through analysis of RNA
extracted from serum or plasma samples obtained from 14 HGV/GBV-C
infected patients with chronic hepatitis from Pakistan, from nine pregnant
women coinfected with human immunodeficiency virus from Zaire and from 12
Edinburgh haemophiliacs. RNA from Pakistan and Zaire samples was amplified
by RT-PCR (sections 2.2.3-2.2.4) using 2 sets of primers derived from the
HGV/GBV-C 5'-UTR: S4571 (sense outer), S4572 (sense inner), S4573
(antisense inner) and S4574 (antisense outer) (Table 3.2). The PCR products
were re-amplified from primary products using primers S4572 and biotinylated
S4573 and sequenced directly from magnetically separated single strands after
immobilization on streptavidin-coated beads (sections 2.3.1.1 and 2.3.2). RNA
from haemophiliac samples was amplified with primers T1721 (sense outer),
T1722 (sense inner), T1723 (antisense inner) and T1724 (antisense outer). The
PCR products were purified and cloned using pTAg vector (section 2.4.1) and
sequenced using both sense and antisense plasmid primers and T7 DNA
polymerase (section 2.3.3). The consensus sequence of one to five clones for
each sample was used for phylogenetic analysis.
Nucleotide positions within the HGV/GBV-C genome are given relative
to the AUG codon that is likely to represent the initiation codon for translation
of the GBV-C polyprotein (Simons et al. 1996). Therefore, the positions in the
5'-UTR are given negative numbers relative to this codon.
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Table 3.2 HGV/GBV-C 5'-UTR sequences obtained for this study
Geographical origin Primers* used in
of samples nested PCR DNA sequencing
Edinburgh T1721-T1724 pTAg primers





B-S4573 = biotinylated S4573 primer.
*
= primer sequences are listed in Table 2.1 (PCR) and Table 2.2 (DNA
sequencing).
#= sequences determined by Fiona Davidson, BTS-Edinburgh.
3.3 RESULTS
COMPLETE GENOME SEQUENCE ANALYSIS
The complete genome sequences of twenty-six HGV/GBV-C isolates were
manually aligned using the Simmonic 2000 sequence editor program and
evolutionary distances determined using the DNADIST program (maximum
likelihood parameter) of the Phylip package 3.5c (Felsenstein, 1993). A
consensus phylogenetic tree was constructed using the CONSENSE program and
the neighbor-joining method of the NEIGHBOR program for 100 bootstrap
replicating datasets generated using the SEQBOOT program. The resulting
unrooted phylogenetic tree was displayed using TREEVIEW1.5.2 (Page,R.M.D.,
1998). Bootstrap values over 70% were considered as providing evidence for the
observed phylogenetic groupings.
This phylogenetic analysis revealed the presence of four independent
clusters, each of which was supported by bootstrap resampling (Figure 3.1). For
example, sequences CG01BD, T55875, HGV-Iw, GT110 and GBVC-EA grouped
with PNF2161 and R10291 isolates in 100% of bootstrap replicates, and together
comprise group 2 or G2 (Nakao et al. 1997; Okamoto et al. 1997; Katayama et
al. 1998). Another cluster was represented by sequences grouping with GT230
and GSI85 (group 3 or G3) (Nakao et al. 1997; Okamoto et al. 1997). The
prototype isolate, GBV-C, segregated with CG12LC sequence as group 1 in
100% of bootstrap replicates. The G05BD and K10-HGV sequences represent
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Figure 3.1 Phylogenetic tree of HGV/GBV-C complete genome sequences.
Evolutionary distances between sequences were calculated using Phylip
DNADIST (maximum likelihood distances). The tree was constructed using
Phylip NEIGHBOR program for 100 bootstrap replicates and displayed using




an additional group also with 100% bootstrap support. Although incomplete
(6546 nucleotides), the K10-HGV sequence was considered in this analysis
because its presence did not modify the pattern of groupings; the same clusters
were obtained when the same phylogenetic analysis was carried outwithout K10-
HGV isolate (data not shown).
Next, phylogenetic analysis of the same HGV/GBV-C isolates was carried
out for only the 5'-UTR sequences in order to test if the variants would form
the same clusters as obtained by analysis of the complete genome sequences. For
this purpose, the nucleotide sequences corresponding to the 5'-UTR of the
HGV/GBV-C isolates were manually aligned using the Simmonic 2000 sequence
editor program and analyzed using the MEGA package (Kumar et al. 1993)
(Figure 3.2). Phylogenetic trees were generated using the neighbor-joining
algorithm for 100 bootstrap replicates. Comparison of the entire 5'-UTR
sequences (from position -553 to position -1) provided bootstrap support of over
81% for groups 1, 2 and 3 but group 4 was observed in only 38% of bootstrap
replicates (Figure 3.3). Surprisingly, the degree of bootstrap support for groups
1-4 was very similar when progressively shorter segments of the 5'-UTR were
analysed by removing up to 200 nucleotides from either the 5'-end (Figure 3.3)
or from the 3'-end (Figure 3.4). The level of bootstrap support became low
(51% for group 2 and 33% for group 3) when 250 nucleotides were removed
from the 5'-end (Figure 3.3). Similar result was obtained by analyzing fragments
where 250 or 300 nucleotides were deleted from the 3'-end, respectively (the
bootstrap support for group 3 was less than 70%) (Figure 3.4). This phylogenetic
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analysis was then extended using additional 5'-UTR fragments deleted at both
5'- and 3'-ends. Deletion of 50 nucleotides at the 3'-end and up to 200
nucleotides from the 5'-end did not affect the bootstrap support for groups 1-3
(over 70%); in contrast, the bootstrap level for groups 2 and 3 was low for a
fragment obtained by removing 50 nucleotides from 3'-end and 250 nucleotides
from 5'-end (Figure 3.5 A). At the same time, analysis of segments obtained by
deletion of 50 nucleotides at 5'-end and up to 300 nucleotides at 3'-end revealed
similar degree of bootstrap support for groups 1-4 as that based on analysis of
complete 5'-UTR fragment (Figure 3.5 B). One exception was observed when
analyzing a fragment obtained by removing 50 nucleotides from 5'-end and 200
nucleotides from 3'-end: the bootstrap support for group 3 was less than 70%.
Shorter fragments obtained by removing 100 nucleotides from 5'-end and 250
nucleotides from 3'-end (Figure 3.5 C) or 150 nucleotides from 5'-end and 250
nucleotides from 3'-end or 200 nucleotides from 5'-end and 250 nucleotides from
3'-end (Figure 3.5 D) affected the level of bootstrap support, especially for
group 3 (less than 70%). Surprisingly, deletion of 150 nucleotides from the 5'-
end and 200 nucleotides from the 3'-end improved the bootstrap support for the
phylogenetic groups 1-3, with levels over 90% for groups 1 and 2 and over 70%
for group 3 (Figure 3.5 D). In conclusion, the phylogenetic groups 1, 2, 3 and
4 of HGV/GBV-C variants were consistently produced but only the first three
were supported by bootstrap values over 70% when segments between positions
-353 and -50 (Figure 3.5 A), -503 and -300 (Figure 3.5 B), -353 and -100 (Figure
3.5 C) or -403 and -200 (Figure 3.5 D) were considered.
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GEOGRAPHICAL DISTRIBUTION OF HGV/GBV-C VARIANTS
Having defined the region of the 5'-UTR that optimally allows the
discrimination ofHGV/GBV-C phylogenetic groups (between positions -403 and
-200 (Figure 3.5 D), this region was then used to genotype sequences obtained
from samples from Zaire (n=9), Pakistan (n=14) and Edinburgh (n= 12) (Figure
3.6). HGV/GBV-C sequences from Zaire clustered with the GBV-C prototype
from West Africa in group 1, while HGV/GBV-C sequences from Pakistan
clustered with sequences previously described as group 2 sequences. The
sequences obtained from Edinburgh haemophiliac samples all clustered with
group 2 isolates except for Ed_3 which clustered with group 1 and Ed_81 which
clustered with group 3. These two haemophiliac patients (Ed_3 and Ed_81) had
received commercial factor concentrates in contrast to the other haemophiliacs
studied who had only received factor concentrates manufactured from blood
donations collected in Scotland.
Bootstrap resampling of all the sequences for the region -366 to -235
again provided strong support for the existence of group 1 (97%), group 2
(85%) and group 3 (76%) but not for group 4 (Figure 3.7).
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Figure 3.7 HGV/GBV-C phylogenetic groupings generated by comparison of 5'-
UTR fragments between positions -366 and -235. A consensus phylogenetic tree
was constructed from p-distance of the HGV/GBV-C 5'-UTR sequences by
neighbor-joining method. Bootstrap values greater than 70% are indicated. The
group number corresponding to the phylogenetic analysis of the HGV/GBV-C











































Scale -I is approximately equal to the distance of 0.02
VARIATION OF HGV/GBV-C 5'-UTR
The sequence alignment of the HGV/GBV-C 5'-UTR sequences revealed
the presence of sequence polymorphisms throughout the region, some of which
were associated with particular phylogenetic groupings (Figures 3.2, 3.6). For
example, clusters of group-specific polymorphisms are located at positions -104,
-103, between positions -366 to -329, -287 and -235. An additional cluster of
group-specific 5'-UTR polymorphisms occurs between positions -490 and -459
but relatively little sequence information is available for this region and some
groups are not represented (Figure 3.2). Other substitutions present within 5'-
UTR are not correlated with phylogenetic groupings. For example, substitutions
located between positions -17 and -15 (within the polypyrimidine stretch) and
at positions -115 and -167 occur in all phylogenetic groups (Figure 3.2).
The majority of substitutions observed were consistent with proposed
secondary structures for HGV/GBV-C 5'-UTR (Simons et al. 1996b; Pickering
et al. 1997b) since they either were present in unpaired regions (e.g., between
positions -490 and -485, -341 and -329) or did not disrupt the base-pairings. For
example, a stem-loop structure between positions -147 and -120 corresponding
to region IVb in the proposed structure of Simons et al. (Simons et al. 1996),
could be predicted for all the HGV/GBV-C sequences from this study, despite
the presence of many substitutions within this region (Figure 3.8). Although
some of these substitutions are group-specific, most of them occur in all
phylogenetic groups.
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Figure 3.8 Predicted stem-loop structures (positions -147 to -120) for different
HGV/GBV-C groups. Substitutions do not affect (±) or disrupt (a) base
pairings,or occur in unpaired regions (°); (★ ) nucleotide insertion. The range of




^ a G A
G G C G G
C
a A A
G G G G G
G C C C C C
T ▼ A T ▼









C U A A G
a A ★ A A
G C U U G G A G
G (-9.17 to -18.33)
C C c u G A A C cue
T T ▼ ★ ▼ T
u c A U U c
GROUP 3
A U A C U G
A ▲ ▲ a ▲ A A A
G G C G G C A G G G G
G (-8.65 to -18.68)
U C G C U G U c c c c
▼ T ▼ ▼ v T ▼ AG




A C GU A
A A a* A AG
G u A G G G G G
!!!!!!!!!!! G (-12.96 to -19.19)
UCGCGUCCCCC
T T T AG
u c u
3.4 DISCUSSION
COMPLETE GENOME SEQUENCE ANALYSIS
The phylogenetic analysis of twenty-seven full-length or nearly full-length
HGV/GBV-C nucleotide sequences has revealed the existence of four
phylogenetic groups with bootstrap values of 100% for each of them (Figure
3.1). This result is consistent with but extends the previously published studies
based on comparative analysis of complete genome HGV/GBV-C sequences
which suggested the existence of only three groups (Nakao et al. 1997; Okamoto
et al. 1997; Katayama et al. 1998). The isolates that grouped together by analysis
of the full-length sequences also clustered together by phylogenetic analysis of
the entire 5'-UTR or of various shorter fragments of the 5'-UTR ( Figures 3.3,
3.4 and 3.5).
One anomaly of this analysis was the Chinese isolate HGVC 964 that
segregated with group 2 isolates when the 5'-UTR sequence was analysed but
with group 3 isolates upon analysis of the complete genome sequence (Figure
3.1). However, the genome sequence of this variant is 78 nucleotides shorter
than the GBV-C prototype sequence (Muerhoff et al. 1997), with
deletions/insertions present throughout the coding regions and the 3'-UTR is
unrelated to any sequence from database. Because of these discrepancies, and
the lack of supporting published information, HGVC 964 was excluded from the
phylogenetic analysis of the 5'-UTR fragments.
82
Analysis of the 5'-UTR or of subfragments failed to provide bootstrap
support (less than 70% of replicates) for group 4 (G05BD and K10-HGV
isolates). G05BD isolate was previously considered as a potentially new genotype
following the phylogenetic analysis of approximately 2kb-sequence that covered
entire El and most of 5'-UTR and E2 regions of HGV/GBV-C genome
(Takahashi et al. 1997). When the phylogenetic analysis was extended to the
complete polyprotein coding region, G05BD clustered with type 3 isolates only
for analysis of the NS5B region (Takahashi et al. 1997). Although the existence
of group 4 isolates looks uncertain at present, the identification of a novel group
of HGV/GBV-C variants based on analysis of 5'-UTR sequences from Thailand
isolates support this observation (Katayama et al. 1997). Comparison of these
nucleotide sequences with G05BD and K10-HGV sequences indicated a high
degree of identity (data not shown) but the overlapping fragments between them
were too short to analyse further their phylogenetic relationships. This issue
would be better investigated when the full-length or longer sequences of the
Thai isolates are available.
In conclusion, the phylogenetic groups of HGV/GBV-C variants
identified upon analysis of complete genome sequences can be distinguished by
analysis of the entire 5'-UTR or of various subfragments (Figure 3.5 A, B, C,
D). The optimal region for identifying the groups appeared to be the region
between positions -403 and -200.
Two of the three major HGV/GBV-C phylogenetic groupings have been
divided into subgroups (la, lb, 2a, 2b) based on the comparison of the 5'-UTR
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sequences (Muerhoff et al. 1996b). Evolutionary distances between types 1, 2 or
3 were approximately 0.1000, while distances between variants of the same type
were approximately 0.034 to 0.056. At the same time, in an attempt to determine
the phylogenetic groupings of 16 HGV/GBV-C isolates obtained from
multitransfused patients a novel subgroup, named 2c, was proposed based on
phylogenetic analysis of the entire 5'-UTR (LopezAlcorocho et al. 1999).
Comparison of evolutionaiy distances indicated that the HGV/GBV-C sequences
isolated from most patients belonged to subgroup 2a while the phylogenetic
trees constructed by analysis of the entire 5'-UTR or a 320bp-fragment of 5'-
UTR showed that 5 of the isolates segregated into a separate branch, close to
those of subgroup 2a and 2b sequences. However, since the bootstrap support
for this segregation is not very strong (70% of replicates), these ambiguous
results might be the result of errors in the sequence alignment. In another
published extended phylogenetic analysis of 5'-UTR and coding region
sequences of HGV/GBV-C variants, the bootstrap support for segregation of
group 1 isolates into subgroups was not very strong while segregation of group
2 sequences was difficult to obtain unless a significant fragment of the 5'-UTR
was analysed (Muerhoff et al. 1997). Based on these findings and because the
complete genome sequence analysis carried out in this chapter included only one
isolate (GBVC-EA) previously defined as subgroup 2b, only the major
HGV/GBV-C phylogenetic groupings were considered for discussion.
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GEOGRAPHICAL DISTRIBUTION OF HGV/GBV-C VARIANTS
In contrast to analysis of subgenomic coding regions, phylogenetic analysis
of fragments of 5'-UTR can be used to define the phylogenetic groupings of
various HGV/GBV-C variants which are well correlated with their geographical
origin, although there is no perfect correlation between the country and
phylogenetic group. This conclusion was supported by analysis of 61 different
sequences carried out in this chapter (Figure 3.7) where the following groups
could be distinguished: Group 1 contains African isolates, Group 2 consists
mainly of isolates from Europe, North America and Indian subcontinent as well
as GBVC-EA from East Africa and HGV-Iw from Japan, and Group 3 is
predominant in Asia (Japan). Two sequences (G05BD and K10-HGV) may
represent a new group (Group 4) since analysis of complete genome sequences
indicates that it is a distinct group from Groups 1, 2, and 3 (Figure 3.1).
At the same time, the geographical distribution of HGV/GBV-C
phylogenetic groups and their diversity and prevalence in different human
populations might offer information on HGV/GBV-C origin. Recently, this issue
was investigated by phylogenetic analysis of the NS3 and NS5A regions from 94
HGV/GBV-C isolates collected from Central Africa and other areas (e.g.,
Australia, Japan, Uzbekistan) (Tanaka et al. 1998). The prevalence of
HGV/GBV-C was high in Central African region where most of the isolates
belonged to Group 1 (95.65%); 15 of Group 1 isolates had a 12-amino acid indel
(i.e. insertion or deletion) in the NS5A region. Phylogenetic analysis of the
85
NS5A region in which GBV-A was used as an outgroup, revealed that the 15
isolates (Indel type) formed a separate outer group suggesting that they had
diverged earlier than the Non-Indel sequences from a common ancestor.
HGV/GBV-C might be of African origin and its transmission to new
communities may perhaps taken place along with human migration. However,
this hypothesis remains to be further analysed.
VARIATION OF HGV/GBV-C 5'-UTR
In general, a high degree of conservation was identified throughout the
entire genome of HGV/GBV-C (Erker et al. 1996; Mukaide et al. 1997;
Okamoto et al. 1997; Wang et al. 1997). The 5'-UTR consists of both well
conserved and variable regions ( Figures 3.2, 3.6). The alignment of 5'-UTR
sequences indicated the presence of nucleotide polymorphisms (e.g., between
positions -490 and -235) that were associated with particular phylogenetic
groups. As previously suggested (Muerhoff et al. 1996b), they could be used to
segregate new HGV/GBV-C sequences into groups. This observation is
supported by the phylogenetic tree of different HGV/GBV-C isolates
constructed by comparison of 5'-UTR fragments located between positions -366
and -235 (Figure 3.7).
In case of HCV, an association between particular polymorphisms in the
5'-UTR and virus genotype has led to the development of HCV genotyping
methods by line probe assay (LIPA) (Stuyver et al. 1993) or by restriction
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fragment length polymorphism analysis (RFLP) (McOmish etal. 1993; McOmish
et al. 1994; Davidson et al. 1995). Similarly, the presence of polymorphisms in
the HGV/GBV-C 5'-UTR provided also evidence for the identification of group-
specific restriction sites for 2 restriction enzymes (ScrF I and BsmF I (Mukaide
et al. 1997). For example, the sequence recognized by BsmF I (GUCCC) for
group 1 and group 3 HGV/GBV-C isolates was found located between positions
-354 and -350.
At the same time, many of the polymorphisms are covariant and
consistent with the predicted secondary structure for the 5'-UTR which has a
potential functional importance in different viral events such as the initiation of
translation (Simons et al. 1996). However, the validity of the model remains to
be confirmed by ribonuclease sensitivity assays.
The extensive phylogenetic analysis carried out in this chapter on
HGV/GBV-C complete genome sequences and 5'-UTR sequences revealed
significant aspects of HGV/GBV-C genetic heterogeneity, suggesting some
guidelines for assigning the phylogenetic groups.
Classification ofHGV/GBV-C isolates in groups is important not only for
evaluating the geographical distribution and diversity of this virus or for
providing basis for the development of reliable detection methods but also for
understanding its evolution within the human population.
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CHAPTER 4
4. BUOYANT DENSITY AND SEDIMENTATION BEHAVIOUR
OF HGV/GBV-C
4.1 INTRODUCTION
The genome organization of HGV/GBV-C is relatively similar to that of
HCV (Leary et al. 1996; Linnen et al. 1996) but it is not currently known if these
similarities extend to the virus structure and morphological properties.
In previous studies, the HCV particle has been visualized by immuno-
electron microscopy and estimated to be 55 to 65 nm in diameter with spike-like
projections 6 nm long (Kaito et al. 1994). Similarly, filtration studies have
indicated that virus particles have a diameter of 30-60 nm (He et al. 1987; Yuasa
et al. 1991). These values are within the range of estimated diameters of
flaviviruses (35 and 50 nm) (Westaway et al. 1985). Lipid solvents such as
chloroform reduce the infectivity of HCV (Bradley et al. 1983; Feinstone et al.
1983) and disrupt the virus envelope (Hijikata et al. 1993) indicating that the
virus has an envelope containing lipids.
Early studies reported the buoyant density of HCV virus particles in
sucrose at 1.08 g/ml (Miyamoto et al. 1992) and 1.09-1.11 g/ml (Bradley et al.
1991), similar to the density of the pestiviruses bovine viral diarrhoea virus (1.09-
1.15 g/ml) and hog cholera virus (1.12-1.16 g/ml) but lower than those of most
flaviviruses (1.19-1.20 g/ml) (Westaway et al. 1985). The HCV present in
fractions with low density (1.03-1.12 g/ml) is infectious (Bradley et al. 1991;
Hijikata et al. 1993) and is precipitated by goat anti-human /3 lipoprotein
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antibodies, indicating an association with plasma low-density lipoproteins (LDL)
(Bradley et al. 1991; Thomssen et al. 1993). However, subsequent studies have
demonstrated the presence in serum of a higher density fraction (1.17-1.20 g/ml)
in which virus is bound to anti-viral antibodies in immune complexes that can
be precipitated by rabbit anti-human immunoglobulins directed against subtypes
IgA, IgG and IgM (Hijikata et al. 1993; Kanto et al. 1995) or by anti-IgG
(Thomssen et al. 1993). An intermediate fraction with density range from 1.10
to 1.16g/ml present in some human sera contains a mixture of viral lipoproteins,
viral aggregates and incomplete virus particles (Thomssen et al. 1993). HCV
RNA is also present in fractions with densities exceeding 1.21 g/ml in the sera
of chronic hepatitis patients (Thomssen et al. 1992) and appear to consist of
nucleocapsids since they can be immunoprecipitated with monoclonal anti-core
HCV antibody (Kanto et al. 1995). A fraction with a similar density containing
HCV nucleocapsids (1.25 g/ml) was isolated after detergent treatment from
plasma of blood donors (Miyamoto et al. 1992). Studies of HCV density
distribution in patients with various stages of chronic hepatitis suggested that
the dominant HCV population shifted from low-density to high-density particles
with the progression of liver disease or increased inflammation (Kanto et al.
1995).
At the same time, antibodies to the HVR-1 region may be responsible for
association of HCV virions with immunoglobulins since they could be detected
in infected plasma by ELISA using overlapping oligopeptides deduced from
HVR of HCV (Kojima et al. 1994). Within E2 sequence encoding for one of the
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major structural glycoproteins of HCV, there are regions of extreme
hypervariability (HVR); one of these-HVRl-which represents the amino
terminal 25-30 amino acids of the E2 protein appeared to be structurally flexible
and antigenically variable during a HCV infection follow-up, due to a significant
number ofmissense mutations (Taniguchi et al. 1993). These successive antigenic
changes of HVR1 may provide the virus a way to escape from humoral immune
response of the host.
Based on the sequence comparisons with HCV, homologues to the El
and E2 envelope proteins have also been identified in HGV/GBV-C but these
do not contain HVR regions (Okamoto et al. 1997). Although these proteins
may be glycosylated (Leary et al. 1996b), only three N-linked glycosylation sites
have been identified in E2 of HGV/GBV-C while there are between eight and
eleven in E2 protein of HCV (Leary et al. 1996; Okamoto et al. 1997).
Another important difference between the polyproteins of HGV/GBV-C
and HCV is the absence of a putative HGV/GBV-C core protein, which is
usually encoded at the 5'end of the genome. The HCV core protein is a highly
basic protein of 191 amino acids located at the amino-terminus of the
polyprotein that is well conserved amongst HCV genotypes 1-6 (Cha et al. 1992;
Bukh et al. 1994). Its biosynthesis and biochemical properties have been
investigated and specific functions mapped to discrete portions of the molecule
(Santolini et al. 1994; Matsumoto et al. 1996). For example, the core protein
released from the HCV polyprotein precursor is a cytoplasmic protein associated
with the endoplasmic reticulum (ER) membranes and possesses RNA binding
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activity. The ribosome- and RNA-binding domain were mapped to the NH2-
terminus of the core protein between amino acids 1 and 75 while the C-terminal
hydrophobic region was found to be responsible for the membrane association
of the HCV core protein (Santolini et al. 1994). At the same time, the
homotypic interaction and multimerization of the HCV core protein in vitro and
in vivo was demonstrated (Matsumoto etal. 1996). The NH2-terminal hydrophilic
domain (amino acids 1-115) is mainly responsible for these events. In contrast,
although many full-length HGV/GBV-C genomes have been published, no
consistent viral nucleocapsid or core protein sequence has been revealed so far
(Erker et al. 1996; Leary et al. 1996; Linnen et al. 1996; Okamoto et al. 1997;
Katayama et al. 1998). However, a putative El signal peptidase recognition
sequence and an Asn-Cys-Cys motif within El protein that is highly conserved
in HCV, GBV-A, GBV-B and HGV/GBV-C have been identified (Leary et al.
1996b). In addition, in vitro translation studies of transcripts containing the 5'-
end of the GBV-C genome indicate that the site of translation initiation is
located immediately upstream of a putative El signal sequence. This implies that
a core-like protein does not exist at the amino-terminus of the polyprotein
(Simons et al. 1996).
Together, these discrepancies in the genome organisation of HGV/GBV-
C suggest that the morphology and physicochemical properties of HGV/GBV-C
particles may be different from those of HCV. This chapter describes an
investigation of the buoyant density and the sedimentation behaviour of
HGV/GBV-C particles from human plasma in comparison with HCV.
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4.2 RESULTS
Three HCV positive plasma samples (A, B, C) and three HGV/GBV-C
positive plasma samples (F, G, H) were used in this study. Samples A and B
were anti-HCV positive while sample C was seronegative on screening by Abbott
second generation enzyme immunoassay (EIA) and confirmed by RIBA-3 assay.
Another plasma sample (N), that was both HCV and HGV/GBV-C negative,
was used as negative control (Table 4.1). The samples (500/rl) were fractionated
on a preformed density gradient ranging from 10% to 60% (w/w) sucrose in
TEN buffer at 27,800 rpm for 44 h at 10°C in a Beckman SW50.1 ultracentrifuge
rotor (section 2.1).
The presence of viral RNA in each fraction was detected by RT-PCR
using nested primers specific for the 5'-UTR of HCV and HGV/GBV-C,
respectively (section 2.2.4). The quantification ofviral RNAwas performed using
the limiting dilution method in which cDNA is titrated to the endpoint for
detection by PCR amplification (section 2.2.7); the number of copies of RNA
per ml of plasma was calculated assuming a 5% efficiency of the reverse
transcription reaction as previously established for HIV (Zhang et al. 1991). The
sensitivity of detection was approximately 103 copies of RNA/ml.
HCV RNA was widely distributed over sucrose density fractions with
densities ranging from 1.04 to 1.21 g/ml (Table 4.2). Quantification of viral RNA
by limiting dilution revealed high levels of HCV RNA at densities of 1.04, 1.06
and 1.16 g/ml for sample A (Figure 4.1), 1.05, 1.12 and 1.19 g/ml for sample B
92
Table 4.1 Plasma samples used in the density analysis of HCV and HGV/GBV-C
in sucrose gradients.
Sample Patient HCV RNA HGV/GBV-C RNA anti-HCV Abs
(genotype) (ELISA+RIBA-3)
A haemophiliac + (3) - +
B blood donor + (1) - +
C blood donor + (3) - -
F haemophiliac - + -
G haemophiliac - + -
H haemophiliac + (1) + +
N blood donor _ _ _
Table 4.2 Presence of HCV and HGV/GBV-C RNA in sucrose fractions.
Fraction density Sample / titre (no.copies RNA x 106/ml plasma)
HCV HGV/GBV-C Negative
g/ml A B C F G H N
1.28 - -
1.26 - - - -
1.23 - - - -
1.21 0.41 0.16 - - -
1.20 0.33
1.19 0.82 2.2 0.16 - -
1.17 - 0.16
1.16 9.1 -
1.15 - 1.31 - 0.25
1.14
1.13 - 0.08
1.12 1.5 1.76 0.51 0.44 0.88
1.11 0.33
1.10 0.88
1.09 0.73 0.82 0.91 1.76 0.66
1.08 0.66 8.8
1.07 - 0.66
1.06 4.1 - - -
1.05 1.5 1.76 0.16 0.08 -
1.04 5.1 1.31 0.2
1.03 -
For the PCR-negative samples , the titre •< 103 copies/ml.
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(Figure 4.2) and 1.04, 1.08 and 1.15 g/ml for sample C (Figure 4.3). The density
at which the peak of HCV RNA concentration was found was 1.16 g/ml for
sample A, 1.19 g/ml for sample B and 1.08 g/ml for sample C. These results are
similar to those reported in previous density centrifugation studies of serum
samples from HCV-infected individuals in which the RNA was detected in both
light (1.03-1.08 g/ml) and heavy (1.17-1.21 g/ml) density fractions (Miyamoto et
al. 1992; Hijikata et al. 1993; Thomssen et al. 1993).
In contrast, the distribution of HGV/GBV-C RNA in the sucrose
fractions of each HGV/GBV-C positive sample was more restricted, with only
single peaks of virus RNA concentration (Table 4.2). The buoyant density at
which the majority of HGV/GBV-C RNA was detected was between 1.07 and
1.12 g/ml according to the sample; the peak values of virus RNA were found at
1.09 g/ml for samples F (Figure 4.4) and G (Figure 4.5) and 1.12 g/ml for sample
H (Figure 4.6). No HGV/GBV-C RNA was detected in fractions with densities
higher than 1.17 g/ml. Two of the samples (B and F) were subjected to repeated
sucrose density fractionation with similar results (data not shown) while a sample
from a HCV and HGV/GBV-C negative individual was negative for all gradient
densities for both viruses.
In order to obtain a more extensive characterization of HGV/GBV-C
particles, an attempt to visualize the virus particles by electron microscopy was
made. For this purpose, two sucrose fractions, each of sample A (at 1.04 and
1.16 g/ml) and of sample F (at 1.09 and 1.12 g/ml) were studied. 200 /xl of each
fraction were diluted in PBS and centrifuged at 15,000 rpm for 2.5 h at 4°C. The
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pellets were resuspended in 50 /A PBS and then 10 /A of each sample was used
to prepare negatively stained grids for electron microscopy examination
following a routine procedure: the suspension was applied to formvar-carbon
grids and then negatively stained with 2% phosphotungstic acid pH 6.2 for 2 min
(the grids were prepared by D.Notman, Clinical Virology Laboratory, Medical
School).
Virus-like spherical particles were observed only in the 1.16g/ml fraction
from sample A (HCV infected) and these closely resembled in appearance and
size published photographs of HCV virions (Kaito et al. 1994). In the other
fraction of sample A and both fractions of sample F, partially decomposed or
incomplete virus-like particles were observed. The presence of lipoprotein
particles (in the fractions with low density) and sucrose, the changes in the
osmotic pressure and the repeated sample freezing-thawing steps during the
preparation may have been damaged the integrity of the virus particles, making
it difficult to visualize them.
4.3 DISCUSSION
Although HCV and HGV/GBV-C are closely related viruses, comparison
of their physico-chemical properties suggest important structural differences that
may be related to differences in genome organization.
HCV RNA was present in fractions with a low density in all three
samples: at 1.04-1.06 g/ml for sample A, at 1.05 and 1.12 g/ml for sample B and
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1.08 g/ml for sample C; these density values correspond with those previously
shown to represent HCV virions associated with low-density lipoproteins
(Bradley et al. 1991; Thomssen et al. 1992; Hijikata et al. 1993; Thomssen et al.
1993). Samples A and B also contained HCV RNA in fractions with higher
densities (1.16 g/ml for sample A, 1.19 g/ml for sample B). This is consistent
with the presence of immune complexes representing HCV particles associated
with immunoglobulin (Hijikata et al. 1993; Thomssen et al. 1993; Kanto et al.
1995). This conclusion is supported by the observation that samples A and B
were both positive by ELISA for anti-HCV antibodies and this reactivity was
confirmed by the RIBA-3 assay (Table 4.1) while in sample C which was ELISA-
negative, relatively little HCV RNA was detected at 1.15g/ml.
A very different sedimentation profile was observed for HGV/GBV-C in
sucrose gradients. A single peak of viral RNA was present in low density
fractions within a range of 1.07 to 1.12 g/ml, corresponding to the density of
HCV virions associated with serum lipoproteins and/or other plasma proteins
(Bradley et al. 1991; Thomssen et al. 1993). Similar results have subsequently
been reported (Sato et al. 1996; Melvin et al. 1998). Direct evidence for an
association between HGV/GBV-C and LDL comes from the demonstration that
antibodies to human lipoproteins A-I and B could precipitate HGV/GBV-C
from low density fractions (Sato et al. 1996). Unlike HCV, no HGV/GBV-C
RNA was detected in fractions with densities higher than 1.17 g/ml expected for
virus particles in immune complexes. These observations indicate that the
HGV/GBV-C particles from human plasma are associated with LDL and other
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plasma proteins but not bound to antibodies. This conclusion is confirmed by the
observation that HGV/GBV-C could not be efficiently precipitated when plasma
samples positive for both HCV and HGV/GBV-C RNA were incubated with
anti-human IgG (Hijikata and Mishiro, 1996). Similarly, no HGV/GBV-C RNA
could be detected in density fractions or sera incubated with goat antibodies to
human IgG (kappa light chain) and precipitated with rabbit anti-goat IgG (Sato
et al. 1996). The lack of evidence for HGV/GBV-C in immune complexes is
consistent with the observation that antibodies to the E2 protein of HGV/GBV-
C can only be detected in sera that are negative for HGV/GBV-C RNA,
suggesting that it is the antibody response that leads to clearance of viraemia
(Dille et al. 1997; Tacke et al. 1997). In contrast, in HCV infection, viraemia and
antibodies specific for HCV coexist, with 97.3% of HCV-RNA positive sera
shown to contain antibodies to HCV-E2 (Lesniewski et al. 1995). At the same
time, attempts to detect other specific antibodies to HGV/GBV-C were
unsuccessful. Although immunoreactive epitopes were found to be located in
regions of the HGV/GBV-C putative NS3, NS4 and NS5 nonstructural proteins
(PilotMatias et al. 1996), antibodies to prokaryotically expressed HGV/GBV-C
recombinant proteins were infrequently detected amongst individuals that were
HGV/GBV-C RNA positive by PCR (Dawson et al. 1996; PilotMatias et al.
1996).
No HGV/GBV-C RNA was detected in fractions with densities higher
than 1.17 g/ml, whereas 1.21 g/ml fractions were PCR-positive for HCV
gradients (Table 4.2), consistent with the presence of nucleocapsids (Thomssen
96
et al. 1992). In another published sucrose density study, treatment of
HGV/GBV-C positive plasma samples with 1% chloroform before fractionation
did not lead to the appearance of HGV/GBV-C RNA in higher density
fractions, although the viral titre was substantially reduced following treatment
with chloroform at higher concentrations (5% and 20%) (Melvin et al. 1998).
In contrast, another recent study reported that HGV/GBV-C RNA was
present in sucrose fractions with densities of 1.07 and 1.17 g/ml while after a
two-step extraction of the plasma samples with an equal volume of chloroform,
viral RNA was only present in fractions with densities of 1.22 to 1.24 g/ml
(Xiang et al. 1998). A similar shift in the HGV/GBV-C RNA peak to fractions
with heavier density (1.23-1.26 g/ml) (Sato et al. 1996) or (1.25-1.29 g/ml)
(Melvin et al. 1998) occurred following the treatment of the plasma samples with
5% Tween-80 and RNasin. However, after this treatment, the RNA could not
be passed through 200 nm filter suggesting that it was converted into an
extended form since particles of the expected size of nucleocapsids (diameter of
20-30 nm) should pass through filters of this pore size (Melvin et al. 1998).
Detection of HGV/GBV-C RNA was significantly reduced or lost after
treatment with Triton X-100 or NP40 in a concentration of 0.5% or higher (Sato
et al. 1996; Melvin et al. 1998). On the other hand, detergent treatment at
concentrations that did not reduce the viral titre produced no change in the
density of HGV/GBV-C RNA containing fractions.
These observations suggest that HGV/GBV-C lacks a nucleocapsid. This
conclusion is consistent with the sequence analysis of several HGV/GBV-C
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complete genome sequences in which no conserved open reading frame exists
upstream of the El protein coding region that is capable of encoding a core-like
protein (Erker et al. 1996; Okamoto et al. 1997; Wang et al. 1997).
In order to investigate this question more completely, a detailed
comparison was made of this region of the HGV/GBV-C genome in the twenty-
four complete genome sequences available in GenBank database in May 1998.
The 5'-terminal fragments (618 nucleotides long) were aligned and then
translated in three reading frames using Simmonic 2000 sequence editor
program. The nucleotide alignment showed that many nucleotide insertions,
deletions and substitutions were present within this region of the genome.
Although there are up to five AUG (methionine Met) codons in-frame with the
HGV/GBV-C polyprotein, the only AUG codon conserved amongst all twenty-
four sequences is that of the NH2-terminus of the El gene (AUG-5) (Figure
4.7). This codon was identified as the site of translation initiation in a GBV-C
isolate in a cell-free in vitro translation system (Simons et al. 1996). Comparison
of amino acid sequences preceding this methionine codon showed that the open
reading frames (ORFs) of the HGV/GBV-C isolates differ significantly in
composition and length even within the same phylogenetic grouping (Figure 4.7).
As a result, the ORF starts from AUG-1 for 1 out of 24 isolates (1/24), from
AUG-2 for 3/24, from AUG-4 for 12/24, from AUG-5 for 1/24 and 7/24 have the
protein encoded from an additional AUG (Figure 4.7). For example, GT11Q
isolate contains the longest sequence of 91 amino acids. In two isolates - R10291
and HGVC 964 - the ORF containing 68 amino acids starts at the second AUG
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codon ( position -205) that is in-frame with the conserved one. The starting
codon for GBVC-EA amino acid sequence would also be the second AUG but
the presence of an in-frame stop codon at position -37 disrupts the sequence. In
some isolates ( PNF2161, HGV-Iw, T55875, CG018D, HGV1539, HGV-IFM1),
the fourth AUG codon at position -96 represents the start of their ORF of 31
amino acids. In BG1HC isolate, this putative amino acid sequence is disrupted
due to the presence of an in-frame stop codon at position -37. The ORF of
other isolates (AF006500, G13HC, GBV-C, GSI85, CG12LC, CG07BD, G05BD)
starts at an additional AUG codon just upstream of the fourth one but is
disrupted by a stop codon at position -55. In GT230 isolate, the ORF starts only
at the fifth AUG codon. Similar conclusions were revealed from the analysis of
5'-terminal sequences amplified from the sera of HGV/GBV-C infected
individuals (Muerhoff et al. 1996b; Pickering et al. 1997b).
Despite this evidence, some authors have suggested that HGV/GBV-C
does encode a core protein of 91 amino acids long (Xiang et al. 1998). A single
nucleotide insertion 43 amino acids into this putative core protein would be
responsible for its lack of conservation among different HGV/GBV-C isolates.
In fact, sequence analysis reveals that heterogeneity of this part of the
HGV/GBV-C genome is due to the presence of nucleotide insertion or deletion
(Muerhoff et al. 1996; Okamoto et al. 1997; Wang et al. 1997) so the possibility
of consistent sequencing errors is excluded. The amino acid sequence starting
at the fourth AUG codon is relatively well conserved amongst a number of
isolates ( Figure 4.7), (Pickering et al. 1997b) and a fourteen amino acid-
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fragment within this ORF has been used as a synthetic peptide in an ELISA to
test the presence of antibody to the HGV/GBV-C core protein in HGV/GBV-C
infected individuals (Xiang et al. 1998). Antibody to this peptide was detected
in plasma samples from HGV/GBV-C RNA positive patients but not in negative
controls, a result that could indicate that this peptide sequence is expressed in
vivo. However, since only four samples were tested in ELISA and the
absorbance values were relatively low, the generality of these findings is
unknown.
Recently, the ability of the HGV/GBV-C anti-genome sequence to
encode a core-like protein was investigated (Kondo et al. 1998). The analysis of
the anti-genome of thirty-eight HGV/GBV-C isolates led to the identification of
a consensus sequence of 118 amino acids, in which the methionine and the stop
codons were conserved amongst all isolates. Overlapping synthetic peptides
based on this fragment located within the E2 region of the HGV/GBV-C anti-
genome were prepared and then used for the detection of specific antibodies by
ELISA. Although 66.7% of the HGV/GBV-C RNA positive sera tested were
positive for some peptides, false-positive reactions occurred and the sensitivity
of the assay was relatively low. Further studies are needed in order to assess the
existence of a new ORFwithin the HGV/GBV-C anti-genome and the possibility
of the ambisense protein to function as core protein.
Viral core proteins protect the viral genome from the RNases and enable
the encapsidation, and so the formation of a nucleocapsid is considered
essential for many viruses. For example, the HCV core protein is capable of
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multimerization in vitro and in vivo, in a process that may represent the first step
of virus assembly (Matsumoto et al. 1996). Kinetic studies of glutaraldehyde
cross-linking of HCV core protein expressed in mammalian cells revealed that
the region responsible for multimerization lies within the amino-terminal
hydrophilic domain (amino acids 1-115). Whether the mechanism of HGV/GBV-
C virion assembly takes place in the absence of a nucleocapsid or by using other
virus or host specific proteins with biological properties similar to those of a
virus core protein has yet to be discovered.
In conclusion, the buoyant density of HGV/GBV-C virus particles in
human sera is estimated to be between 1.07 - 1.12 g/ml, much lower than that
of the other members ofFlaviviridae family, except HCV. This low density seems
to be related to the binding of viral particles to human plasma components, such
as LDL. The distinct sedimentation behaviour of HGV/GBV-C in sucrose
gradient from that of HCV may reflect structural differences between the HCV
and HGV/GBV-C genomes, consistent with HGV/GBV-C lacking a core gene.
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CHAPTER 5
5. ANALYSIS OF THE PRIMARY AND SECONDARY STRUCTURE
OF THE HGV/GBV-C 3' UNTRANSLATED REGION
5.1 INTRODUCTION
It has been proposed that the termini of an RNA virus genome present
certain nucleotide sequences functionally important for viral RNA replication,
transcription, translation and packaging (Strauss and Strauss, 1983). These
elements could be represented by conserved nucleotide sequences that are
recognized by viral enzymes or these sequences could be part of secondary
structures stabilised by hydrogen bonds in which the structure, rather than the
sequence, is recognized. The genomic organization of HGV/GBV-C is similar
to that of other members of Flaviviridae family, with a long ORF flanked by a
5'-UTR and a 3'-UTR but at present there is very little information about the
secondary structure of these regions or their role in virus replication.
Amongst the Flaviviridae, the primary and secondary structures of the 5'-
and 3'-UTR have been described for flaviviruses (Brinton et al. 1986; Hahn et
al. 1987; Proutski et al. 1997), pestiviruses (Deng and Brock, 1993) hepatitis C
viruses (Brown et al. 1992; Smith et al. 1995; Kolykhalov et al. 1996; Blight and
Rice, 1997) and GB viruses (Simons et al. 1996). Certain structural elements in
these regions are functionally important for viral translation, replication,
transcription and assembly, although the precise mechanisms of these events are
not well understood. For example, the 3'-UTR of the flavivirus Yellow Fever
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virus (YFV) contains a set of three closely spaced repeated sequences, each
approximately 40 nucleotides long, while a stable secondary structure is formed
by the 3'-terminal 87 nucleotides (Rice et al. 1985). Comparison of the 3'-
terminal sequences of West Nile virus (WNV), Saint Louis Encephalitis (SLE)
and YFV has identified features common amongst different flaviviruses
(Brinton et al. 1986). The existence of a stable 3'-terminal secondary structure
was confirmed by direct RNA sequencing and partial enzymatic cleavage
methods (3'-end radiolabeling of genomic RNA followed by partial digestion
with specific RNases and electrophoresis of the products on sequencing gels).
Seven regions of conserved sequence of variable lengths were identified among
the 3'-UTRs of WNV, SLE and YFV and these may represent signals for viral
polymerase recognition and binding. The conservation in size and structure of
this region supports the hypothesis that it contains important elements for viral
RNA replication.
Besides these subgroup-specific features, two short conserved RNA
sequences (CS1 and CS2) , located 5' to the 3'-terminal structure, are shared by
all mosquito-borne flaviviruses and are considered to play important cis-acting
roles in RNA replication or packaging (Hahn et al. 1987). CS1 is about 26
nucleotides in length and located immediately adjacent to the terminal secondary
structure. Eight contiguous nucleotides of CS1 were found to be complementary
to an eight-nucleotide conserved domain in the 5'-region of the flavivirus RNA.
Their base-pairing could lead to cyclization of the viral genome that may be
important for regulating genome translation, replication or packaging. CS2 is
103
approximately 24 nucleotides in length, highly conserved, and located 12 to 22
nucleotides upstream of CS1. CS2 is present in two copies in members of the
Dengue (DEN) and Japanese Encephalitis (JE) subgroups.
Imperfectly repeated sequences have also been identified in the 3'-UTR
of pestiviruses, although the nucleotide sequence and location of the repeats is
not conserved between different viruses (Deng and Brock, 1993). A secondary
structure model for the 3'-UTR of pestiviruses contains a long conserved 3'-
terminal stem-loop (Deng and Brock, 1993).
Similar features were reported for HCV, which is classified with
flaviviruses and pestiviruses in the Flaviviridae family. The viral genome has a 3'-
UTR that consists of three domains: a highly variable sequence (21 to 40
nucleotides) followed by a poly U/polypyrimidine tract of variable length and
composition and a 98 nucleotide-highly conserved sequence (Kolykhalov et al.
1996). Computer prediction of the secondary structure and en:zymatic analysis
are consistent with this region having a stable and conserved stem-loop (SL)
within the 3'-terminal 46 bases suggesting that this element may represent a
recognition site for viral and/or cellular proteins (Kolykhalov et al. 1996; Blight
and Rice, 1997). A 58-kDa cellular protein identified as the polypyrimidine tract-
binding protein (PTB) binds to the highly conserved 3'-terminal 98 nucleotides
of the HCV RNA (Ito and Lai, 1997); protein binding seems to require
secondary structure elements and specific sequences within the 98 nucleotide-
region.
104
In contrast, the 52 nucleotides at the 5'-end of the conserved 98
nucleotide 3'-fragment do not seem to form a stable stem-loop structure.
However, this conserved sequence may play a role in the recognition of viral
RNA by proteins in a sequence-specific manner. A significant fraction of HCV
genome RNA from a highly infectious inoculum contains the 3'-terminal 46
base-element which is likely to be essential for authentic HCV replication and
recovery of infectious RNA from cDNA. Indeed, a recent study reported that
this region of the 3'-UTR of the HCV is essential for infectivity in vivo (Yanagi
et al. 1998).
For HGV/GBV-C, there have been very few reports of the sequence or
secondary structure of the 3'-UTR of different isolates (Erker et al. 1996; Nakao
et al. 1997; Okamoto et al. 1997; Katayama et al. 1998). The secondary structure
model of Okamoto et al. was constructed only for the 3'-terminal 140
nucleotides of the 3'-UTR and based on only three sequences (Okamoto et al.
1997) while Katayama et al. only predicted the structure of the last 30
nucleotides of 3'-UTR (Katayama et al. 1998).
This chapter describes a more comprehensive comparison and analysis of
the primary sequence and secondary structure of the 3'-UTR. Nucleotide
sequences were obtained for different HGV/GBV-C isolates from Edinburgh,
Pakistan, Zaire, Brazil, Gambia and Papua-New Guinea. These sequences were
compared with published sequences and used to construct a consensus secondary




Twenty-two partial or complete sequences of the 3'-UTR of HGV/GBV-
C derived from complete genome isolates were obtained from GenBank in May
1998 (Table 5.1). Seventeen additional nucleotide sequences were obtained by
sequence analysis of PCR products amplified with primers directed against
conserved regions of HGV/GBV-C at the carboxyl-end of the NS5B gene and
the extreme 3'-end, respectively (Table 2.1). The sera analysed were those used
for sequence analysis of the 5'-UTR ( Edinburgh, Pakistan and Zaire samples)
(Chapter 3) as well as others from Brazil, Papua-New Guinea and Gambia
samples identified as being PCR positive for the 5'-UTR of HGV/GBV-C
(Prescott,L.-unpublished ). PCR products were cloned into pGemT vector
(section 2.4.2) and sequenced (section 2.3.3).
All of the sequences were collinear with only two sites of
deletion/insertion (positions 8705 and 8709). The alignment revealed highly
conserved regions between positions 8530 (UGA stop codon) to 8558, 8580 to
8675, 8680 to 8703, and 8715 to 8844, while the intervening regions showed
limited variability (Figure 5.1). The high degree of sequence conservation in this
region is consistent with the existence of important recognition signals for the
virus-specific replicase (Strauss and Strauss, 1983).
Comparison of the thirty-nine HGV/GBV-C 3'-UTR sequences offered
the possibility of searching for putative repeat sequences similar to those
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Table 5.1 HGV/GBV-C isolates used in 3'UTR analysis. The sequences obtained
in this study are identified by prefixes Pak for Pakistan, Ed for Edinburgh, Zai
for Zaire, Brz for Brazil, Png for Papua-New Guinea and Gam for Gambia.
Sequence name Source Accession number Group
GT110 Genbank D90600 2
HGV-1539 Genbank AF031829 2
T55875 Genbank AF031827 2
HGV-1517 Genbank AF031828 2
PNF2161 Genbank U44402 2
HGV-Iw Genbank D87255 2
GBVC-EA Genbank U63715 2
Ed_34 this study - 2
Ed_62 this study - 2
Ed_45 this study - 2
Ed_69 this study - 2
BrzI this study - 2
Pak_502 this study - 2
Pak_540 this study - 2
Pak_566 this study - 2
HGVCN Genbank U94695 3
GSI85 Genbank D87262 3
GSI93 Genbank D87263 3
Ed_81 this study - 3
K1737 Genbank D87709 3
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identified in flaviviruses and pestiviruses that may represent viral replication
signals (Rice et al. 1985; Deng and Brock, 1993). In this study, the search for the
nucleotide sequence repetition was done using fragments of ten nucleotides each
that were aligned by Simmonic 2000 sequence editor program. It revealed only
one repeat sequence of 10 nucleotides located at positions 8591 and 8762,
respectively, that was conserved among all the viral isolates with few exceptions.
Substitutions occurred at position 8593 (C->U) for GT230, at position 8763
(C^G) for five isolates (GSI93, K1737, K2141, Png_29, Png_48) and at position
8762 (G->A) for HGV-Iw (Figure 5.2 A). In addition, two short, highly
conserved sequences were identified: CACA located at position 8779 and ACU
at position 8842 (the last three nucleotides of the 3'-UTR fragment) (Figure
5.1). The first sequence is also present in the 3'-terminal region of flavivirus
(Brinton et al. 1986) and pestivirus genomes (Deng and Brock, 1993); the second
sequence occurs at the extreme 3'-end of flavivirus genome RNAs (Brinton et
al. 1986). The conservation of these elements suggests that they are important
in virus replication.
Complementarity between the 5'-UTR and 3'-UTR of the viral genome
of positive strand RNA viruses has been described previously, consistentwith the
viral replicase having similar recognition sites for (+) and (-) strand synthesis
(Strauss and Strauss, 1983; Rice et al. 1985). However, the 5'- and 3'-terminal
sequences of HGV/GBV-C genome are not complementary (Figure 5.2 B). A
six nucleotide-sequence in the 3'-UTR at positions 8724-8729 is complementary
to the positions -293 - -288 of the 5'-UTR (Figure 5.2 C). This was the longest
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Figure 5.2 Primary structure of HGV/GBV-C 3'-UTR
A. Repeated sequence in the 3'-UTR of HGV/GBV-C RNA.The identical
nucleotides are underlined. Substitutions are indicated by arrows.
position
8584 8591 U 8600 8606
I II I I
G G U U C C C GCCCUCCCCG C C C C A G
A G
I I
U C G C A G A GCCCUCCCCG G A U G G G
II l|
8755 8762 8771 8777








C. Nucleotide complementarity between 5'-UTR and 3'-UTR of HGV/GBV-C
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complementary sequence found by manual search.
The nucleotide composition of the 3'-UTR of HGV/GBV-C (calculated
using the MEGA package (Kumar et al. 1993)) is 17.5% A, 30.1% C, 31.3% G,
21.1% U with a GC content of 61.4%, similar to that of the whole virus genome
(17.88% A, 27.36% C, 31.97% G, 22.74% U). In contrast, the flavivirus genome
is characterized by a lower GC content and a relatively high purine content
(27.3% A, 21.3% C, 28.4% G, 23% U) (Rice et al. 1985).
SECONDARY STRUCTURE
Secondary structure prediction of the 3'-UTR of HGV/GBV-C genome
was performed using the RNAdraw program (Matzura and Wennborg, 1996) for
2 or 3 different sequences from each of the four phylogenetic groups defined by
the analysis of complete genome sequences (Chapter 3). G-U base pairs were
accepted for this analysis, in addition to Watson-Crick base pairs and the
optimal structure/basepair-probability matrix/heat curve calculation algorithms
in RNAdraw were imported from the Vienna RNA package (Hofacker et al.
1994).
Comparison of secondary structures predicted for examples of the
different phylogenetic groups revealed several hairpins thatwere invariant in size
and position. Free energy values for the 3'-UTR structures (positions 8509 to
8847) ranged from -103.19 kcal (for the PNF2161 sequence) to -111.98 kcal (for
the GBV-C sequence) (Table 5.2). Based on these similarities, a consensus
108
Table 5.2 Free energy values calculated at 37°C for the predicted secondary
structures of the sense strand RNA (AGa) and reverse complement strand RNA
(AGb) for the 3'-UTR of different HGV/GBV-C isolates. The percentage
reduction in free energy was calculated as mean value based on nucleotide order
randomization using RNAdraw program.




























Mean value -107.703 19.37 -96.401 13.74
model of the secondary structure of the 3'-UTR of the HGV/GBV-C RNA was
constructed containing a series of stem-loop structures numbered I to VII
(Figure 5.3). Covariant nucleotide substitutions revealed by sequence alignment
were then identified by manual search through the potential hairpin structures.
The extended stem-loop structure I, which contains 20 nucleotides of the
coding sequence upstream from the stop codon UGA. was present in all
phylogenetic groups. While the la region showed some variation in length (the
stem is one pair-shorter in group 2 sequences), stem-loop lb, located between
positions 8529 and 8552, was invariant in shape and size.
Hairpin Ila located between positions 8558 to 8580 was highly conserved
and supported by the presence of numerous covariant substitutions (Figure 5.4).
Although the primaiy nucleotide sequence within this region varied amongst
different isolates (Figure 5.1), the size and position of the hairpin remained
invariant. These substitutions not only maintained the proposed base pairings
but were associated with different HGV/GBV-C phylogenetic groups. Stem-
loops lib, Ilia and IHb were also stable structures, formed by regions with
conserved nucleotide sequence.
The nucleotide fragment between positions 8638 and 8687 was conserved,
except for substitutions at positions 8676 (C-^-U), 8678 (A->U) and 8679
(A-»C) (Figure 5.1); however, no consistent secondary structure was observed
for different HGV/GBV-C isolates.
The region between positions 8688 and 8745 was predicted to form an
extended stable stem-loop structure of three hairpins IVa, IVb, IVc, all of which
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Figure 5.4 Group-specific nucleotide variation within hairpin Ha. Positions
at which substitutions are covariant such that base pairing is maintained are
shown in bold.
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were present amongst all the sequences examined. Hairpin IVb contains
covariant substitutions at positions 8705/8710 and 8704/87011 although the stem
is one pair shorter in group 3 sequences because of deletion of positions 8705
and 8709.
The terminal part of the 3'-UTR is also conserved with stable, stem-loops
- Va (positions 8753 and 8763), Vb (positions 8767 and 8778) and VI (positions
8783 and 8808). The few substitutions occurring within hairpin Va either
maintained the base pairing (positions 8753/8763) or occurred in an unpaired
region (position 8759 in the loop). The base-pairing of the stem is only disrupted
at positions 8754/8762 (hairpin Va) in HGV-Iw isolate and at positions
8768/8777 (hairpin Vb) in K2141 isolate.
The last and longest predicted stem-loop (VII) is located between
positions 8816 and 8841 and is well conserved and stable among all HGV/GBV-
C isolates. In two cases, (Brz I and Gam_2 sequences), the stem shape is slightly
altered with its upper part disrupted by the formation of a small bulge due to
a substitution at position 8824 (G->A).
A second sequence alignment representing the reverse complement (5'-
terminal sequence of the minus-strand RNA) of the same HGV/GBV-C isolates
was generated using Simmonic 2000 sequence editor program and a consensus
model of the secondary structure was predicted using the RNAdraw program as
described above. This model contains a series of stem-loop structures numbered
1 to 12 (Figure 5.5) with the free energy values for different sequences varying
between -90.94 kcal (K1741 sequence) and -105.20 kcal (GBV-C sequence)
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Figure5.5Consensusmod lofthcondarystructuret rever ec mplem ntstrandfthHGV/GBV-C3'-UTR.
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(Table 5.2).
While most of the hairpins in the minus strand were invariant in size and
position for all HGV/GBV-C sequences studied, hairpins 7 (positions 163 to
173) and 12 (positions 319 to 329) were less stable. For example, the
substitutions occurring within hairpin 7 at positions 170 (U->A) and 172 (G—>A)
would disrupt the base-pairing in all group 3 sequences apart from GSI93 and
GT230 isolates and also in GBVC-EA, Ed_69, Brz I, Pak_502, Pak_540,
Pak_566 (group 2 sequences), GBV-C (group 1 sequence), Png_29 and Png_48
(unassigned group sequences).
Similarly, for hairpin 12, the base-pairing is disrupted at positions 320/328
because of G->A substitution in GT110 and Ed_62 (group 2 sequences) and
G->C or G->U substitutions in group 3, group 1 and unassigned group
sequences.
Hairpin 5 located between positions 134 and 148 is well conserved with
covariant substitutions at positions 137/144 and 138/143, respectively. In group
3 sequences, the stem is one pair shorter because of deletions occurring at
positions 139 and 142. Covariant substitutions are also present within hairpin 10
located between positions 268 and 290 although its shape is slightly different
amongst the HGV/GBV-C isolates (Figure 5.6).
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Comparative sequence analysis of the 336 3'-terminal nucleotides of the
HGV/GBV-C genome from 39 isolates reveals a high degree of nucleotide
sequence conservation. The existence of conserved regions could be due to the
presence of structures or sequences required for viral RNA replication,
translation or packaging (Strauss and Strauss, 1983). Two short sequences
identified in the 3'-UTR of HGV/GBV-C genome at positions 8779 (CACA)
and 8842 (ACU) respectively, are homologous to those found in 3'-UTR of
flaviviruses and pestiviruses and may represent signal sequences involved in the
recognition and binding of viral polymerases. A repeated sequence of 10
nucleotides found within 3'-UTR of HGV/GBV-C RNA at positions 8591 and
8762 is conserved among all isolates and may also play a role as recognition
signal for viral replicase (Figure 5.2 A). At the same time, since the search for
nucleotide repetition was limited to identify only perfectly repeated fragments
of 10 nucleotides long, the existence of other fragments of a larger size and
imperfect repeat sequence is not excluded.
The 5'- and 3'-terminal sequences ofHGV/GBV-C genomic RNA are not
complementary (Figure 5.2 B), implying that the recognition sites for the (+)
strand and (-) strand replicase for HGV/GBV-C are different. Similarly, for
pestiviruses, no complementary sequences have been found (Deng and Brock,
1993). However, the presence of a conserved six nucleotide-sequence element
at position 8724 in the 3'-UTR which is complementary to a conserved sequence
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at position -303 in 5'-UTR is intriguing since similar types of conserved
sequences have been identified in 3'-UTR of flavivirus RNAs and are believed
to represent potential cyclization sequences (Hahn et al. 1987; Proutski et al.
1997). The role of RNA cyclization in the replication process is not known;
cyclization could promote the replication of full - length molecules of viral RNA
if binding of the viral replicase to both 5'- and 3'-regions simultaneously was
required to initiate RNA replication (Hahn et al. 1987).
While there is evidence for cyclization of alphavirus and bunyavirus RNAs
(Strauss and Strauss, 1983), the importance of cyclization in the replication of
these viruses is unknown.
Studies of some RNA viruses have suggested that interactions between
the 5'- and 3'-UTR sequences ('cross-talk' interaction) is essential for
transcription, replication and packaging. For example, conserved sequences
located at the 5'- and 3'-ends of influenza virus RNA segments ( a negative -
strand RNA virus) are complementary and act as cis regulatory elements in
RNA synthesis (O'Neill and Palese, 1994). In the case of HCV, there is no
evidence for base-pairing interactions between the 98-nucleotide element of 3'-
UTR and upstream sequences (Blight and Rice, 1997) since addition of 5'- and
3'-UTR sequences or the full-length HCV genome did not modify the in vitro
RNase cleavage pattern of the 98 nucleotide-3'-terminal region. However, the
possibility that this type of interaction occurs in vivo cannot not be excluded.
Secondary structure predictions combined with comparative sequence
analysis of the 3'-UTR of the HGV/GBV-C genome have led to the construction
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of a consensus model and the identification of a series of stable and conserved
stem-loop structures (Figure 5.3). The conservation of these elements amongst
thirty-nine isolates together with the presence of covariant substitutions suggest
that these structures exist in vivo and are functionally important in viral RNA
replication. At the same time, the free energy values of this secondary structure
calculated for several HGV/GBV-C isolates of different phylogenetic groups
indicated that the proposed structure is thermodynamically stable (Table 5.2).
In addition, the RNAdraw program allowed the structure prediction and
comparison of a number of 'scrambled sequences' for a specific HGV/GBV-C
3'-UTR. New files can be created with randomized portions of the sequence and
used to assess whether changes in nucleotide order would have any effect on the
free energies predicted by RNA folding. Sequence scrambling was carried out
using different HGV/GBV-C isolates for both sense strand and reverse
complement strand RNA (Table 5.2). The percentage reductions in free energy
on sequence scrambling of the sense strand were significantly greater (mean
reduction 19.37%) than those of the reverse complement strand (mean 13.74%;
p = 0.012 by Mann-Whitney U test) (Table 5.2). The predicted secondary
structure corresponding to the reverse complement strand, in which most of the
hairpins are conserved amongst the isolates, is less stable than the conformation
presented by the positive strand RNA (Table 5.2). Despite this, the models share
a certain degree of structural similarity since hairpins 2 and VI, 3 and Vb, 5 and
IVb are identical in size and position (Figure 5.5). A structural identity also
exists between hairpins 11 and lb as well between hairpin IHb and the upper
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region of hairpin 8 (Figures 5.3 and 5.5). However, the covariances present
within hairpin 10 are not associated with the HGV/GBV-C groups to the same
extent as those within hairpin Ha of the sense strand (Figure 5.6).
The consensus model proposed and analyzed in this chapter contradicts
several aspects of a previously reported model based on the analysis of the last
140 nucleotides of the 3'-UTR from only three isolates (PNF2161, GT110,
GT230) (Figure 5.7) (Okamoto et al. 1997). When thirty-nine HGV/GBV-C
sequences described above were used to analyze the Okamoto et al. model,
several substitutions were identified that disrupted the proposed base-pairings.
For example, pairing of positions 8711 (U) and 8842 (A) is disrupted in all
group 3, group 1 and unassigned sequences because of U-»C substitution at
position 8711 and in one group 2 sequence (Ed_34) because of a U-*G
substitution; another U-A pair between 8722 and 8730 is affected in three
sequences ( Ed_34, Png_29, Png_48) because of a U-»C substitution. Other
positions at which substitutions produce mismatches in regions predicted to be
base-paired by Okamoto et al. are: C-C at positions 8753 and 8806 in four group
3 and two unassigned sequences; G-G at positions 8763 and 8802 in three group
3 and 2 unassigned sequences; A-G at positions 8744 and 8814 in one group 2
sequence (Figure 5.7). In addition, the Okamoto et al. model is not supported
by any covariant substitutions and does not include the fragment upstream of
position 8705 in which important structural elements could be identified and
confirmed by either covariant substitutions or by highly conserved nucleotide
sequences as presented in Figure 5.3.
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Figure 5.7 Secondary structure model for the 3'-terminal 140 nucleotides of the 3'-
UTR of HGV/GBV-C proposed by Okamoto et al. The substitutions responsible
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Computer-predicted folding patterns and RNase cleavage experiments
have previously demonstrated the existence of a long stable hairpin structure (3'-
LSH) within the distal part of the 3'-UTR of several different flaviviruses (Rice
et al. 1985; Brinton et al. 1986; Proutski et al. 1997), some positive strand RNA
plant viruses (Strauss and Strauss, 1983), HCV (Kolykhalov et al. 1996; Blight
and Rice, 1997) and pestiviruses (Deng and Brock, 1993). Other studies have
provided evidence for a specific interaction between the 3'-LSH of flaviviruses
and host cellular proteins, components of the virus replication complex
(Blackwell and Brinton, 1995) or have demonstrated a specific binding of
cellular proteins to the 3'-terminal 98 nucleotides of the HCV RNA (Ito and
Lai, 1997).
The analysis of 3'-UTR sequences presented here provides evidence for
a similar, long stable hairpin (hairpin VII) at the 3'-end of the HGV/GBV-C
genome that was present among all HGV/GBV-C isolates studied. This element
has also been identified from analysis of a shorter fragment of the 3'-UTR,
(Katayama et al. 1998) and is part of the structure proposed by Okamoto et al.
(Figure 5.7). This stem-loop could be considered as a 3'-LSH and might be
functionally important in RNA replication and/or in virus assembly. The
existence of a long stable hairpin 3'LSH located at the 3'end of the genome
RNA appears to be a common feature of the divergent members of Flaviviridae
family (flaviviruses, pestiviruses, HCV and HGV/GBV-C viruses). At the same
time, this structure might play a role in the recovery of infectious RNA
transcripts from cloned cDNA since highly conserved structural elements and
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correct terminal sequences are essential for virus replication (Boyer and Haenni,
1994; Yanagi et al. 1998).
The high conservation of the structure through covariance and free
energy values amongst HGV/GBV-C isolates of different phylogenetic groups
indicates that the possibility of the existence of such a structure in vivo that
would be functionally important to the virus.
HGV/GBV-C, together with GBV-A and GBV-B, represent the GB
viruses, recently discovered RNA viruses that appear to be members of the
Flaviviridae family. Phylogenetic analysis of 5'-UTRs and structural genes showed
that GBV-A and HGV/GBV-C share a common ancestor while GBV-B is more
similar to HCV (Leary et al. 1996b). Comparison of nucleotide sequences of four
GBV-A isolates available in GenBank suggests that their 3'-UTR sequences are
incomplete, since they vaiy from 81 nucleotides (AF023245 isolate) to 197
nucleotides (HGU22303 isolate). As observed for HGV/GBV-C isolates, no
poly(U) or poly(A) tails have been identified and instead GC-rich sequences are
present. In contrast to the findings for HGV/GBV-C, folding predictions of the
3'-UTR sequence of different GBV-A isolates revealed very different secondary
structure patterns, and these showed no significant similarity with the proposed
structure of the 3'-UTR of HGV/GBV-C. These differences suggest that the 3'-
terminal sequences of GBV-A isolates may be incomplete.
In conclusion, the analysis of the 3'-UTR of HGV/GBV-C RNA
presented in this chapter has provided evidence for the existence of primary and
secondary structure elements that may have potential biological functions in
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important processes such as RNA replication, transcription and viral assembly.
The existence of these structural elements remains to be confirmed by
experimental analysis of RNA with single- and double-strand specific RNases.
Their role in viral replication will have to be determined by functional assays.
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CHAPTER 6
6. SUSCEPTIBILITY OF DIFFERENT TYPES OF CULTURED CELLS
TO HGV/GBV-C AND HCV INFECTION
6.1 INTRODUCTION
The development of cell culture systems susceptible to infection and
capable of supporting the viral replication is required in order to fully
understand the mechanisms of the pathogenesis and persistence of HCV and
HGV/GBV-C. Both viruses, distantly related to each other within Flaviviridae
family, have single-stranded, positive-sense RNA genomes with a similar
organization of gene products. By analogy with flaviviruses, the replication of the
viral plus-strand RNAs is thought to occur via a minus-strand intermediate
molecule. This minus-strand RNA intermediate serves as a template for
synthesis of new genomic plus-strands which can be translated, used for further
rounds of minus-strand synthesis or encapsidated into new virus particles.
Considerable efforts have been made to determine and characterize the
cell tropism of HCV by identifying the virus localization at the cellular and
subcellular levels (Bouffard et al. 1992; Zignego et al. 1992; Aria et al. 1993;
Blight et al. 1993; Gabrielli et al. 1994; Lau et al. 1994; Gastaldi et al. 1995).
Since over 60% of acute hepatitis C infection becomes chronic and often leads
to liver cirrhosis and hepatocellular carcinoma (Gerber, 1995), the liver is
regarded as the main target for replication of HCV in vivo.
Several assays such as in situ hybridization (ISH), in situ reverse
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transcription PCR (IS-RT-PCR) and immunochemistry have been used for in
situ detection of HCV genome and gene products in liver. For example, HCV
RNA has been detected in the liver tissue samples of infected individuals by in
situ hybridization using radiolabeled (Lamas et al. 1992; Haruna et al. 1993) or
non-radioactive probes (Aria et al. 1993; Tanakaei al. 1993; Gastaldi etal. 1995).
In addition, in some of these ISH studies, minus-strand HCV RNA, considered
as a marker for virus replication, has also been detected (Lamas et al. 1992; Aria
et al. 1993; Gastaldi et al. 1995).
The presence of HCV RNA in liver has also been demonstrated by in situ
RT-PCR in which the PCR products can be detected by either direct
incorporation of digoxigenin-labelled dUTP during amplification (Nuovo et al.
1993; Lau et al. 1994; Walker et al. 1998) or indirect detection based on the use
of a labelled probe, as in ISH (Nuovo et al. 1993; Walker et al. 1998). At the
same time, immunohistochemical techniques have been applied to detect and
locate HCV antigens in liver tissue sections (Hiramatsu et al. 1992; Blight et al.
1993; Blight et al. 1994; Gonzalez-Peralta et al. 1994; Yap et al. 1994; Brody et
al. 1998; Walker et al. 1998). Primaiy antibodies directed towards HCV viral
antigens were applied on chemically fixed paraffin-embedded or frozen liver
sections. Various HCV viral antigens such as core (Hiramatsu et al. 1992;
Gonzalez-Peralta et al. 1994; Yap et al. 1994), El (Hiramatsu et al. 1992), E2
(Blight et al. 1994), NS3 (Hiramatsu et al. 1992; Blight et al. 1994), NS4 (Blight
et al. 1993; Blight et al. 1994; Gonzalez-Peralta et al. 1994) and NS5 (Blight et
al. 1994) were reported to be detected in different liver tissue samples using this
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assay.
However, conflicting results and certain limitations have been identified
based on all these techniques. Using ISH, various patterns of cellular and
subcellular localization of HCV RNA within the liver have been reported. For
example, HCV RNA was detected in the cytoplasm of hepatocytes (Lamas et al.
1992; Aria et al. 1993; Haruna et al. 1993; Tanaka et al. 1993; Lau et al. 1994;
Gastaldi et al. 1995) and also in their nucleus (Blight et al. 1992; Lamas et al.
1992; Aria et al. 1993). In addition, positive signals indicating the presence of
HCV RNA were detected in mononuclear cells (Blight et al. 1992; Lamas et al.
1992; Aria et al. 1993) and even in sinusoidal cells and bile duct epithelium (Aria
et al. 1993). At the same time, the sensitivity of this technique is relatively low
due to the possible degradation of the viral RNA during tissue preparation.
Similar differences in the findings were revealed by IS-RT-PCR studies in which
the HCV-specific positive signal appeared to be mainly cytoplasmatic (Lau et al.
1994) or mainly perinuclear (Nuovo et al. 1993) or intranuclear with either a
diffuse or a peripheral pattern (Walker et al. 1998). In some cases, apart from
hepatocytes, IS-RT-PCR also indicated the presence of HCV RNA in bile duct
cells and portal lymphocytes (Walker et al. 1998), in Kupffer cells (Nuovo et al.
1993) and occasionally, in mononuclear cells (Lau et al. 1994). The diffusion of
PCR products seemed to be a fairly common problem when the number of PCR
cycles was more than fifteen (Lau et al. 1994), making the localization of HCV
RNA difficult to assess. In addition, when indirect IS-RT-PCR was carried out,
the signal was weak, affected by denaturation and stringent washing steps (Lau
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et al. 1994).
In the case of immunohistochemical detection of HCV antigens in liver,
the cellular and subcellular localization was consistent. Various HCV antigens-
core, El, NS3 (Hiramatsu et al. 1992), E2, NS3, NS4, NS5 (Blight et al. 1994),
core, NS4 (Gonzalez-Peralta et al. 1994)-were always detected in the cytoplasm
of hepatocytes. However, in only a few studies was the relationship between the
hepatic expression of HCV antigens and pathobiological effect analyzed,
revealing different conclusions. While no direct association was observed
between the distribution of NS4-positive hepatocytes and areas of hepatocyte
necrosis in liver biopsy specimens collected from anti-HCV positive patients
(Blight et al. 1993), the HCV antigen expression in liver samples from chronic
hepatitis C patients was correlated with disease activity and advanced disease
stage (Hiramatsu et al. 1992).
The presence of HCV has also been investigated in extrahepatic sites
such as peripheral blood mononuclear cells (PBMCs), bonemarrow cells, spleen,
pancreas, kidney and lymph nodes that could be capable of supporting the virus
replication. For example, minus-strand RNA has been detected in PBMCs or
subpopulations of PBMCs isolated from patients infected with HCV by in situ
hybridization (Moldvay et al. 1994) and strand-specific RT-PCR (Bouffard et al.
1992; Zignego et al. 1992; Muller et al. 1993; Lerat et al. 1996) suggesting that
HCV RNA might replicate in these cells.
Because the levels of HCV RNA found in infected individuals are
relatively low, the RT-PCR is often considered the most reproducible and
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sensitive technique to detect the presence of viral RNA in comparison to ISH.
However, the strand specificity of RT-PCR using either sense or antisense
primers for the detection of minus-strand RNA has been questioned. There is
evidence that either false priming or self-priming of the plus-strand HCV RNA
due to the hairpin loops of secondary structure present in the 5'-UTR leads to
reverse transcription of the plus-strand RNA in the absence of antisense primers
(Lanford et al. 1994; Mcguinness et al. 1994; Sangar and Carroll, 1998). In order
to avoid these non-specific events, various modifications of strand-specific assays
have been carried out. One such assay is tail or tagged PCR in which the primer
used for cDNA synthesis contains an additional sequence at the 5'-end unrelated
to any part of the virus genome (Chaves et al. 1994; Lanford et al. 1994). After
reverse transcription, the tagged cDNA is amplified by PCR using only the tag
sequence as one of the primers and an HCV-specific oligonucleotide as the
opposing primer. Using this procedure, the strand-specificity is increased by
preventing the amplification of cDNA products obtained by false priming of the
incorrect RNA strand in conventional PCR. Alternatively, false priming can be
avoided by using a thermoresistant RT (rTth) for cDNA synthesis at 70°C
(Lanford et al. 1994; Lanford et al. 1995). Since the strand specificity requires
that no RT activity is present during PCR amplification, this is achieved by
chelation ofMn2+ with EGTAwhile the DNA polymerase activity of the enzyme
is activated by addition of Mg2+. Another method used to overcome the
nonspecific cDNA synthesis due to random priming by contaminating cellular
nucleic acids is chemical modification of the 3'-end of RNA before the RT step
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(Gunji et al. 1994). Under these conditions, RNA molecules with modified 3'-
end (the 3'-terminal nucleotide is converted to a di-alcohol) cannot act as
primers and the cDNA is specifically synthesized during RT only by addition of
a specific primer. Another approach to avoid non-specificity in RT-PCR assays
is to use primers that will amplify the core region of HCV genome (Lerat et al.
1996) or to use core primers in combination with the tag primer (Mellor et al.
1998). Primers specific to the HCV 5'-UTR has been widely used for
amplification of HCV genomic strands because this region is the most highly
conserved domain. However, most of the methods developed for the detection
of negative strand HCV RNA based on amplification of 5'-UTR may generate
false positive results due to self-priming events which the secondary structure of
this region might be responsible for (Lanford et al. 1994; Tokita et al. 1994). The
use of primers specific to conserved domains of HCV core region, in comparison
with the tagged 5'-UTR primers, increased the overall specificity of the assay for
the detection of negative strand RNA molecules (Lerat et al. 1996). In order to
maximize the specificity of the detection method, primers for the core region
that were highly conserved between published variants of HCV were designed
and a tag sequence was added at the 5'-end of the outer primers (Mellor et al.
1998). The use of tagged core primers together with highly stringent
amplification conditions (pre-denaturation of the template RNA at 70°C for 10
min prior to the addition of AMV reverse transcriptase at 42°C, heat-
inactivation of the enzyme at 98°C for 10 min after RT reaction followed by hot-
start PCR) reduced further non-specific priming. Analysis of samples from HCV-
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infected individuals using these improved strand-specific RT-PCR techniques
suggests that HCV does not replicate in PMBCs, or only replicates at very low
levels (Gunjieta/. 1994; Lanford et al. 1995; Lerat et al. 1996; Laskus etal. 1997;
Mellor et al. 1998). For example, no minus-strand HCV RNA was detected in
PBMCs in any sample despite the presence of abundant plus-strand RNA using
strand-specific 77/z-based RT-PCR (Lanford et al. 1995; Laskus et al. 1997).
Similarly, using RT-PCR method combined with chemical RNA modification at
the 3'-end, minus-strand HCV RNA was detected in PBMCs in only one case
(10%) while plus-strand RNA in eight cases (80%) (Gunji et al. 1994). In ten
chronically HCV-infected patients, the highly stringent strand-specific PCR assay
based on tagged core primers detected plus-strand HCV RNA in different
PBMC subsets (mainly in B lymphocytes) and minus-strand RNA in a single
subset (dendritic cells) of one of the samples analyzed (Mellor et al. 1998).
The presence of HCV in bone marrow cells has been also investigated
using RT-PCR based methods (Gabrielli et al. 1994a; Galli et al. 1995a; Lanford
et al. 1995a; Lerat et al. 1996a; Laskus et al. 1998a), but the findings are
controversial. Although HCV replicative intermediates have been identified in
bone marrow cells from patients with cryoglobulinemia (Gabrielli et al. 1994;
Galli et al. 1995), no HCV negative strand RNA was detected in a bone marrow
biopsy from a chronically infected chimpanzee (Lanford et al. 1995), in fresh
bone marrow cells from chronic hepatitis C patients (Lerat et al. 1996) or in
bone marrow collected postmortem from HCV-infected patients who died of
acquired immunodeficiency syndrome (AIDS)-related complications (Laskus et
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al. 1998a).
In the case of HGV/GBV-C, the degree of controversy is even higher.
Initially, an association between HGV/GBV-C infection and acute liver disease
in humans was suggested since viral RNA was detected in sera from patients
with acute, post-transfusion nonA-E hepatitis (Linnen et al. 1996) and in 50%
of patients with fulminant hepatitis from Germany (Heringlake et al. 1996). The
same conclusion was reached in another study in which sera from 35% of Italian
patients with acute nonA-E hepatitis and 39% with chronic nonA-E hepatitis
were HGV/GBV-C positive (Fiordalisi et al. 1996). However, the association
between HGV/GBV-C viraemia and hepatitis has become more controversial
since in hepatitis patients infected only with HGV/GBV-C, neither the presence
or titre of viral RNA is correlated with biochemical evidence of liver disease
(Alter et al. 1997). To investigate whether HGV/GBV-C replicates in the liver
of infected patients, the presence of HGV/GBV-C RNA was assessed and
quantified by strand-specific PCR techniques involving either cDNA synthesis
at a high temperature with thermostable enzyme Tth (Laskus et al. 1997b;
Laskus et al. 1998b), use of specific primers for 5'-UTR (Kudo et al. 1997),
chemical modification of the 3'-end of RNA (Madejon et al. 1997; Saito et al.
1997; Kanda et al. 1998) or tagged primers specific for the NS3 region (Mellor
et al. 1998). Detection of negative strand RNA would be considered as evidence
of viral replication. However, in liver samples from HCV and HGV/GBV-C-
coinfected patients, the plus strand of HGV/GBV-C RNA was only detected at
very low levels compared to those of HCV RNA (Kudo et al. 1997) while the
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minus strand was not found (Laskus et al. 1997; Kanda et al. 1998; Laskus et al.
1998; Mellor etal. 1998). These findings suggest that HGV/GBV-C, unlike HCV,
is not hepatotropic, implying that its cell tropism might be different to that of
HCV. In contrast, other reports indicated the presence of negative strand
HGV/GBV-C RNA in liver biopsy samples using chemical modification method
(Madejon et al. 1997; Saito et al. 1997). Since there is a limitation of this assay
for detecting strand specificity when large amounts of HGV/GBV-C are present
in the sample (Kanda et al. 1998), these results might not be accurate.
Since the discovery of HCV in 1989, many attempts have been made to
develop an efficient system for HCV replication in cell culture either by
infection or transfection.
In the infection experiments, serum or plasma collected from HCV-
infected individuals has been used to infect cultured cells such as MOLT-4
human T-cell line (Shimizu et al. 1992), Daudi cells (B-cell line) (Nakajima et
al. 1996), chimpanzee hepatocytes (Lanford et al. 1994), PBMCs from healthy
donors (Cribier et al. 1995), MT-2 cells (human T-cell leukaemia virus type I-
infected cell line) (Kato et al. 1995; Mizutani et al. 1996), HepG2 and HuH7
cells (human hepatoma cell lines) (Seipp et al. 1997), HFH cells (human foetal
hepatocytes) (Iacovacci et al. 1997) and normal human hepatocytes in primary
culture (Fournier et al. 1998). Although in some cases, long-term infection of up
to 198 days (Mizutani et al. 1996) or more than 1 year (Mizutani et al. 1996) has
been achieved, in general, HCV replication in cultured cells is transient or
intermittent. Various reports have described different procedures for the
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replication of HCV in vitro including: shift of temperature for culture incubation
from 37°C to 32°C after virus inoculation (Mizutani et al. 1996), use of a large
number of serum samples as inocula (Fournier et al. 1998), stimulation of LDL
receptor expression and use of highly supplemented culture medium (Seipp et
al. 1997). In most cases, detection of minus-strand HCV RNA by strand-specific
PCR (Lanford et al. 1994; Cribier et al. 1995; Fournier et al. 1998) or nested-
PCR followed by hybridization (Shimizu et al. 1992; Seipp et al. 1997) was
considered as evidence of viral replication. The expression of virus-encoded
proteins was also tested by examining the cultured cells for putative HCV core
and NS4 antigens using indirect immunofluorescence method with mouse
monoclonal anti-HCV antibodies (Shimizu et al. 1992). However, these
investigations have been hampered by the limited specificity and sensitivity of
methods used to detect plus- and minus-strand HCV RNA, by the low titres of
RNA present, and by variation in infectivity between serum samples.
The alternative approach used to establish an in vitro permissable HCV
culture system is by transfection of infectious RNA transcripts into HuH7 cells
(Yoo et al. 1995) and HepG2 cells (Dash et al. 1997). In both reports, not only
the full-length HCV RNA transcript but also HCV transcripts without the highly
conserved 3'-end 98 nucleotide-sequence were found to be infectious. The
interpretation of these results must be done with care since the last 46
nucleotides of this conserved region of HCV RNA were predicted to form a
stable stem-loop structure considered to be critical for viral replication
(Kolykhalov et al. 1996; Blight and Rice, 1997) and transcripts of a chimeric full-
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length cDNA clone of HCV proved to be infectious in vivo when the infectivity
was tested by intrahepatic transfection of a chimpanzee with transcribed RNA
(Yanagi et al. 1998).
In contrast, efforts to develop reliable cell culture systems that are
permissive to in vitro replication of HGV/GBV-C are at a very early stage. Two
cell lines, MT-2C (a human T-cell leukaemia virus type I-infected cloned T cell
line) and PH5CH (a non-neoplastic human hepatocyte line), have been reported
as susceptible to HGV/GBV-C infection and capable of supporting the viral
replication when the temperature was shifted from 37°C to 32°C after the virus
inoculation (Ikeda et al. 1997).
The aims of the study described in this chapter were to examine the
susceptibility of three types of cultured cells (PBMCs, U937 and HepG2 cells)
to HCV and HGV/GBV-C infection and to identify the potential factors that
could mediate the infection process in an attempt to develop reliable cell culture
systems. Different approaches were used to infect the cells and a modified
nested PCR-based assay using tagged primers in the core region of HCV and
NS3 region of HGV/GBV-C that allows specific strand detection of single-strand
RNA (Mellor et al. 1998) was performed.
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6.2 CELLS AND SAMPLES USED
PBMCs freshly isolated from the blood of healthy donors and two
immortalized cell lines-the human monocytic leukaemia cell line U937 and the
human hepatoma cell line HepG2-were tested for their susceptibility to HCV
and HGV/GBV-C infection .
PMBCs were separated from heparinized blood using a Ficoll density
gradient and resuspended in RPMI 1640 medium containing 10% FCS,
antibiotics (104IU/ml), L-Glutamine (lOOmM) and IL-2 (104IU/ml) (section
2.5.1). In order to stimulate cell division, the cells were incubated with PHA
(5/j.g/ml) for 48h before virus inoculation.
U937 cells grow as a single cell suspension and they have been shown to
have characteristics of an undifferentiated monocytic cell (Sundstrom and
Nilsson, 1976). These cells are variable in shape (round and polygonal) and can
be induced to differentiate into macrophages by a variety of agents such as
dimethylsulfoxide (DMSO) (Kay et al. 1983), vitamin D (Rigby et al. 1984) or
phorbol ester (Lewis et al. 1987). In this study, the differentiation of U937 cells
was achieved by the addition of phorbol 12-myristate, 13-acetate (PMA) to
cultured cells before virus inoculation (section 2.5.1). Differentiated cells become
adherent to tissue culture plastic and monolayers were incubated with HCV or
HGV/GBV-C positive sera in separate flasks.
The human hepatoma cell line HepG2 was maintained in RPMI 1640
medium supplemented with 10% FCS and antibiotics (104IU/ml) as monolayers
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in culture flasks at 37°C in a 5% C02 atmosphere ( section 2.5.1). HepG2 cells
bind, take up and degrade low-density lipoproteins (LDL) through specific LDL
receptors similar to those demonstrated on extrahepatic tissue cells (Havekes et
al. 1983). Since HCV and HGV/GBV-C were found to be associated with low
density lipoproteins in human plasma (Chapter 4), a putative LDL-mediated
entry of the viruses into the cells was examined. For this purpose, the cells were
grown in FCS-free Ham's F12 medium with supplements and lovastatin before
virus inoculation (section 2.5.1). Lovastatin is an inhibitor of one of the enzymes
involved in the cholesterol biosynthesis pathway HMG-CoA (3-hydroxy-3-
methylglutaryl-coenzyme A reductase), with the result that the LDL-receptor on
the cell surface is upregulated.
HCV and HGV/GBV-C positive serum samples with high viral RNA
titres together with the negative control of a HCV and HGV/GBV-C negative
serum were used for in vitro infection of the cells (Table 6.1). All experiments
were carried out in duplicate.
In order to identify parameters that might increase the permissiveness of
cells to viral infection, a number of different culture conditions were analysed.
For example, different volumes of the inoculum were used during the in vitro
infection step: 10 /A for PBMCs, 25 /x1 or 100 fA for U937 cells and 100 [A for
HepG2 cells. The incubation period of cells with the viral inoculum was either
4h (PBMCs, U937), 24h (PBMCs, U937) or 90min (HepG2) at 37°C in a 5%
C02 atmosphere. Inoculum was then removed (day 0) and cells were washed
three times with PBS and fresh medium was added. In all the experiments, at
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Table 6.1 Serum samples used as inocula for in vitro infection of cultured cells




SI (haemophiliac) 1.0 x 106 -ve PBMC
S2 (haemophiliac) -ve 1.0 x 106 PBMC
S3 (haemophiliac) 1.0 x 105 -ve U937
S4 (blood donor) -ve 5.0 x 108 U937
S5 (haemophiliac) 1.0 x 104 -ve U937
S6 (haemophiliac) 1.0 x 106 -ve HepG2
S7 (haemophiliac) 1.0 x 107 -ve HepG2
S8 (blood donor) -ve 1.5 x 107 HepG2
S9 (blood donor) -ve 3.0 x 106 HepG2
S10 (blood donor) -ve -ve all
-ve = PCR-negative
HCV-positive samples were quantified by J. Ellender (University of Edinburgh).
HGV/GBV-C-positive sampleswere quantified by F. Davidson (BTS-Edinburgh).
various times during the culture period (days post-inoculation), 1/10 of the
inoculated culture was harvested and separated by centrifugation at lOOOrpm for
5min. The supernatants and cell pellets were kept at -40°C for RNA extraction
(sections 2.2.1 and 2.2.2). HCV plus-strand RNA was detected by RT-PCR using
primers specific to the 5'-UTR and by strand-specific PCR using tagged primers
specific to the core region, while the presence of minus-strand was examined
using tagged primers specific to the core region (Table 2.1). Similarly, the
presence of HGV/GBV-C plus-strand RNA in the supernatants and cells of
HGV/GBV-C infected cultures was investigated by RT-PCR using primers
specific to the HGV/GBV-C 5'-UTR and by strand-specific PCR using tagged
primers specific to the NS3 region while the minus-strand RNA was detected
using tagged primers specific to the HGV/GBV-C NS3 region (Table 2.1).
Reaction conditions for conventional RT-PCR and for strand-specific RT-PCR
were as described in sections 2.2.4 and 2.2.5. Negative controls using HCV and
HGV/GBV-C negative serum were included in each experiment and




6.3.1 IN VITRO INFECTION OF PBMCs
PHA-stimulated PBMCs (1 x 106 cells/ml) were inoculated with three
separate serum samples for 4h or 24 hr at 37°C. In both cases, cell growth was
not affected by inoculation. Cultures were harvested on days 1, 3 and 8 post-
inoculation (p.i.) for the 4h-incubation experiment (Table 6.2 A) and on days 1,
2, 7 and 10 p.i. for the 24h-incubation experiment (Table 6.2 B). In both
experiments, plus-strands of HCV RNA and HGV/GBV-C RNA were detected
in supernatants collected after inoculation (Table 6.2 A, B). Plus-strand HCV
RNA was also detected in cells harvested at day 1 p.i. for the 4h-incubation
experiment (Table 6.2 A) and in cells at day 7 p.i. for the 24h-incubation
experiment (Table 6.2 B). Minus-strands of HCV or HGV/GBV-C RNA were
not detected in either the supernatants or cells of any of these cultures. HCV
and HGV/GBV-C RNA were uniformly absent in the negative control cultures.
Similar results were obtained when the 4h-incubation experiment was repeated
when PHA-stimulated PBMCs (1 x 106 cells/ml) were inoculated with 2 different
HCV and HGV/GBV-C positive serum samples (data not shown).
6.3.2 IN VITRO INFECTION OF U937 CELLS
The susceptibility of U937 cells to infection by HCV and HGV/GBV-C
was investigated in two separate experiments using undifferentiated U937 cells
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Table 6.2 Detection of HCV RNA and HGV/GBV-C RNA in PMBC culture,
lx 106 cells/ml inoculated with 10/xl serum SI (HCV) or S2 (HGV/GBV-C).
A. 4h-incubation experiment
Supernatants Cells
HCV RNA HGV RNA HCV RNA HGV RNA
plus minus plus minus plus minus plus minus
days
p.i.
0 + - + - nd nd nd nd
1 + -
3 - - - - - -
8 - - - - - "
B. 24h-incubation experiment
Supernatants Cells
HCV RNA HGV RNA HCV RNA HGV RNA
plus minus plus minus plus minus plus minus
days
p.i.
1 + - + - - .
2 - - - - - -
7 - - - - + -
10 - -
nd = not done
plus = plus-strand RNA
minus.=minus-strand RNA
p.i.=post-inoculation
(cell suspension) and differentiated (PMA-treated) U937 cells (monolayers).
Since the differentiation of U937 cells increased permissiveness for
haemorrhagic fever virus infection and production (Lewis et al. 1987),
monolayers were prepared and used, in parallel with cell suspension, to
determine any possible effect of cell differentiation on in vitro HCV or
HGV/GBV-C infection. In both cases, cells were inoculated separately with
either HCV or HGV/GBV-C positive serum samples.
Plus-strand HGV/GBV-C RNA could only be detected in PMA-treated
U937 cells at day 1 p.i. and was absent from other cell or supernatant samples
up to 4 days p.i. (Table 6.3 A). For the untreated non-adherent cells,
HGV/GBV-C plus-strand RNA was only detected in the supernatant 1 day p.i.
but not in other supernatant or cell samples harvested up to 4 days p.i. (Table
6.3 B). Plus-strand HCV RNA was only detected in cells and/or supernatants
collected at days 2, 3 and 4 p.i. from the untreated cells, but no minus-strand
RNA was detected up to 4 days p.i. (Table 6.3 B).
These findings were further investigated by maintaining a suspension of
U937 cells in culture for 18 days p.i. The failure to detect minus-strand RNA in
the cells during short-term culture (Table 6.3 B) suggested that the entry of the
virus particles into the cell might require a longer exposure time (25 /A or 100
l±1 inoculum incubated for 24h at 37°C, in parallel experiments). Plus-strand
HCV RNA was detected at 15 days p.i. in cells inoculated with either of HCV-
positive inocula (S3 or S5) and also at day 18 p.i. for inoculum S5 (Table 6.4 B).
However, no minus-strand RNA was found in either the supernatants or cells
134
Table 6.3 Detection of HCV RNA and HGV/GBV-C RNA in U937 cells
A. PMA-treated U937 cells incubated with 100/xl inoculum (HCV-S3 or HGV-
S4) for 4h at 37°C
Supernatants Cells
HCV RNA HGV RNA HCV RNA HGV RNA






4 - - - - - -
B. U937 cell suspension (2 x 105 cells/ml) incubated with 25/xl inoculum (HCV-
S3 or HGV-S4) for 4h at 37°C.
Supernatants Cells
HCV RNA HGV RNA HCV RNA HGV RNA
plus minus plus minus plus minus plus minus
days
P-i-
1 nd nd + _ nd nd
2 + - - +
3 + - - -
4 + nd nd +
nd= not done
plus = plus-strand RNA
minus = minus-strand RNA
Table 6.4 Detection of HCV RNA and HGV/GBV-C RNA in U937 cell
suspension. 25/xl or 100/xl inoculum incubated with 2 x 105cells/ml for 24h at
37°C.
A.















nd nd nd nd +
B.
Cells
HCV RNA HCV RNA HGV RNA








from these cultures (Tables 6.4 A and B).
For U937 cell suspensions exposed to HGV/GBV-C inoculum, only plus-
strand RNA was detected in the supernatants immediately after inoculation (day
0) but not in later samples or in the cells (Table 6.4 A).
No HCV or HGV/GBV-C RNA was detected in either the supernatants
or cells harvested from U937 monolayers or cell suspensions inoculated with the
negative control serum.
6.3.3 IN VITRO INFECTION OF HepG2 CELLS
Prior to virus inoculation, HepG2 monolayers were harvested by
trypsinisation and the cells washed and resuspended (1 x 106 cells/ml) in FCS-
free Ham's F12 medium with supplements and treated with lovastatin (final
concentration 10 yuM) in order to stimulate the expression of the LDL receptor
on the cell surface (section 2.5.1). The HepG2 monolayers were then inoculated
with 100 /rl of HCV-(S6, S7) or HGV/GBV-C-(S8, S9) positive serum samples
for 90 min at 37°C. The inoculated monolayers were grown in serum-free highly
supplemented Ham's F12 medium and harvested on days 0, 3, 7, 14 and 21 p.i.
All samples, at all times, were negative for HCV or HGV/GBV-C minus-
strand RNA. The presence of plus-strands of HCV RNA and HGV/GBV-C
RNA could only be detected in the supernatants collected immediately after
inoculation (day 0) and day 3 p.i. (Table 6.5 A). Cells harvested during the
culture period remained PCR negative for the presence of HCV RNA and
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Table 6.5 Detection of HCV RNA and HGV/GBV-C RNA in HepG2 cells.
Lovastatin-treated HepG2 cell monolayers incubated with lOOyxl inoculum for
90min at 37°C.
A.
inoculum S6 S7 S8 S9
Supernatants
HCV RNA HCV RNA HGV RNA HGV RNA
plus minus plus minus plus minus plus minus
days
P-i-
0 + - + - + - +






HCV RNA HCV RNA HGV RNA HGV RNA
plus minus plus minus plus minus plus minus
days
P-i-
HGV/GBV-C RNA, respectively (Table 6.5 B).
6.4 DISCUSSION
Establishment of easily maintained culture systems for in vitro infections
with HCV or HGV/GBV-C is critical for investigation of virus-cell interaction
and other important aspects related to replication and pathogenesis of these
viruses. In this study, three types of cultured cells were inoculated with serum
samples from HCV- or HGV/GBV-C infected individuals in order to investigate
their susceptibility to infection. The sera selected as inocula contained high viral
RNA titres (Table 6.1) and various culture conditions were applied before or
during the virus inoculation to increase the putative permissiveness of these cells
to virus infection. However, different volumes of inoculum, variable incubation
times, induction of cell differentiation before virus inoculation or stimulation of
the LDL receptor expression had no significant effect in supporting the in vitro
replication of either HCV or HGV/GBV-C. The presence of HCV RNA or
HGV/GBV-C RNA in supernatants or cells after inoculation (day 0) and during
the first days of culture in PBMCs (Table 6.2), in U937 (Tables 6.3, 6.4) and
HepG2 cells (Table 6.5) might be ascribed to the inoculum or non-specific
attachment/adhesion of virus particles to the cell surface.
The lack of evidence for the in vitro replication of HCV and HGV/GBV-
C in any of the cultured cells used in this study could be analyzed considering
the following aspects:
136
a) Type of inoculum used.
Compared to hepatitis B virus, the levels of HCV and HGV/GBV-C
RNA in infected individuals are relatively lower and their routine detection
normally relies on nested RT-PCR. In this study, serum samples with high levels
of viral RNA were used as inocula (Table 6.1), in order to maximise the chance
of the cells becoming infected in vitro. However, although PCR is a sensitive
detectionmethod, it cannot discriminate between infectious and inactivated virus
particles, and the infectivity of the inoculum will not necessarily correlate with
the level of viral RNA. This possibility is reinforced by experiments in which a
number of sera from chronically HCV-infected individuals were screened for in
vitro infection of normal chimpanzee hepatocytes (Lanford et al. 1994) or
primary cultures of adult human hepatocytes (Fournier et al. 1998). In the latter
study, evidence of infection of the cells with HCV was obtained using strand-
specific xTth RT-PCR for only 10 out of the 33 sera, and three of the non¬
infectious inocula had high RNA titres (1.12 x 108-1.41 x 108 copies/ml). To
avoid this problem, multiple serum samples (5 HCV- and 4 HGV/GBV-C
positive) were used in this study but no evidence for replication was obtained.
b) Sensitivity and specificity of RT-PCR assay.
The strand-specific RT-PCR assay based on detection of the negative
strand intermediate molecules of HCV and HGV/GBV-C has been used in most
of the studies that investigated the viral replication in the infected cells in vivo
and in vitro (Lanford et al. 1994; Lanford et al. 1995; Lerat et al. 1996; Kudo et
al. 1997; Laskus et al. 1997; Saito et al. 1997; Mellor et al. 1998). Potential causes
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of non-specific amplification of both positive and negative strands of viral RNA
that could lead to false positive results have been considered and examined
(Gunji et al. 1994; Kudo et al. 1997; Mellor et al. 1998; Sangar and Carroll,
1998).
The specificity and sensitivity of strand-specific RT-PCR assays used in
this study have been assessed and validated in a previous report which
investigated whether sub-populations of PBMCs could be considered as possible
extra-hepatic sites for in vivo replication of HCV and HGV/GBV-C (Mellor et
al. 1998). To maximise the two essential characteristics of the detection,
amplification conditions were highly stringent: the template RNA was pre-
denatured at 70°C for lOmin prior to the addition of reverse transcriptase, and
after the cDNA synthesis the samples were heated at 98°C for 2 min to heat-
inactivate the RT enzyme, 'hot-start' PCR with an elevated annealing
temperature of 55°C for 30 cycles was carried out (Mellor et al. 1998) (section
2.2.4). At the same time, to maximise the specificity, PCR was performed using
newly designed tagged primers specific for the core region of HCV or NS3
region of HGV/GBV-C (Table 2.1). This strand-specific detection system,
validated using synthetic RNA transcripts for each strand of both viruses,
indicated that the non-specific priming that could be attributed to residual
plasmid DNA, was significantly reduced (no positive signals detected in the
titration of synthetic HCV transcripts serially diluted up to 1:1010 or of
HGV/GBV-C transcripts up to 1:107) (Mellor et al. 1998).
Using this strand-specific PCR assay, no negative strand of HCV RNA
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or HGV/GBV-C RNA could be detected in the supernatants or cells harvested
at different times after inoculation of PMBCs, U937 or HepG2 cells. Although
plus-strand HCV RNA was detected at days 15 and 18 p.i. in the cell pellets
from U937 cell suspensions (Table 6.4 B), the failure to detect minus-strand or
plus-strand of HCV RNA released as new virions in supernatants at the same
time suggests that this does not reflect viral replication. However, the possibility
of a low level of replication cannot be totally excluded since no RNA
quantification of PCR-positive samples was carried out. As previously suggested,
low-level replication or replication limited to a small number of cells would
remain undetected because minus-strand HCV RNA is generally detected, in
cells supporting replication, at 100- to 1000-fold-lower levels than plus-strand
RNA (Lanford et al. 1995).
c) Cell tropism of HCV and HGV/GBV-C.
The question of whether PBMCs can be infected by HCV in vivo or in
vitro has been a controversial issue mainly due to the methodology employed to
detect minus-strand RNA molecule, the replicative intermediate (Zignego et al.
1992; Muller et al. 1993; Cribier et al. 1995; Lanford et al. 1995; Lerat et al. 1996;
Laskus et al. 1997; Mellor et al. 1998). However, most of the reports that used
strand-specific PCR-based assays of sufficient sensitivity and specificity conclude
that if HCV replication occurs in PBMCs, it is only at a very low level.
Following the observation that PBMCs are permissive for HCV
replication in vitro (Cribier et al. 1995), their susceptibility to HCV and
HGV/GBV-C infection was tested in this study by incubating PMBCs isolated
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from healthy donors with HCV- or HGV/GBV-C-positive sera. The lack of
evidence for in vitro replication ofHCV in PBMCs (Table 6.2) is consistent with
previously published findings suggesting that the rate of HCV replication in
PBMCs inoculated in vitro is low and that virus remains primarily cell-associated
(Cribier et al. 1995). Similarly, in the case of HGV/GBV-C, PBMCs could not
be infected in vitro (Table 6.2) in agreement with the lack of evidence for
HGV/GBV-C replication in vivo in PBMCs collected from HGV/GBV-C
infected individuals (Laskus et al. 1998; Mellor et al. 1998; Radkowski et al.
1998).
The second type of cultured cells used in this study (U937 cells) is a
continuous cell line that exhibits morphologic and functional characteristics of
undifferentiated monocytic cells (Sundstrom and Nilsson, 1976). These cells have
proved useful for studies of viral infection with Herpes simplex virus type 1
(Linnavuori and Hovi, 1981), measles virus (Brandriss et al. 1982), and
haemorrhagic fever virus (Lewis et al. 1987). In case of HCV, the presence of
viral RNA and core antigen was detected in a monocyte/macrophage population
of PBMCs from infected patients (Bouffard et al. 1992).
Previously, various cell lines were tested for their susceptibility to HCV
infection, and U937 cells were found to be relatively susceptible because positive
strand RNA was detected in cells 7 days p.i. (Kato et al. 1995). In reality, the
detection of positive strand HCV RNA, especially during the first days of culture
period, could simply indicate the adsorption of the viral particles to the cell
membrane and cannot be considered as evidence for viral replication. Consistent
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with this observation, under the experimental conditions tested, U937 cells were
not susceptible to HCV or to HGV/GBV-C infection (Table 6.4). Replication
was also not observed when U937 cells were induced to differentiate to
macrophage-like cells by phorbol esters (PMA) (Table 6.3 A) although the
degree of cellular differentiation seems to be a determining factor of the
susceptibility of these cells for infection by viruses (Lewis et al. 1987).
Differentiation of early monocytic precursors to more mature monocytes that
resemble macrophages using phorbol esters was previously shown to be a
membrane-mediated process (Cooper et al. 1982). The sequence of events by
which the changes occur is not well understood. However, the inducer appears
to be bound to a specific surface receptor on the cells and it is not internalized
(Cooper et al. 1982). For HCV or HGV/GBV-C, PMA-induced alterations of
U937 cells did not facilitate the viral entry, an essential step in cell-virus
interaction.
HepG2 cells are well differentiated hepatoblastoma cells that display
certain functions similar to human hepatocytes such as synthesis of a number of
plasma proteins and apopoliproteins and the presence of high-affinity LDL
receptors (Havekes et al. 1983). The hypothesis that the LDL receptor present
on the surface of hepatocytes facilitates the entry of HCV into cells is supported
by the observation that positive strand HCV RNA could be detected for 50 days
p.i. when LDL receptor expression was stimulated by lovastatin in HCV-infected
HuH7 cells (human hepatoma cell line) grown in FCS-free supplemented Ham's
F12 medium (Seipp et al. 1997).
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However, the HepG2 cells examined in this study did not show
susceptibility to either HCV or HGV/GBV-C infection when LDL receptor
expression was stimulated (Table 6.5).
The replication of HGV/GBV-C in cultured human cells (MT-2C and
PH5CH) has been reported (Ikeda et al. 1997). These cell types have been
previously found to be capable of supporting the replication of HCV (Mizutani
et al. 1996). After inoculating the cells with serum containing high titres of both
HCV RNA and HGV/GBV-C RNA, a shift of temperature from 37°C to 32°C
seemed to be effective in supporting HGV/GBV-C as well as HCV replication.
HCV RNA and HGV/GBV-C RNA could be detected in both cell lines more
than 30 days p.i. by RT-nested PCR using primers from 5'-UTR of HCV RNA
and HGV/GBV-C RNA and from 3'-UTR ofHGV/GBV-C RNA. However, the
presence of negative strand RNA of either HCV or HGV/GBV-C was not
examined in this study. As previously suggested, standard RT-PCR is not strand-
specific because of false priming of the incorrect strand or self-priming related
to RNA secondary structures (Lanford et al. 1994). Since, generally, the presence
of replicative intermediates must be established as evidence for replication
(Cribier et al. 1995; Lanford et al. 1995; Laskus et al. 1997; Laskus et al. 1997;
Seipp et al. 1997; Fournier et al. 1998; Mellor et al. 1998), strand-specific RNA
detection should be performed before drawing a final conclusion about HCV or
HGV/GBV-C replication in these cultured cells.
In conclusion, the lack of evidence for HGV/GBV-C replication in certain
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cultured cells (PBMCs, U937 and HepG2 cells) under experimental conditions
tested together with previous studies of in vivo replication (Laskus et al. 1997;
Kanda et al. 1998; Laskus et al. 1998; Mellor et al. 1998; Radkowski et al. 1998)
suggest that the identification of the in vivo sites of replication may be necessary





Since the discovery and isolation of HGV/GBV-C in 1995 (Simons et al.
1995a; Linnen et al. 1996a), there has been considerable interest in the
prevalence and clinical characteristics of HGV/GBV-C infection. The virus can
cause acute and persistent infection in humans and has a worldwide distribution
(Europe, Asia, South America, Africa), being present in both healthy and
diseased population groups (Chapter 1). However, the pathogenicity of
HGV/GBV-C is controversial since in most cases, infection appears to be
asymptomatic with slight or no increase of serum ALT levels and the causative
role of HGV/GBV-C in hepatitis is increasingly being questioned.
The aim of this study was to investigate and analyse the heterogeneity of
HGV/GBV-C and to characterize the terminal regions of the viral genome.
Comparative analysis of nucleotide sequence data revealed a very different
pattern of HGV/GBV-C variability from that identified in HCV. For example,
it is possible to classify HCV isolates into six major genotypes which can be
divided further in subtypes, on the basis of sequence comparisons of complete
genomes or of subgenomic regions (Simmonds et al. 1993a; Simmonds et al.
1994a). At the same time, it is known that infection with different HCV
genotypes is associated with important clinical differences in serological
responses, pathogenicity, and the response to interferon treatment (Dusheiko et
al. 1994; Simmonds, 1997). The extensive phylogenetic analysis carried out in
this study, in which a large number of HGV/GBV-C full-length and 5'-UTR
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sequences have been compared has demonstrated the presence of four
phylogenetic groups of isolates which are well correlated with their geographical
origin (Chapter 3). Although the diversity between HGV/GBV-C variants is
limited in comparison to that between HCV types, phylogenetic groupings of
HGV/GBV-C can be reproduced by analysis of the 5'-UTR and of sub-
fragments.
This information about virus heterogeneity and the geographical
distribution of HGV/GBV-C groups is relevant to discussions about the origin
of this virus. For example, in the case of HCV, the existence of numerous
subtypes in a single geographical area is consistent with the long-term presence
of HCV in these populations (Mellor et al. 1995; Smith et al. 1997). The rate of
HCV sequence change measured amongst a cohort of individuals infected with
HCV following administration of anti-D immunoglobulin was calculated at 4.1
x 10"4 per site per year for NS5B and 7.4 x 10"4 per site per year for El, while
the divergence of HCV types was estimated to occur more than 500 years ago
(Smith et al. 1997). A similarly high rate of sequence change of 3.9 x 10"4 per site
per year was estimated for the whole genome of HGV/GBV-C over 8.4 years
(Nakao et al. 1997). Since HGV/GBV-C variants are more similar to each other
than HCV types, this rate of substitution would imply that HGV/GBV-C variants
have emerged within a few hundred years.
Another approach to elucidating the origin of HGV/GBV-C is based on
construction and analysis of phylogenetic trees of the NS3 and NS5A regions
from different HGV/GBV-C isolates (Tanaka et al. 1998). Using the New World
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monkey isolate GBV-A as an outgroup, a distinct subgroup of group 1 of
isolates from African pygmies and containing a duplicated region within the
NS5A gene, appeared to be ancestral, interpreted by the authors as indicating
an African origin of GBV-C. However, more recent analysis based upon
complete genome sequences and in which the chimpanzee isolate HGV/GBV-
was used as an outgroup have failed to confirm that group 1 isolates are
ancestral (D.B.Smith, personal communication). The HGV/GBV-C^ is a novel
flavivirus recently detected in non-captive chimpanzees from Central and West
Africa (Adams et al. 1998). Sequence comparisons of 5'-UTR, NS3 and NS5
regions showed that this virus is distinct from both HGV/GBV-C and GBV-A,
but more closely related to human viruses. Distinct variants of this virus,
recovered from different subspecies of chimpanzees are more diverse than
variants of HGV/GBV-C found in humans. For example, 19.3% nucleotide and
9.5% amino acid sequence diversity in the NS5 region was found between
variants recovered from chimpanzees, compared to levels of 10.4% nucleotide
and 1.9% amino acid diversity between variants of HGV/GBV-C infecting
humans (Adams et al. 1998). These findings suggested the existence of a species-
specific association of GB viruses with their hosts, although the degree of
sequence similarity contradicts with the high rate of sequence change of
HGV/GBV-C estimated by Nakao (Nakao et al. 1997). In order to investigate
this apparent paradox, a recent study examined the existence of restrictions on
variability at certain sites in the HGV/GBV-C genome that may be responsible
for the limited divergence of virus sequences over time (Simmonds and Smith,
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1999). Potential RNA secondary structures detected and analysed by a
covariance algorithm were found to be distributed throughout the HGV/GBV-C
genome. Structural constraints imposed by the mechanism of RNA secondary
structure formation may determine very slow, long term rate of sequence change
in the HGV/GBV-C genome (Simmonds and Smith, 1999).
The identification of clusters of group-specific polymorphisms within the
HGV/GBV-C 5'-UTR could improve the design of oligonucleotide primers for
virus detection. In addition, the information could be used to improve the choice
of restriction enzymes for the identification of HGV/GBV-C groups through
RFLP typing of the 5'-UTR (Mukaide et al. 1997). This typing method, which
has to be continuously modified to include new sequence data, can be used as
a rapid and reliable technique to characterize new HGV/GBV-C variants
isolated from different geographical areas.
Although phylogenetically, HGV/GBV-C has a genome organization
similar to HCV and other members of Flaviviridae family (Leary et al. 1996;
Linnen et al. 1996), it appears that this virus does not encode a core protein
analogous to that of HCV. This possibility has been investigated further here by
comparing the structure ofHGV/GBV-C and HCV virions by ultracentrifugation
(Chapter 4). HGV/GBV-C RNA was found to be present in single peaks at low
density fractions within a range of 1.07 to 1.12 g/ml. This low density suggests
an association between HGV/GBV-C particles and LDL, a prediction which was
later confirmed in precipitation studies (Sato et al. 1996). The absence of viral
fractions with densities higher than 1.17 g/ml is consistent with the results of
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sequence analysis of the 5'-UTR suggesting that HGV/GBV-C lacks a
nucleocapsid. The only AUG codon conserved amongst all twenty-four
HGV/GBV-C sequences is the one near the amino-terminus of the El gene
previously identified as the site of translation initiation by Simons et al. (Simons
et al. 1996). An alternative possibility is that the HGV/GBV-C nucleocapsid is
encoded by an open reading frame on the anti-genome strand (Kondo et al.
1998), although further studies are needed to confirm this.
The analysis of primaiy sequences proved to be a useful tool in
determining structural features of the HGV/GBV-C 3'-UTR and predicting a
consensus model for the secondary structure (Chapter 5). The high degree of
nucleotide sequence conservation and the identification of a series of stable and
conserved stem-loop structureswithin the HGV/GBV-C 3'-UTR suggest that this
region is involved in RNA replication, similar to its function for other positive-
strand RNA viruses (Brinton et al. 1986; Hahn et al. 1987; Deng and Brock,
1993; Kolykhalov et al. 1996; Blight and Rice, 1997). In particular, structural
elements such as the long stable hairpin VII identified within the terminal part
of the 3'-UTR have previously been shown to be particularly conserved amongst
flaviviruses (Rice et al. 1985; Brinton et al. 1986; Proutski et al. 1997),
pestiviruses (Deng and Brock, 1993), and HCV (Kolykhalov et al. 1996; Blight
and Rice, 1997). Recently, experimental studies on flaviviruses have provided
more information about the biological relevance of the predicted structures of
the 3'-UTR of HCV (Yanagi et al. 1999) and BVDV (Yu et al. 1999). A series
of HCV mutants containing large deletions in the 3'-UTR obtained from an
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infectious clone by in vitro mutagenesis were tested sequentially for infectivity
in a chimpanzee (Yanagi et al. 1999). The poly U/polypyrimidine region and the
highly conserved region of 98 nucleotides at the 3'-terminal part which was
predicted to form three stem-loop structures (Kolykhalov et al. 1996; Blight and
Rice, 1997) proved to be critical for infectivity since mutants carrying deletions
within these two regions of the HCV 3'-UTR failed to replicate in the
chimpanzee.
In the case of BVDV, the predicted secondary structure of the 3'-UTR
(Deng and Brock, 1993) was determined by RNase cleavage experiments
combined with chemical modification of the native RNA transcripts (Yu et al.
1999). Largely in agreement with the proposed model, the conserved terminal
part of the 3'-UTR was shown to contain two stem-loops (SLI and SLII)
separated by a long single-stranded sequence (SS motif). Fifteen different
mutations which affected either the 3' terminus of SLI or the SS motif were
carried out in order to establish the functional role of these elements during
RNA replication. Abolition of the stem regions of SLI and substitution of
certain nucleotides within the SS motif totally destroyed the ability of the
respective mutants to replicate in BHK cells.
In case ofHGV/GBV-C, similar experimental approachesmust be carried
out to map the 3'-UTR structural elements predicted here (Chapter 5).
Identifying and characterizing their functional significance by in vitro
mutagenesis studies will require either an infectious clone as developed for HCV
(Yanagi et al. 1998) or in vitro culture system as for BVDV (Yu et al. 1999). In
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order to develop an efficient in vitro propagation system for HGV/GBV-C, the
susceptibility of three types of cultured cells to virus infection was examined
(Chapter 6). No evidence of viral replication in these systems was obtained
under the experimental conditions tested. The highly stringent strand-specific
RT-PCR assays performed here have previously been validated and used in a
study which investigated whether extra-hepatic replication of HGV/GBV-C and
HCV occurs in PBMCs (Mellor et al. 1998). While this in vivo study provided
no evidence that PBMCs represent a replication site for HGV/GBV-C,
confirming similar observations (Laskus et al. 1998; Radkowski et al. 1998), a
more recent study suggested that HGV/GBV-C could infect and replicate in
PBMCs in vitro (Fogeda et al. 1999). One HGV/GBV-C positive serum sample
was used as inoculum in five different cell culture systems maintained for a 30
day-period (PBMCs isolated from four healthy donors and a cell pool obtained
by mixing PBMCs from each donor). According to this study, intracellular plus-
strand HGV/GBV-C RNA was detected soon after infection and remained
present during the culture period while intracellular minus-strand HGV/GBV-C
RNA appeared at day 7 p.i. and was detected either sporadically or
continuously, depending on the different donors' PBMCs. However, these results
remained to be confirmed in independent experiments while the identification
of HGV/GBV-C replication sites remains an unresolved issue.
Considerable efforts have been made to improve current methodologies
for the sensitive and specific detection of plus and minus strand RNA molecules.
Problems related to false positive results have not been completely eliminated,
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and results remain controversial. The protocols and conditions for the strand-
specific detection of HCV and HGV/GBV-C RNAs described by various
research groups need to be evaluated, compared and verified in order to
establish reproducible assays with good sensitivity and specificity which can be
widely used. Accurate and reliable detection assays for both plus- and minus-
strand HGV/GBV-C RNAs will facilitate the identification of replication sites
of this virus and the investigation of its possible pathogenicity.
Further investigations concerning the structure of HGV/GBV-C and
whether or not the virus infection actually causes any disease are necessary to
find the real answers. Although some reports support the idea that HGV/GBV-
C is an 'innocent bystander' in comparison to the 'classical' agents of viral
hepatitis, future research into the molecular virology of this virus should remain
open to address basic questions such as: why HGV/GBV-C does not express
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2.1 DENSITY GRADIENT ULTRACENTRIGATION
Sucrose (AnalaR)
TEN buffer : 50mM Tris-HCl (pH 8.0)
ImM EDTA
150mM NaCl
Beckman L8-60M ultracentrifuge with SW 50.1 rotor
polyalomer ultracentrifugation tubes....(5ml)
Abbe refractometer
2.2 POLYMERASE CHAIN REACTION
2.2.1 EXTRACTION OF VIRAL RNA FROM SERUM SAMPLES














Centrifuge (Hereus Biofuge 15R)
2.2.1 EXTRACTION OF RNA FROM CULTURED CELLS




Phenol:Chloroform:Isoamylalcohol (125:24:1) buffered with 42mM sodium
citrate (pH 4.7) (Promega)
Isopropanol
2M Sodium acetate (pH 4.0)
Nuclease-free water
2.2.3 REVERSE-TRANSCRIPTION OF VIRAL RNA





0.05/xg//xl bovine serum albumin
15% dimethylsulfoxide
Nucleoside triphosphate mixture (lOOmM stock; dilute to 4mM;
Boehringer Mannheim)
Rnasin (Rnase inhibitor; Promega-0.5/rl is equal to 10 units)
Avian Myeloblastosis Virus Reverse Transcriptase (AMV; Promega-l/rl
is equal to 10 units)
Liquid paraffin (William Ranson&son)
Thermal cycler Techne GeneE
2.2.4& 2.2.5 PCR AMPLIFICATION




Nucleoside triphosphate mixture (lOOmM stock;
dilute to 3mM)
Taq polymerase (Promega; 1/xl is equal to 5 units)
Liquid paraffin
Thermal cycler (Techne GeneE)
207
2.2.6 ANALYSIS OF PCR PRODUCTS
2% agarose gel: 6g agarose (Flowgen)
300ml 1 x TBE
10/xl Ethidium Bromide (Sigma)
10 x TBE: 108g Tris base (AnalaR)
55g Boric acid (Molecular Biology Certified; Kodak)
40ml 0.5M EDTA (Molecular Biology Certified; Kodak)
Make up to 1L with distilled water
1 x TBE used as electrophoresis buffer in the gel tank.
2.3 DNA SEQUENCING
2.3.1 PREPARATION OF DNA FOR SEQUENCING
2.3.1.1 SOLID PHASE PURIFICATION OF PCR PRODUCTS
Binding and washing buffer (BW): lOmM Tris-HCl (pH 7.5)
ImM EDTA
2M NaCl (final concentration 1M)
0.15M NaOH
TE buffer: lOmM Tris-HCl (pH 7.5)
ImM EDTA
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Dynabeads M-280 streptavidin (Dynal)
Dynal magnetic particle concentrator 6 (MPC-6; Dynal)
2.3.1.2 ALKALINE DENATURATION OF PLASMID DNA
Denaturation solution: 2M NaOH
2mM EDTA
3M Sodium acetate (pH 4.5-5.5)
100% Ethanol (AnalaR)
DEPC-water
2.3.2 DIRECT SEQUENCING OF AMPLIFIED PCR PRODUCTS
5 x Sequenase reaction buffer: 200mM Tris-HCl (pH 7.5)
lOOmM MgCl2
250mM NaCl





Termination mixtures : 80/iM of all four dNTPs supplemented with 8/xM ddATP,






Sequenase Version 2.0 T7 DNA Polymerase (1/xl is equal to 13 units) in 20mM
KP04 (pH 7.4), ImM DTT, O.lmM EDTA, 50%Glycerol.
2.3.4 DENATURING PAGE
5% Denaturing PAGE gel: 21g urea (AnalaR)
6ml Ultrapure Sequagel concentrate (50%; National
Diagnostics)
5ml 10 x TBE (Sanger)
0.05g Ammonium persulfate (APS; Sigma)
Make up to 50ml with dH20
Add 25/xl TEMED (Sigma) prior to puring gel mix.
10 x TBE (Sanger; 21itre): 324g Tris base
85g Boric acid
19g EDTA
Make up to 21 with dH20.
BIOMAX autoradiography film (Eastman Kodak).
2.4 CLONING OF PCR PRODUCTS
Geneclean kit (BIO 101 Inc.): 6M Sodium iodide
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New Concentrate (NaCl/Tris/EDTA)
GLASSMILK suspension (silica matrix in water)
100% Ethanol
TE buffer
10 x Ligase buffer: 200mM Tris-HCl (pH 7.6)
50mM MgCl2
lOmM ATP
T4 DNA ligase (0.5pl is equal to 2-3 Weiss units; R&D SystemsLtd.)
Competent cells derived from DHI cells
Luria Broth (LB) medium: lOg Bacto-tryptone (DIFCO)
5g Bacto-yeast extract (GIBCO.BRL)
lOg NaCl
Dissolve in H20 and adjust to pH 7.0 using NaOH. Make up 1 liter with H20.
Sterilize by autoclaving for 20 minutes at 15psi on a liquid cycle.
LB agar: Add 15g agar (Bacteriological grade;ICN) to 1 liter of LB medium and
sterilize by autoclaving for 20 minutes. Allow to cool to 40-50°C before adding
the antibiotics and IPTG/X-Gal.
lOOmM IPTG stock solution: 24mg IPTG per ml H20
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filter sterilize and keep on ice until ready to use.
5% X-Gal stock solution: 50mg X-Gal per ml of N,N' dimethyl-formamide in a
sterile glass bottle. Cover with silver foil and store on ice until ready to use.
Solution GTE (100ml): 0.9g glucose
2ml 0.5M EDTA
2.5ml 1M Tris HC1
NaOH/SDS solution (10ml): 400 pi 5M NaOH
8.6ml distilled water
lml 10% SDS
Solution III: 29.5ml glacial acetic acid (AnalaR-BDH)
adjust to pH 4.8 with KOH pellets (Analar-BDH)
made up to 100ml with distilled water.
2.5 CELL CULTURE
RPMI 1640 growth medium (Gibco BRL)
Supplements for 100ml medium: 10% FCS (Gibco BRL)
lOOmM L-Glutamine (Gibco BRL)




phorbol 12-myristate, 13-acetate (Sigma) at
a final concentration of 160nM
Ham's F-12 minimal medium (Life Technologies ltd.)
Supplements for 100ml medium: 50ng/ml epidermal growth factor (ICN
Pharmaceuticals ltd.)
lng/ml glucagon (ICN Pharmaceuticals ltd)
lOjug/ml insulin (Life Technologies ltd)
6.5ng/ml somatostatin (Sigma)
3.5/xM hydrocotisone (ICN Pharmaceuticals
ltd.)
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Discrimination of hepatitis G virus/GBV-C geographical
variants by analysis of the 5' non-coding region
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Saeed Hamid,3 Christopher A. Ludlam4 and Peter Simmonds1
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We have investigated the ability of different sub-
genomic fragments to reproduce the phylogenetic
relationships observed between six complete
genome sequences of GBV-C/hepatitis G virus
(HGV). While similar relationships were observed
following analysis of part of the 5' non-coding
region (5 NCR), for the coding region they were not
accurately reproduced for some large fragments or
for the majority of fragments of 300 or 600
nucleotides. Analysis of 5'NCR sequences from a
large number of isolates, including newly obtained
sequences from Pakistan, Zaire and Scotland, pro
duced separate groupings of Asian, African and
European/North American variants. These group¬
ings are associated with specific polymorphisms in
the 5'NCR, many of which were covariant and
consistent with a proposed secondary structure for
this region. The relatively low level of amino acid
sequence variation observed between these geo¬
graphically and phylogenetically defined groups of
variants suggests that they are unlikely to display
significant biological differences.
Introduction
Investigation of the genetic heterogeneity of GBV-C/
hepatitis G virus (HGV) (Simons et al., 1995; Linnen et al,
1996) is at an early stage. This newly discovered human virus
has a genome structure related to that of hepatitis C virus
(HCV) with a 5' non-coding region (5'NCR) capable of acting
as an internal ribosome entry site (IRES) (Simons et al., 1996)
followed by a long open reading frame capable of encoding
presumed structural (El and E2) and nonstructural (NS2, NS3,
NS4a, NS4b, NS5a and NS5b) proteins (Simons et al., 1995;
Linnen et al., 1996). GBV-C/HGV RNA can be detected in
2—4% of blood donors throughout the world (Jarvis et al.,
1996; Linnen et al., 1996; Moaven et al., 1996; Schlueter et al.,
1996; Stark et al., 1996), but an association with disease in
infected individuals has yet to be established.
Analysis of the 5'NCR has led to the suggestion that
variants of GBV-C/HGV can be divided into three or more
Author for correspondence; Donald Smith.
Fax +44 131 650 6531. e-mail Donald.B.Smith@ed.ac.uk
The GenBank accession numbers of the sequences reported in
this paper are AF0031 52-AF0031 86.
'genotypes' (Fukushi et al., 1996; Muerhoff et al., 1996). Some
of these groupings are associated with the geographical origin
of the variant, but otherwise nothing is known about the
virological or clinical implications of genomic differences
between them. Attempts to demonstrate phylogenetic
groupings ofGBV-C/HGV isolates based on sequence analysis
of subgenomic coding regions have generally been unsuc¬
cessful. For example, comparison of sequences within the NS3
helicase region for isolates from around the world failed to
differentiate between Asian, African and European/North
American isolates (Tsuda et al., 1996; Pickering et al., 1997),
and as much diversity was observed within isolates from
Taiwan as between isolates from different continents (Kao et
al., 1996). Similarly, analysis of a fragment of NS5b failed to
distinguish between African and Asian isolates, and as much
variation was observed between variants from Russia or
Germany as between isolates from different continents (Viazov
et al., 1997). In neither case was there a difference in the
distribution of sequence distances within groups compared to
between groups. In contrast, for HCV three non-overlapping
distributions corresponding to virus type, subtype and isolate
have been described for coding regions (Simmonds et al.,
1993 a, 1994), but these groupings are less clear from analysis
0001-4671 © 1997SGM
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of the 5'NCR (Simmonds et al., 1993 b; Ohba et al, 1995),
probably because of its extreme conservation and the existence
of covariant substitutions (Smith et al., 1995).
In this study we have used the complete genome sequences
of six different GBV-C/HGV isolates to investigate the ability
of different subgenomic regions to reproduce the phylogenetic
relationships displayed by comparison of the complete se¬
quences. While these relationships are not reproduced by
analysis of short fragments of coding regions, they can be
reproduced by comparison of 5'NCR sequences. We describe
the features of variability within the 5'NCR that may be useful
in the development of methods to discriminate between
different variant groupings.
Methods
■ Samples. Sera were obtained from 14 patients infected with GBV-
C/HGV with chronic hepatitis from Pakistan, 12 of whom were co-
infected with HCV or hepatitis B virus, and from nine women from Zaire
who were co-infected with human immunodeficiency virus. Samples of
plasma were also available from 12 haemophiliacs previously treated in
Edinburgh with locally manufactured clotting factor concentrates not
inactivated for enveloped viruses (Jarvis et al., 1996). Two haemophiliacs
had received commercially produced concentrates, one exclusively
(Ed 3), while the other (Ed 81) had also received locally produced, but
inactivated concentrates. Samples were stored at — 70 °C before
extraction of RNA using proteinase K—Sarkosyl and phenol—chloroform
extraction as described previously (Jarvis al: 1994).
■ RT-PCR and sequencing. Purified RNA was reverse-transcribed
and amplified by nested RT-PCR using primers derived from the 5'NCR
of GBV-C/HGV: S4571 — sense outer (positions —445 to —428, see
below for method of numbering), S4572 — sense inner (positions —419
to —399), S4573 — antisense inner (positions —76 to —97) and S4574
— antisense outer (positions —22 to —42) Qarvis et al., 1996). RNA from
the haemophiliac samples was also amplified with primers T1721 - sense
outer (5' GGGCAAACGACGCCCACGTACGGTC 3', positions — 244
to -220), T1722- sense inner (5' TCGCCCTTCAATGYCTCTC-
TTGRCC 3', positions —215 to —191), T1723 - antisense inner (5'
GTGCACCCCAGRGCCACMAGGCA 3', positions 142 to 164) and
Tl724 — antisense outer (5' CCCGCCTGATACAGYGGCCAGCA 3',
positions 181 to 203).
Reverse transcription was performed using avian myeloblastosis virus
reverse transcriptase (Promega) at 42 °C for 30 min, while conditions for
PCR were hot start at 80 °C for 2'5 min followed by 30 cycles of 94 °C
for 18 s, 55 °C for 21 s and 72 °C for 90 s. Secondary PCR was carried
out using 1 nl of the primary PCR product, and amplified products were
visualized after electrophoresis through a 2% agarose gel stained with
ethidium bromide.
■ Nucleotide sequences. PCR products were re-amplified from
primary products using primers S4572 and biotinylated S4573 and
sequenced directly from magnetically separated single strands after
immobilization on streptavidin-coated beads (Dynabeads, Dynal). Sec¬
ondary PCR products produced using primers T1722 and T1723 were
purified and cloned using the LigATor kit (R&D Systems), and sequenced
using T7 DNA polymerase (Sequenase, USB) and both sense and
antisense plasmid primers. The consensus sequence of one to five clones
was used for phylogenetic analysis. Other nucleotide sequences obtained
from GenBank are identified by their accession number, or by isolate
name for the six complete genome sequences [GBV-C, U36380;
PNF2161, U44402; R10291, U45966; GBV-C(EA), U63715; HGVC964,
U75356; and HGV-Iw, D87255],
■ Numbering of nucleotide positions. The true 5' terminus of the
GBV-C/HGV genome is currently unknown. Although the sequence of
PNF2161 extends the furthest upstream, the existence of additional 5'
sequences is suggested by the lack of a well-defined 5'-terminaI hairpin
structure similar to those defined for GBV-A (Simons et al., 1996) and for
different genotypes of HCV (Smith et al., 1995). Because of this
uncertainty we have adopted a system similar to that commonly used for
describing nucleotide positions within the HCV genome. Positions are
given relative to the AUG codon near the start of the long open reading
frame which follows the multiple stem—loop structures and the
polypyrimidine tract of the internal ribosome entry site (IRES) (Simons et
al., 1996). This AUG (positions 524—526 of Simons et al., 1996) is likely
to represent the initiation codon for translation of the GBV-C /HGV
polyprotein because of its position relative to the IRES, the initiation of
in vitro translation products at this site (Simons el al., 1996), and the lack
of a conserved upstream open reading frame or of an alternative in-frame
AUG codon (Muerhoff et al., 1996). Positions in the coding region are
numbered from the AUG of the prototype sequence (GBV-C) while
positions in the 5'NCR are given negative numbers relative to this AUG.
The 5'NCR contains 11 sites of insertion relative to the GBV-C sequence
in our data set, and these positions are un-numbered.
■ Sequence analysis. Sequences were aligned using Esee (version
1.09, Eric Cabot) or Simmonic Software (version 1.0, Peter Simmonds).
Phylogenetic trees were produced using the MEGA package (Kumar et
al., 1993). Free energies for stem—loop structures were obtained using the
program FOLDRNA in the GCG package (Genetics Computer Group,
Wisconsin, USA, accessed via the SEQNET facility of Daresbury).
Results
Phylogenetic analysis of complete coding sequences
Three major 'types' of GBV-C/HGV have been described
based on analysis of the 5'NCR, two of which were further
divided into 'subtypes' (Muerhoff et al., 1996). This analysis
included three variants for which complete genome sequences
are available, namely GBV-C ('type 1'), and PNF2161 and
R10291 ('subtype 2a'). Three additional complete genome
sequences are now available, and we investigated their
phylogenetic relationships through analysis of their coding
regions (Fig. la). HGV-Iw, isolated from a Japanese hepatitis
patient (Shao et al., 1996), is more closely related to PNF2161
than to R10291, and grouped with these sequences in 100% of
bootstrap re-sampling replications, and so is 'subtype 2a'.
GBV-C(EA), isolated from an East African child, is more
divergent but grouped with the 'subtype 2a' variants in 100%
of bootstrap replications, and shares a higher degree of
sequence identity with these sequences than with GBV-C
(Erker et al., 1996). Comparison of the Chinese variant
HGVC964 with the other five complete genome sequences
revealed two areas where numerous nucleotide and amino acid
substitutions occur (positions 5917—5948, and 8502 onwards).
The strong conservation of five out of the six sequences
available for these regions suggests that sequencing errors
could be responsible for the extreme variation of HGVC964 in
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Fig. 2. Level of bootstrap support for phylogenetic groupings based on analysis of fragments of the 5'NCR. The level of
bootstrap support (500 replications) for the grouping of PNF21 61, R10291 and HGV-lw (A) or of these three sequences and
that of GBV-C(EA) (B) is indicated by different patterns. The 5' and 3' boundaries of the regions analysed are indicated at the
bottom of the figure, numbered relative to the initiator AUG of GBV-C.
encoded by positions 5917—5948 can be obtained by shifting
the HGVC964 sequence by one nucleotide. Comparisons
between the complete genome sequences have therefore been
made by including this frameshift and by removing the second
discrepant region for which no obvious realignment could be
found. These alterations had little effect on the topography of
the trees generated and HGVC964 did not group with any of
the other sequences. We present evidence below from analysis
of 5'NCR sequences that GBV-C(EA) belongs to 'subtype 2b'
and that HGVC964 represents a new group of variants distinct
from the Japanese variants which form 'type 3'.
We next investigated the extent to which analysis of
different subgenomic fragments supported the grouping of
isolates PNF2161, R10291 and GBV-Iw (A), or the grouping of
these isolates and GBV-C(EA) (B) in bootstrap re-sampling
replications (Fig. lb). Two 1800 nucleotide (nt) fragments in
the 3'-half of the coding region failed to support the grouping
of PNF2161, R10291 and GBV-Iw sequences, while one or
both groupings were not supported by bootstrap re-sampling
in 3/6 (50%) 1200 nt fragments, in 8/14 (57%) 600 nt
fragments or in 23/28 (82%) 300 nt fragments. The five 300 nt
regions that did provide bootstrap support for both groupings
were positions 301-600 (El), 601-900 (E2), 1801-2100 (NS2),
4201-4500 (NS3) and 4801-5100 (NS4a).
Phylogenetic analysis of 5'NCR sequences
Because of the difficulties associated with phylogenetic
analysis of coding regions, and since analysis of the 5'NCR has
previously been shown to discriminate between GBV-C/HGV
isolates from different parts of the world (Muerhoff et «/.,
1996), we tested the ability of fragments of the 5'NCR to
reproduce the phylogenetic relationships observed amongst
complete coding sequences (Fig. 2). Comparison of the largest
region for which sequences were available for all six sequences
(positions —456 to —1) failed to provide support for the
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grouping of PNF2161 and HGV-Iw with R10291 (A), or for
the grouping of these sequences with GBV-C(EA) (B). These
groupings were also not observed for fragments between
— 325 and —1, but were supported by analysis of 5'NCR
fragments between positions — 402 to — 246. This represents
less than a third of the 5'NCR, and is much smaller than that of
coding regions giving similar degrees of bootstrap support
(from 300 to 4200 nt depending on the region).
Geographical distribution of GBV-C/HGV groupings
In order to test the ability of phylogenetic analysis of a
restricted portions of the 5'NCR to discriminate between
GBV-C/HGV isolates from different geographical regions, we
analysed sequences available from GenBank and new se¬
quences obtained from pregnant women from Zaire (n = 9),
patients with chronic hepatitis from Pakistan (n = 14) and
haemophiliacs treated in Edinburgh (n = 12). Separate clusters
of African, Asian and European/North American sequences
were observed consistently when 5'-terminal regions of the
5'NCR were analysed. For the region —366 to —235, virus
sequences from Zaire were similar to those present in published
sequences from West Africa, while those from Pakistan and
from most of the Edinburgh haemophiliacs grouped with
sequences previously described from infected individuals in
Europe and North America (Fig. 3). The only exceptions were
two haemophiliacs infected with variants related to the African
(Ed 3) or Asian groupings (Ed 81), both of whom had received
commercial factor concentrates, and in contrast to the other
haemophiliacs who had only received factor concentrates
manufactured from blood donations collected locally. Two
other exceptions from the general pattern were GBV-C(EA)
from a child in East Africa with acute non-A—E hepatitis, and
HGV-Iw from a Japanese hepatitis patient. Complete genome
sequences are available for both of these isolates, and
phylogenetic analysis of the full-length coding sequences (Fig.
la) is consistent with the groupings obtained by analysis of
5'NCR sequences. Phylogenetic analysis of fragments of a
similar size from the 3' terminus of the 5'NCR did not
consistently produce the same groupings of isolates as those
based on geographical origin (data not shown). These
observations suggest that analysis of the region —366 to
— 235 accurately reproduces the phylogenetic relationship of
GBV-C/HGV isolates, consistent with the analysis of similar
regions from the complete genome sequences (Fig. 2).
5'NCR polymorphisms correlated with different
phylogenetic groupings
We next searched for polymorphisms in the 5'NCR that
were associated with these phylogenetic groupings since they
might simplify the identification of GBV-C/HGV groups from
sequence information, or allow the development of methods of
identification that avoid the need for sequence analysis.
Polymorphisms that are strongly correlated with phylogenetic
groupings are clustered in three separate regions of the 5'NCR
(Fig. 4), and the majority of these were consistent with a
proposed secondary structure for GBV-C/HGV 5'NCR
(Simons et al., 1996) since substitutions either maintained
proposed base pairings, or occurred in unpaired regions.
Group-specific polymorphisms are also present outside these
regions (positions —65, —103, —104, —108, —149, —306,
— 307), but the remaining polymorphic positions vary without
regard to group. For example, substitutions within the unpaired
polypyrimidine stretch between positions —21 to —10
generally are confined to alteration between U or C residues
and no group-specific pattern can be discerned. Another such
region is that between positions —147 to —120, where
despite the considerable sequence variability, all sequences are
capable of forming stem—loop structures with free energies of
between —42-6 and — 89'0 kj (Fig. 5). Some substitutions in
this region are group-specific, but at the majority of poly¬
morphic sites, substitutions occur in all of the phylogenetic
groups. Similarly, most substitutions between positions —185
and —177 do not correlate with the phylogenetic groupings
based on analysis of complete genome sequences, but the
ability to form a short stem—loop structure (region IVa' of
Simons et al., 1996) is conserved.
Discussion
Variation of GBV-C/HGV coding regions
Our phylogenetic analysis of six complete genome se¬
quences of GBV-C/HGV has revealed several unexpected
findings. While certain phylogenetic groupings are apparent
from the analysis of the complete coding region, these
groupings are only poorly supported when smaller genome
segments are compared. These observations provide an
explanation for the previous inability to observe consistent
phylogenetic relationships between GBV-C/HGV isolates
from different parts of the world based on analysis of 118 nt
within NS3 (positions 3767—3884) (Kao et al., 1996; Pickering
et al., 1997) or from the analysis of 354 nt within NS5b
(positions 6742-7095) (Viazov et al., 1997). Analysis of similar
genome regions from complete sequences revealed that neither
a 300 nt fragment of NS3 nor a 1200 nt fragment of NS5 were
able to reproduce the phylogenetic relationships of the
complete coding sequence. This finding suggests that the use
of short coding sequences such as 118 nt or less of NS3 in
investigations of the epidemiology of GBV-C/HGV (Berg et
al., 1996; Heringlake et al., 1996; Masuko et al., 1996; Schmidt
et al., 1996; Schreier et al., 1996; Tsuda et al., 1996) may not be
reliable for the reconstruction of phylogenetic relationships.
The finding that analysis of relatively long coding regions is
required to distinguish between different groups of GBV-
C/HGV variants differs markedly from the situation for HCV,
for which phylogenetic groupings observed by analysis of
complete virus genomes are closely mirrored by those





























































































































































L is equivalent to a distance of 0.02
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4 HGVC_964 .C.TT. . .C C. .T .AA ...A... .G. . .
1 Ed 3 AG.GC..C..C.G.C. C.C. .T.A...A... . AA .G. AT. . . -A .C A. T. .C. . .
1 Zai 2 AG.G...C..C.G.C. ....C.C. -T.A...A... .AA -G. CT. . . .A .c A. ..CCTA. .C. . .
1 U59545 . .A. ..TG...G.C.C.... .A.ACT AG.GC..C..C.G.C. C.C. .T.AT..A... AA .G. CT. . . .A .c A. .C. . .
1 U59546 . .A. . .TG..AG.C.C . . . . .A.ACT AG.GC..C..C.G.C. C.C. .T.AT..A... .AA .G. CT. . . .A .c A. .C. . .
1 U59544 . .A. ..TG...G.C.C .A.ACT AG.G...C..C.G.C. C.C. .T.AT..A... .AA .G. CT. . . .A .c A. .CT. .
1 U59543 . A ..TG...G.C.C.... AG.G...C..C.G.C. C.C. .T.A...A... .AA .G. CT. . . .A .c A. .T. . .
1 U59542 . .A. -A. . . ..TG...G.C.T ...AC. .G.G...CA.C.G.C. C.C. .T.A...A... .AG A.T .G. .T. . .c A. .C. . .
1 U59540 . .G. ..TG...G.C.C.... ...AC. .G.G....A.C.G.C. ...C.C. .T..T..A... .AA A. . -G. .T. . .c A. .c.. .
1 U59541 . .A. .A. . . ..TG...G.C.T.... ...AC. .G.G...CA.C.G.C. C.C. .T.A...A... .AG A.T .G. .T. . .c A. .c.. .
1 Zai 1 •G.G...C.TC.G.C. ...C.C. .T.A...A.G. .AA A. . .G. CT. . . -A .c T. .c.. .
1 Zai 5 .G.G....A.C.G.C. . . ..C.C. .T.AT..A.G. AA A. . .G. CT. . . .A .c T. .T. . .
1 Zai 6 .G.G....A.T.G.C. C.C. .T.A...A.G. .AA A. . .G. CT. . . .A .c T. .c.. .
1 Zai 7 .G.G...CA.C.G.C. . . .C.C. .T.A...A.G. AA A. . .G. -T. . . -A .c T. TC. . .
1 Zai 8 .G.G A.C.G.C. C.C. .T.AT..A.G. .AA A. . .G. CT. . . -A .c T. ■ T. . .
1 Zai 9 .G.G...CA.CAG.C. ...C.C. .T.A...A.G. .AA A. . .G. CT. . . .A .c T. .C. . .
1 Zai 10 .G.G A.C.G.C. ...C.C. .T.AT..A.G. .AA A. . .G. CT. . . .A . c T. .T. . .
1 Zai 11 .G.G....A.T.G.C. C.C. .T....AA.G. .AA A. . • G. CT. . . .A T. .C. . .
1 U59556 CTA. ? G.C.C. . . . ...AC. .G.G.A.CA...G.C. ....T..A.G. .AA A. . .G. CT. . . .A .c . . . G . A. .C. . .
1 L'59557 CTA. G.C.C ...AC. .G.G.A.CA...G.C. ....T..A.G. .AA A. . .G. CT. . . .A .c T. .c.. .
1 U59558 CTA. G.C.C. .. . .G.G.A.CA...G.C. T..A.G. .AA A. . .G. .T. . . .A .c T. TC. . .
1 U59555 CTG. G.C.C ...AC. .G.G.A.CA...G.C. T..A.G. .A. A. . .G. CT. . . .A .c T. T. .c.. .
1 GBV-C CTG. . .T. . . .G.C.C. . . . ...AC. .G.G...C..C.G.C. .A.AT..A.GA .AA A. . .G. CT. . . .A .c T -C . . .
1 U59550
1 U59549 CTA. GTC.A.... ..-AC. .G.G.A.CA...GCC. ...AT..A.G. .AA AT. .G. AT. . . .A .c A. .CT. . . .T
1 U59552 CTA. GTC.A.... ...AC. .G.G.A.CA...GCC. ...AT..A.G. AA AT. .G. AT. . . .A ■ C A. .CT. . . -T
1 U59551 CTA. GTC.A.... ... AC. .G.G.A.CA...GCC. ...AT..A.G. .AA AT. ■ G. AT. . . .A .c A. .CT. . . .T
1 U59548 CTA. GTC.A.... ... AC. .G.G.A.CA...G.C. ..CAT..A.G. .AA AT. .G. AT. . . .A .c . .T. . .A. .CT. . . .T
1 U59553 CTG. G.C.A ...AC. .G.G...C....G.C. .T.AT..AAG. AA AT. .G. AT. . . .A .c A. G. . .CT. .
1 U59554 CTA. G.C.A.... . . .AC . .G.G. . .C. . . .G.C. .T.AT..AAG. .AA AT. .G. AT. . . .A .c A. G. . .CT. .
1 U59547 .AA AT. . .CT. .
3 U59538 .T. . .AC. . . -TT. . . .AC C. .G.TT...C...G.C. ...A.C. .T..T .AA .A A
3 U59539 .T. . .AC . . . .TT. . . .AC c. .G.TT...C...G.C. . . .G.C. ■ T. .T .AA .A
3 Ed 81 .G.TT...C...G.C. C. .T. .T .AA • A A
3 U69266 .G.TT...C...G.C. G.C. .T..T .AA ■A.??.. A
3 D87249 ■ T. . .AC. . ..TT.A. .AC c. .G.TT...C...G.C. G.C. .T..T .AA • A
3 D87250 ■ T. . .AC. . . .TT.A. .AC c. .G.TT G.C. ...G.C. .T..T . AA .AC A
3 D87251 .T. . .AC . . . .TT.A. -AC ....c. .G.TT...C...G.C. G.C. ■ T. .T AA .A A
3 D87252 .T. . .AC . . . .TT.A. .AC c. .G.TT...C...G.C. G.C. .T. .T .AA • A A
3 D87253 1 .T. . • AC. . . . TT . . . . AC c. .G.TT...C...G.C. ...A.C. .T. .T .AA ■ A
3 D87254
Fig. 4. Group-specific 5'NCR polymorphisms. Sequences for the regions —490 to —459, —366 to —329 and —287 to
— 235 are grouped on the basis of phylogenetic analysis of positions —366 to —235. Sequence identity with PNF2161 is
indicated by dots, missing information by spaces and ambiguous or mixed nucleotides by question marks.
Fig. 3. Consensus phylogenetic tree of geographically disparate isolates. The tree was generated by comparison of positions
— 366 to —235 of the 5'NCR. The percentage of bootstrap replicates in which major groupings were observed amongst 500
replicates is indicated. Sequences are identified by accession numbers or, for the sequences reported in this study, by the
prefixes Pak for Pakistan, Ed for Edinburgh and Zai for Zaire. The geographical origin of each sequence is indicated at the right.
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Fig. 5. Predicted stem-loop structures for different GBV-C/HGV groups.
The stem-loop structure for positions — 147 to — 1 20 (corresponding
to region IVb in the proposed structure of Simons et at., 1 996) is shown
for the consensus sequence of each sequence group. Substitutions
that do not affect proposed base pairings, or which are covariant
with substitutions that preserve the base pairings are indicated by (A),
while substitutions that disrupt base pairings are indicated by (A)-
Substitutions that occur in unpaired regions are indicated by (#) while
positions of nucleotide insertion relative to the consensus sequence are
indicated by (-^). The single Group 4 sequence is included with
Group 2a. The free energy (kJ) of the stem-loop for the consensus
sequence of each group is indicated, with the range observed amongst
variants within each group given in parentheses.
and as small as 222 nt (Simmonds et al., 1994, 1996; Ohba et
al., 1995).
Variation of the GBV-C/HGV 5'NCR
The extent of variation is unequal across the 5'NCR, with
some areas being relatively well-conserved and others being
more variable, as previously noted (Erker et al., 1996; Muerhoff
et al., 1996). However, in contrast to the lack of discrimination
of short fragments of coding regions, analysis of 5'-terminal
fragments of the 5'NCR can be used to reproduce the
phylogenetic groupings displayed by complete genome seg¬
ments (Fig. 2). This conclusion is also supported by analysis of
a large set of sequences (n = 89), since isolates generally
grouped according to their geographical origin (Fig. 3). On the
basis of this analysis the following groups can be distinguished:
Group 1, a diverse collection of African sequences, Group 3
consisting of relatively similar Asian sequences, Group 2
consisting of sequences from North America, Europe and the
Indian subcontinent, as well as HGV-Iw from Japan and GBV-
C(EA) from East Africa. This last isolate together with some
other European and North American isolates may represent a
subgroup (Group 2b) since they share an unusual pattern of
substitution in the 5'NCR (Fig. 4). Similarly, there is evidence
for subgroupings amongst the diverse sequences comprising
Group 1. A single Chinese sequence (GBV-C 964) may
represent a distinct group (referred to here as group 4) since
analysis of the complete coding sequence confirms that it is
distinct from Groups 1 and 2. Although comparison with the
complete coding sequences of Group 3 isolates is not yet
possible, this sequence contains several unusual substitutions
in the 5'NCR (Fig. 4).
The finding that 5'NCR polymorphisms are associated with
phylogenetic groupings obtained by analysis of complete
coding regions and that group according to geographical
origin makes it possible to develop rapid methods for
identifying GBV-C/HGV isolates, similar to those developed
for the genotyping of HCV (Stuyver et al., 1993; McOmish et
al., 1994). Group-specific polymorphisms are present through¬
out the 5'NCR, but they are most frequent between positions
— 490 and —235 (n = 39) where they are concentrated into
three clusters (Fig. 4). Sequence information for the region
between positions —490 and —459 may be more difficult to
obtain because very little upstream sequence information is
currently available from which to design universal primers for
RT—PCR amplification. Although there are nine group-specific
polymorphisms between positions — 234 and — I, this region
also contains three highly polymorphic regions that vary
without regard to geographical grouping, and so phylogenetic
analysis of this region fails to reproduce the relationships of
complete coding sequences (Fig. 2) or to produce geographical
groupings (data not shown). Similarly, a previous study failed
to observe an association between phylogenetic groupings
and geographical origin for the region —267 to +17
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(Pickering et al., 1997). Consequently, the optimal region for
identifying the group of GBV-C/HGV isolates at present
appears to be the region between positions —490 and —235,
encompassing three blocks of group-specific polymorphisms.
Significance of phylogenetic groupings
The existence of distinct groups of GBV-C/HGV variants
is implied by phylogenetic analysis of complete genome
sequences, and by the presence of polymorphisms in the
5'NCR that correlate with geographical origin. However, the
biological significance of these groupings is presently unclear,
especially since representatives of different GBV-C/HGV
Groups 1, 2 and 4 differ over their complete coding regions at
only 3-7—4% of amino acid positions. This level of amino acid
sequence variation is much less than that observed for
individual genes between different serotypes of vesicular
stomatitis virus (30—50%), poliovirus (20—30%) or dengue
virus (23—38%), or between different types of papillomaviruses
(10—17%) or subtypes of HIV (12—36%). Relative to HCV,
variation is at the lower end of the range observed between
complete polyprotein sequences of epidemiologically un¬
related isolates of the same HCV subtype (3-5—8-1%), and
much less than that observed between different HCV subtypes
(13—19%) or between different HCV types (23—29%). While
different types of HCV show substantial variation in anti¬
genicity and differ in clinical features such as the frequency
with which infection can be eliminated by interferon treatment,
similar differences have not been associated with the more
minor differences between HCV subtypes such as subtypes la
and lb, or the still more subtle differences between isolates of
the same subtype. Comparison with HCV and other viruses
would therefore suggest that the limited diversity between
GBV-C/HGV variants is unlikely to be associated with major
biological or clinical differences. For this reason we have used
the descriptive terms 'group' and 'subgroup' rather than the
terms 'type' or 'subtype' (Berg et al., 1996; Fukushi et al.,
1996; Muerhoff et al., 1996; Schreier et al., 1996) that suggest
that variation between phylogenetic groups is significant.
While there is relative conservation of the GBV-C/HGV
polyprotein between different groups of variants, their se¬
quences still vary by 11—13 % overall because of substitution at
synonymous sites. The ratio of nonsynonymous to syn¬
onymous evolutionary distances between different variant
groups ranges from 0'029 to 0054 (mean 0'04), compared with
between 0T and 0T4 for different representatives of HCV
subtype la. The reason for this difference between GBV-
C/HGV and HCV is not known, but presumably reflects
differences in selective pressures related to their interaction
with the host immune system during infection. Evolutionary
distances at synonymous sites between variants of GBV-
C/HGV (0*56—0*7) are greater than those observed between
different isolates of HCV subtype la (0T4—0-17) or subtype lb
(0-24—0-36) but less than those observed between different
subtypes (1*02—1*65). For HCV, evolutionary distances at
synonymous sites have been used to date the time of
divergence of different subtypes at more than 300 years ago
(Smith et al., 1997). A similar estimate is not possible for GBV-
C/HGV since the rate of evolution is currently unknown, but
the substantial synonymous distances between sequences from
different variant groups as well as their strong correlation with
geographical origin, suggest that divergence of these groups is
not a recent phenomenon.
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